GADA Applauds the Presidential Signing of the Animal Generic Drug User Fee Act of 2008

WASHINGTON, Aug. 14 /PRNewswire/ — The Generic Animal Drug Alliance (GADA) today announced that President Bush signed into law the Animal Generic Drug User Fee Act of 2008 (Title II of H.R.6432). Under the Animal Generic Drug User Fee Act (AGDUFA), generic animal health companies for the first time will pay user fees to provide essential resources to improve generic animal drug review times-getting high quality, affordable generics to veterinarians, and animal and pet owners, faster.

Farm animals and livestock, and the majority of pets, are not covered by health insurance. Ranchers, farmers, and pet owners pay out-of-pocket for prescription medications. In contrast to human medicine where generics enter the market as soon as a drug’s patents expire, few veterinary drugs have FDA approved generic versions, even years after patent expiry.

Although both new animal drugs and generic animal drugs are reviewed and approved by the Center for Veterinary Medicine (CVM), the review times for generic drug applications average more than four times as long as those for new animal drugs-preventing generic versions of medications that have long been off patent from getting to veterinarians.

“The success of AGDUFA will allow the review process for generic animal drugs to become more efficient and predictable while continuing to meet the rigorous standards for drug approval” stated Stephanie Batliner, Chair of the Generic Animal Drug Alliance and Director of Regulatory Affairs at IVX Animal Health, a GADA member company. “Generic animal drugs are essential to both pet owners and food producers to reduce costs and increase accessibility to medications.”

Jean Hoffman, CEO of Putney, a GADA member company, commented “The AGDUFA legislation marks the beginning of a new era for animal health. Much as generics have changed the face of human healthcare-making drugs more affordable for Americans-the timely availability of animal generics will help ranchers and farmers manage the cost of caring for our country’s food and production animals, and allow pet owners access to lower cost medications for their companion animals who are considered members of the family.”

About Generic Animal Drug Alliance

The Generic Animal Drug Alliance (GADA) is an independent professional trade organization that represents the interests of generic animal health companies before Federal regulatory agencies and Congress. Member companies are focused on the development, approval and marketing of high quality generic drugs for animals and pets-making the cost of care for all animals affordable for ranchers, farmers and pet owners.

The Generic Animal Drug Alliance

CONTACT: Shannon Bennett of The Generic Animal Drug Alliance,+1-207-553-4451, [email protected]

Russian Military Will Leave Gori in 2 Days

TBILISI. Aug 14 (Interfax) – The city of Gori, which is located close to the Georgian-South Ossetian border, is controlled jointly by the Georgian police and the Russian troops, Russian Defense Ministry official Vyacheslav Borisov told the Georgian press.

In the next two days, all posts in the city will be controlled by the Georgian police and Russian troops, after which the Russian troops will leave Gori, he said.

“The police have now returned to the city and all civilians will be able to return too after control is established,” Borisov said.

Locals have started returning to the city and there is no major destruction there, he said.

In the meantime, the Georgian media reported this week that Russian planes had bombed Gori.

High-ranking officials in Tbilisi made statements saying that the city had been abandoned by the authorities and there was looting going on there. The Russian military have denied this information.

(c) 2008 Daily News Bulletin; Moscow – English. Provided by ProQuest LLC. All rights Reserved.

Doctor’s Memoir to Be Featured At Frankfurt Book Fair

WESTFIELD, N.J., Aug. 14, 2008 (PRIME NEWSWIRE) — Dr. Gloria O. Schrager, Clinical Professor of Pediatrics at Columbia University College of Physicians and Surgeons, is celebrating her 60th anniversary as a physician with a trip to the Frankfurt International Book Fair in Germany. Her autobiography, “Medicine, Matzoh Balls and Motherhood: The Complex Life of a Woman Doctor”, will be featured at the fair, which is one of the largest and most prestigious book fairs in the world, attracting publishers from many countries.

Her book is an intriguing memoir about her struggle to become a doctor at a time when women physicians were an anomaly, facing ridicule, harassment and discrimination. She relates how the Great Depression and World War II disrupted her early life and how the McCarthy Unamerican Activities Committee, the Korean War, and her concern for equitable health care affected her later life and medical career. Dr. Schrager describes the adventures and mishaps of medical school, internship, private practice and her training of young doctors, as well as the domestic challenges of maintaining a successful marriage and raising a family. She discusses some of the differences, both good and bad, between the practice of medicine today and how it has been practiced over the past sixty years.

Dr. Schrager began her education in a small Adirondack village, Schroon Lake, during the Great Depression. To complete her higher education, she was sent to live with relatives in Brooklyn, New York and graduated Brooklyn College in 1944. She was unaware that women could become doctors until a college professor convinced her to apply to medical school. She met her future husband, Alvin J. Schrager, M.D. during their internship and her memoir is a love story of passion and depth, describing their stormy courtship, their marriage, and their private practice together in Westfield, N.J. Their two sons become physicians and a niece and grandniece continue the tradition, establishing three generations of women physicians in their family.

In 1972, Dr. Schrager left private practice to become the full-time Director of Pediatrics at Overlook Hospital in Summit, N.J., where she organized the Pediatric Residency Program, an independent training program affiliated with Columbia University. She retired from Overlook Hospital in 1989, but still teaches at Columbia.

     Medicine, Matzoh Balls, and Motherhood * by Gloria O. Schrager, M.D.                  The Complex Life of a Woman Doctor                  Publication Date: June 20, 2006         Trade Paperback; $18.69; 272 pages; 978-1-4257-0589-3         Cloth Hardback; $28.79; 272 pages; 978-1-4257-0590-9 

To request a complimentary paperback review copy, contact the publisher at (888) 795-4274 x. 7479. Tearsheets may be sent by regular or electronic mail to Marketing Services. To purchase copies of the book for resale, please fax Xlibris at (610) 915-0294 or call (888) 795-4274 x.7876.

This news release was distributed by PrimeNewswire, www.primenewswire.com

 CONTACT:  Xlibris           Marketing Services           (888) 795-4274 x. 7876           [email protected] 

Facing Cancer Puts Lump in Throat

By GERRY CALLAHAN

I felt like I had been bound and gagged and buried alive.

I couldn’t talk, I couldn’t move, I couldn’t quite grasp what I was hearing. The last thing I asked before the anesthesia took hold was how long the biopsy would take, and I was told it would be about two days. But the first thing I saw when I awoke was my wife’s face, and I kind of got the feeling they had used the express lane.

They had my results in two hours.

“Can you understand me?” Tracy asked.

I was still hooked up to an IV and still a little hazy, but I reached for my pen and notepad. I would do that a lot for the next month, after my doctor ordered me to refrain from speaking at all. Not even a whisper, he said.

It had been a running joke among friends and colleagues – yeah, someone finally found a way to shut me up – but the jokes pretty much ceased on April 25, 2007. On that day, I wasn’t sure I would ever speak again.

“I’m fine,” I scribbled on the notepad, even though I had a feeling I wasn’t fine at all. Then for the first time I heard one of those words that hits you like a steel-toed boot in the stomach.

“It’s malignant,” my wife said.

I had gone into the hospital that morning for routine throat surgery, which I suppose is how it begins for a lot of cancer patients. This is my story. I thought I had a throat polyp that had caused my voice to go hoarse. A polyp is what it sounds like – a harmless little bump that is no more threatening than a pimple.

Unfortunately, my cute little polyp turned out to be a nasty little tumor, which turned my life upside down for the next four months. I had a million questions, but couldn’t ask any of them, at least not without pen and paper. Most of the other patients I met were older and almost all were former smokers. I wanted to know how I ended up in the same waiting room with these poor old folks.

“Sometimes,” said my surgeon and friend Ramon Franco, sitting in his office at the Massachusetts Eye and Ear Institute, “it’s just bad luck.”

Sometimes that’s the only explanation you get: bad luck. And the question becomes, how long does my bad luck last? When do I awake from this nightmare?

Before I could make any decisions regarding treatment, I needed a CT scan to see if the cancer had spread, and unfortunately for me, the express lane was now closed. The scan would wait six days. It felt more like six years. In a Cuban prison.In these quiet moments, there is no way around it: You hope for the best, but you think long and hard about the worst. The first time you hear those awful, ugly words – it’s malignant – there is a palpable end to the innocence. You are no longer on the outside looking in, no longer one of the lucky ones who tiptoes through life’s landmines and looks at cancer patients with the same fleeting sympathy you feel for, say, earthquake victims in Asia. OH, THE POOR THINGS. ONE OF THESE DAYS,I REALLY SHOULD HELP.

Instead, you join the club, and immediately you are humbled by the strength and optimism of your fellow members. A few days after I got home, I got a letter from an 8-year-old girl named Faith, a patient at Dana-Farber’s Jimmy Fund Clinic. She drew me a picture of a horse and told me she would say a prayer for me. Any thoughts of self pity end right there.

There is another powerful force at work for a parent with cancer. I went through two surgeries and 6 1/2 weeks of radiation, and each miserable day I thanked God for one thing: It was me lying there, and not one of my kids. I’m not sure I could handle it the other way around.

I was indeed one of the lucky ones, still able to look my healthy children in the eyes and hand them the same note each afternoon as they came through the door. “How was school?” it said. They would laugh and say “good” as they made a beeline for the computer or the TV.

Each day the Jimmy Fund Clinic is teeming with children of all ages, babies and toddlers and teenagers whose luck ran out too soon. I was 45 when I looked around the waiting room and felt as if I didn’t belong there. These are kids, and every one of them should be outside this summer, running around the playground or digging in the sand on the beach or riding around in Mom and Dad’s car, the Jonas Brothers blasting on the stereo.

Faith should be riding a horse, Lindsey should be trying out for soccer at Woburn High, Lauren should be leaving for Villanova, RJ should be working on his wrestling moves. All the kids at the clinic should be allowed to be kids. Instead they are cancer patients, courageously playing the rotten hands they were dealt. And the truth is they are not looking for your sympathy or your tears, but they sure could use your money.

And today, once again, we’re going to call out the lucky ones. You know who you are, and you know why you should give. Because you HAVEN’Thad to wait outside the chemo room for your bald, gaunt little boy. Because you HAVEN’Thad to sit up all night with your nauseous teenager while all her friends were at the junior prom. Because your child hasn’t looked up at you and asked, “Why, Dad, why?”

Because you’re like me. You’re one of the lucky ones.

“You’re never going to sing in the opera, but you’re going to be OK,” said smiling Jim McIntyre, my radiation oncologist at the North Shore Cancer Center, a partner of Dana-Farber. “You’ll be able to argue about sports. You can go back to your life.”

That’s all I wanted to do. Argue about sports. Coach kids. Go back to my life. I can do all that now, thank God. Some people aren’t so fortunate. They want to go back to their lives, but it’s not that easy. They need help, they need money, they need you.

Do you have something better to do today?

Originally published by By GERRY CALLAHAN.

(c) 2008 Boston Herald. Provided by ProQuest LLC. All rights Reserved.

EMSC Announces National Provider Agreements With Community Health Systems Professional Services Corporation and Quorum Health Resources, LLC

Emergency Medical Services Corporation (NYSE: EMS) (the “Company”) today announced that it has entered into an agreement as a national provider of hospital-based physician services (emergency department, hospitalist, anesthesiology and radiology), to Community Health Systems Professional Services Corporation (CHSPSC) and Quorum Health Resources, LLC (QHR), wholly owned subsidiaries of Community Health Systems, Inc. The organization’s affiliates own, operate or lease more than 110 hospitals in 28 states and provide hospital management, consulting and advisory services to more than 160 independent community hospitals and health systems throughout the U.S.

Under the terms of the 3-year agreements with CHSPSC and QHR, facilities may contract for services with EmCare, and will benefit from preferred pricing for certain services provided under the agreement, with opportunities for additional cost savings as more agreements are entered into for hospital-based services.

William A. Sanger, EMSC Chairman and Chief Executive Officer, said, “We are pleased to strengthen our partnership with CHS. EmCare has been a service provider to CHSPSC for many years. This is the third national contract we have announced this year, and it reflects the value we can bring to healthcare systems, facilities and insurers.”

About Emergency Medical Services Corporation

Emergency Medical Services Corporation (EMSC) is a leading provider of emergency medical services in the United States. EMSC operates two business segments: American Medical Response, Inc. (AMR), the Company’s healthcare transportation services segment, and EmCare Holdings, Inc. (EmCare), the Company’s emergency department and hospital-based management services segment. AMR is the leading provider of ambulance services in the United States. EmCare is the nation’s leading provider of outsourced emergency department staffing and related management services. In 2007, EMSC provided services to 10.6 million patients in more than 2,000 communities nationwide. EMSC is headquartered in Greenwood Village, Colorado.

About EmCare, Inc.

EmCare, Inc. and the physician groups operating under the EmCare(R) brand are leading providers of outsourced emergency department and hospital-based physician services to healthcare facilities in the United States. EmCare has more than 400 exclusive contracts with hospitals and independent physician groups to provide emergency department, anesthesiology, hospitalist and radiology staffing, management and other administrative services.

Forward-Looking Statements

Certain statements and information herein may be deemed to be “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Any forward-looking statements herein are made as of the date of this press release, and EMSC undertakes no duty to update or revise any such statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in EMSC’s filings with the SEC from time to time, including in the section entitled “Risk Factors” in the Company’s most recent Form 10-K. Among the factors that could cause future results to differ materially from those provided in this press release are: the impact on our revenue of changes in transport volume, mix of insured and uninsured patients, and third-party reimbursement rates; potential penalties or changes to our operations if we fail to comply with extensive and complex government regulation of our industry; and the loss of existing contracts and the accuracy of our assessment of costs under new contracts.

ZyGEM Enhances Technical Support for Its DNA Extraction Kits With Appointment of Technical Director and Release of Application Notes

SOLANA BEACH, Calif., and HAMILTON, New Zealand, Aug. 14 /PRNewswire/ — ZyGEM Corp. Ltd., a provider of novel enabling enzymatic tools for life sciences applications, today announced the availability of a selection of targeted application notes, customer posters and other technical resources designed to provide enhanced support to users of its prepGEM(TM), forensicGEM(TM) and livestockGEM(TM) DNA extraction kits. The company also announced that Nicholas J. Price, Ph.D., has been appointed as ZyGEM’s U.S.-based technical director.

The application notes, supplemented by a variety of scientific and technical documents including validation tests and other in-house research, technical publications evaluating ZyGEM’s reagent kits and samples of scientific studies conducted using the kits, are intended to help end-users take full advantage of the distinctive features of ZyGEM’s technology. For example, among the studies included in the application notes is one that showcases the ability of prepGEM(TM) to extract microbial DNA from Greenland ice dating back to 1660. The application notes can be accessed at http://zygem.com/Products/Products-Pubs.html.

ZyGEM’s family of kits use a proprietary thermophilic enzyme to extract DNA and other nucleic acids from samples using a single closed-tube system, which simplifies laboratory workflow, minimises error and reduces the risk of contamination while also reducing costs. The kits are easy to automate using off-the-shelf robotic systems and have been specially optimised for DNA extraction from a variety of sample types in basic research, forensics, clinical diagnostics and agriculture.

As U.S. technical director, Dr. Price will develop additional technical resources for partners, developers and end-users, while assisting and overseeing product development activities. He noted, “These enhanced scientific and technical resources are intended to provide additional support to our diverse and growing population of partners and end-users. The data and analyses now available on our website should facilitate researchers’ ability to tailor kits to their specific needs and also to benefit from the experience of other end-users. We will continue to update and expand this resource going forward.”

Prior to joining ZyGEM, Dr. Price served as R&D program manager and scientist at Invitrogen Corp., where he led multiple development projects focused on nucleic acid and genomic applications for diagnostics and other life sciences uses, including novel technologies for isolation and purification of DNA and RNA and improved methods for nucleic acid delivery. His work resulted in the development and launch of a number of novel research kits and other products. Dr. Price holds a Ph.D. in biology from Universidade Nova de Lisboa in Portugal, an M.S. in biotechnology from the University of Kent and a B.S. in applied chemistry from Nottingham and Trent University, both in the U.K.

About ZyGEM’s DNA Extraction Kits

prepGEM(TM) kits have been formulated for high-throughput DNA extraction from animal tissue samples for life science research, animal testing and traceability, selective breeding and other animal health and agricultural applications. prepGEM(TM) kits enable high-throughput DNA extraction of 384 samples in less than 30 minutes. They contain reagents that have been optimised for downstream PCR-based applications including quantitative PCR, genotyping using STRs or SNPs, RFLP analyses, etc. They are proven on a range of animal samples including blood, micro-biopsies (ear tags), meat, rat tails, fish, fish tails and insects.

forensicGEM(TM) kits have been formulated for high-throughput DNA extraction from crime scene and other sample sources, providing PCR-ready, forensic grade DNA for 96 samples in just 20 minutes. The one-tube forensicGEM(TM) process is simple to use and easy to automate with current robotic platforms, making it ideal for database testing as well as case work samples. All reagents are rigorously quality controlled to test for efficacy and for the absence of human DNA. forensicGEM(TM) kits are validated for forensic analysis.

livestockGEM(TM) kits have been formulated for high-throughput DNA extraction from a range of animal sample types without the need for further purification, including ear punch microbiopsies, saliva and hair, as well as from blood and saliva DNA storage cards. The kits provide PCR-ready DNA for 96 samples in just 20 minutes with no hands-on attention required. livestockGEM(TM) kits are easy to use and automate for high-throughput applications using off-the-shelf robotic systems. With livestockGEM(TM) kits, both experienced and novice staff can prepare DNA samples up to three times faster than with existing products.

For more information on ZyGEM’s families of DNA extraction kits, visit http://zygem.com/Products/Products-Ovw.html or email [email protected]

About ZyGEM

ZyGEM Corporation Limited is a rapidly growing biotechnology company with a range of innovative enzyme-based products and technologies based on the company’s exclusive collection of microorganisms from extreme environments. ZyGEM’s technology has significant competitive advantages over existing methods and has potential applications in a number of sizeable global markets. ZyGEM currently produces DNA extraction and detection products, molecular biology enzymes and individual enzymes and diagnostics, serving life sciences customers in basic research, forensics, clinical diagnostics and agriculture. ZyGEM has facilities in New Zealand and the U.S.A. For more information, visit www.ZyGEM.com.

   Contacts:                            Media:   Corporate:                           GendeLLindheim BioCom Partners   Paul Kinnon                          Barbara Lindheim   President and CEO of ZyGEM           212 918-4650   858 720-8333  

ZyGEM Corp. Ltd.

CONTACT: Corporate: Paul Kinnon, President and CEO of ZyGEM,+1-858-720-8333; Media: Barbara Lindheim, GendeLLindheim BioCom Partners,+1-212-918-4650

Web Site: http://www.zygem.com/http://zygem.com/Products/Products-Ovw.htmlhttp://zygem.com/Products/Products-Pubs.html

Rising Stars Heat Up the County Fair Main Stage

By FRANK ROBERTS

By Frank Roberts

Correspondent

COURTLAND

Two of the hottest acts in country music will be spending some quality time at the Franklin-Southampton County Fair this weekend.

As any country fan will tell you, Bucky Covington and Lady Antebellum, both of whom will be performing tomorrow night, are top- of-the-chart constants. If you’re hankering for some bluegrass, check out Shiloh Grass.

There is still more music including The English Channel, which, as the name suggests, performs Brit hits of the ’60s with covers of The Beatles, Rolling Stones, The Who, The Hollies and their ilk.

Canyon Road and Silver Street, two popular local bands, will also take the stage tonight.

If you need something for everyone, check out Glen Shelton, who offers music of almost every description.

While music is an integral part of the fair, it alone does not a country fair make.

You also need a midway, vendors galore, enticements for the children, lots of food and some special attractions. The latter includes the “Wild West Follies,” which has fun cowboy entertainment that you won’t find on Starz’ Western network.

You will see some western skills at the show, including trick roping, whip cracking and knife throwing – all with audience participation.

If you are looking for something unusual, check out Statue Viva. This living statue comes to life in an improv show. She also uses audience participation, so watch out.

Animal acts are always a hit, and the fair has a little pooch hocus pocus with “Michelle’s Magical Poodles” and “Agricadabra.” A pot belly pig will even be on hand.

The Master of Chainsaw will be slicing away (at wood carvings, that is) as the RS Cloggers, of course, clog.

Farm animals will be on display, and some will even be up for sale. The sloppy at heart are invited to participate in a watermelon- eating contest, so bring your appetite and an apron.

Frank Roberts, [email protected]

Thursday

4-10 p.m. – Numbered building contest involving home arts, exhibition, livestock, forestry and horticulture

4 p.m. – Junior stockman contest, Livestock Pavilion

6 p.m. – Canyon Road, Main Stage

8 p.m. – Silver Street, Main Stage

Friday

4 p.m. – Veggie art , Youth Pavilion

5 p.m. – 4-H market hog show, Livestock Pavilion

5 p.m. – RS Cloggers, Entertainment Building

7:30 p.m. – Lady Antebellum, Main Stage

9:30 p.m. – Bucky Covington, Main Stage

Saturday

8 a.m. – Horseshoe registration

9 a.m. – Horseshoe tournament

9:30 a.m. – Dog show registration

10 a.m. – Dog show

11:30 a.m. – Registration for watermelon-eating contest

1 p.m. – Watermelon-eating contest

3 p.m. – RS Cloggers, Entertainment Building

4 p.m. – 4-H market lamb show, Livestock Pavilion

4 p.m. – Shiloh Grass, Main Stage

7 p.m. – Glen Shelton, Main Stage

9 p.m. – English Channel, Main Stage going?

What Southampton/Franklin County Fair

Where Southampton Agri-Civic Center, 21300 Plank Road, Courtland

When Thurs.-Fri., 4 p.m. to 11 p.m.; Sat., 8 a.m.-11 p.m.

Cost admission is $6, free for children age 6 and under

More info 562-3765 Southampton/Franklin County Fair schedule

Originally published by BY FRANK ROBERTS.

(c) 2008 Virginian – Pilot. Provided by ProQuest LLC. All rights Reserved.

Nutra Pharma Announces Initial Positive Safety Data From Clinical Study in Adrenomyeloneuropathy (AMN)

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, has reported initial positive safety data from its Phase IIb/IIIa clinical study of RPI-78M for treating Adrenomyeloneuropathy (AMN). RPI-78M is ReceptoPharm’s leading drug candidate for treating neurological and autoimmune disorders.

“Initial reports and feedback from physicians involved with this clinical study have reported that patients have experienced no adverse side effects from RPI-78M,” explained Paul Reid, CEO of ReceptoPharm. “This is an important indicator of the success of this clinical study, as it provides the medical and pharmacological communities with early evidence supporting the safety of our leading drug candidate, RPI-78M,” he concluded.

Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder that affects approximately 30,000 people worldwide. The disorder is characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy). Neurological disability in AMN is slowly progressive over several decades.

AMN interests the wider neurologic community because of its similarities to Multiple Sclerosis (MS). There is currently no approved treatment for AMN. Additionally, the disease’s rarity designates it as an orphan drug candidate both in Europe and in the U.S. The Company has applied for Orphan drug status in the U.S. and intends on doing so for the EU.

ReceptoPharm expects to present the complete clinical findings and data from this study by the end of September.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company’s subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis (“MS”). The Company’s subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

http://www.ReceptoPharm.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases “would be,””will allow,””intends to,””will likely result,””are expected to,””will continue,””is anticipated,””estimate,””project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The Company’s business is subject to various risks, which are discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”). The initial safety data from the clinical study in Adrenomyeloneuropathy (AMN) should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Cerner Corporation to Offer Zynx Health Plans of Care With Its Inpatient EMRs

Zynx Health, the leader in evidence-based healthcare, and Cerner Corporation (NASDAQ:CERN), a leading supplier of healthcare information technology solutions, announced they will expand their existing strategic relationship.

Currently, Cerner offers ZynxOrder(TM), a solution used by hospital clients to customize and update evidence-based order sets, with its Cerner Millennium(R) computerized provider order entry (CPOE) solution. Under the expanded agreement, Cerner will also offer ZynxCare(TM), a solution used to customize and maintain interdisciplinary plans of care and bring evidence-based knowledge to clinical teams at the point of decision making, with its CareNet(R) and PowerPlan(TM) solutions. ZynxCare will provide clinicians with access to more than 150 customizable interdisciplinary plans of care. Use of both ZynxOrder and ZynxCare will empower all providers, including physicians, nurses, and the interdisciplinary care team, to provide patients with consistent, evidence-based care.

“We are very pleased to be expanding our relationship with Cerner,” said Pat Button, EdD, RN, chief nursing officer for Zynx Health. “The ZynxCare plans of care, in combination with ZynxOrder physician order sets and Cerner solutions, provide an opportunity to drive evidence to the point of clinical decision making for all members of the interdisciplinary team.”

“Cerner is committed to providing our clients with knowledge-driven solutions designed to help them improve the care they provide to patients,” said Mike Valentine, Cerner executive vice president and general manager, United States. “This relationship with Zynx Health allows clinicians providing care in the inpatient setting to use customizable interdisciplinary plans of care to provide quality care to their patients.”

About Zynx Health

Zynx Health was founded in 1996 by thought leaders in evidence-based healthcare and healthcare quality improvement and acquired by Hearst Corporation in 2004. Zynx has grown to become a recognized leader in evidence-based clinical decision support, and offers a suite of online solutions that help clinicians treat their patients based on the best available evidence from systematic research. The Zynx team of physicians, nurses, and allied health professionals rigorously reviews the latest peer-reviewed literature to develop clinically relevant summaries and distill evidence-based best practices.

More than 1,400 hospitals nationwide trust Zynx evidence-based decision support to address regulatory initiatives, optimize pay-for-performance reimbursement, and measurably improve the quality, safety, and efficiency of patient care. For more information about Zynx Health, visit www.zynx.com or call 888.333.ZYNX (9969).

About Cerner Corporation

Cerner is taking the paper chart out of healthcare, eliminating error, variance and waste in the care process. With more than 6,000 clients worldwide, Cerner is the leading supplier of healthcare information technology. The following are trademarks of Cerner: Cerner, Cerner’s logo, Cerner Millennium, CareNet, and PowerPlan. NASDAQ: CERN. www.cerner.com.

This release contains forward-looking statements that involve a number of risks and uncertainties. It is important to note that the Company’s performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. The words “will” or the negative of these words, variations thereof or similar expressions are intended to identify such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possibility of product-related liabilities; potential claims for system errors and warranties; the possibility of interruption at our data centers or client support facilities; our proprietary technology may be subject to claims for infringement or misappropriation of intellectual property rights of others, or may be infringed or misappropriated by others; risks associated with our recruitment and retention of key personnel; risks related to our reliance on third party suppliers; changing political, economic and regulatory influences; government regulation; significant competition and market changes; and, failure of the parties to achieve the intended benefits. Additional discussion of these and other factors affecting the Company’s business is contained in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial condition or business over time.

Miraculins to Sell Research Use Kits to Detect PSP94

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that the Company has completed development of a prototype assay for PSP94 (Prostate Secretory Protein) on the Luminex Bio-Plex 200 Protein Array System and plans to manufacture and begin selling PSP94 based test kits for research purposes by the end of 2008. As previously disclosed by Miraculins, PSP94 plays a significant role in the Company’s P2V(TM) panel test that is currently being internally developed.

PSP94 is a cancer biomarker that has been recognized in the scientific literature for its ability to a separate benign prostatic hyperplasia (BPH) specimens from prostate cancer specimens in urine (Teni et al Cancer Letters: 43 (1988) p9), a finding that has been confirmed independently by Miraculins through numerous research studies on mass spectrometry. On June 4, 2008 the Company announced its intention to internally develop the immunoassays for PSP94 and the fragment of Vitronectin, comprising its P2V(TM) panel for the detection of prostate cancer. The functioning prototype assay for PSP94 represents a major step towards the achievement of this goal.

The Company’s prototype PSP94 assay is successfully detecting recombinant protein in samples, and has completed a recovery study establishing its ability to detect PSP94 spiked urine samples with the same accuracy as spiked control fluid, thereby clearly establishing that urine does not interfere with the assay. Although development work is being conducted using the clinically accepted Luminex system, the Company is still evaluating a number of options for research kit and the final clinical commercialization platform. The availability of a high quality research use only kit will allow for the development of a wider body of scientific study on PSP94.

“This prototype clearly demonstrates the scientific capability of Miraculins to develop immunoassays in our laboratory”, stated Dr. Stephen Frost, Director, Research and Development for Miraculins Inc. “Our functional PSP94 immunoassay detects PSP94 in urine and we are now ready to begin internal manufacturing scale up to create kits for further characterization of assay performance including testing of a number of prostate cancer positive urine samples stored in Miraculins internal sample bank.”

“Although research use only kits cannot be used for human diagnostic use, our kit will allow for further study of PSP94 in preclinical and nonclinical settings. Of particular note, manufacturing and selling these kits will further demonstrate our commitment and ability to transition to a later stage development and commercialization Company,” stated Christopher J. Moreau, President & CEO of Miraculins Inc. “We have been very pleased with our team’s rapid progress on our prototype PSP94 immunoassay and I look forward to providing an update on that development once appropriate.”

About the P2V(TM) Prostate Cancer Test

The P2V(TM) test is a combination of two biomarkers, PSP94 and a fragment of Vitronectin. The validated performance of the test, through data provided by the Company’s pivotal study in May 2007, positions the test as being able to eliminate 23% of unnecessary prostate biopsies, targeting an estimated market size of approximately $500 million.

In May, 2008 the Company announced the initiation of a second pivotal study to focus on a population of men who have been referred to a urologist and subsequently have been selected for a prostate biopsy, but will be restricted to men who have a PSA score of between 2.5 ng/ml and 10 ng/ml with a normal DRE (digital rectal exam) result.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on non-invasive tests for unmet clinical needs. Miraculins is bridging the gap between commercially available diagnostic tests and research conducted at leading institutions around the world.

Through an internal biomarker discovery research program, Miraculins has advanced its prostate cancer diagnostic technology through to the development stage. The Company’s lead product in development, P2V(TM), is a simple urine test to be used as a pre-biopsy screen to eliminate a number of men who would otherwise undergo unnecessary prostate biopsy surgery.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as “believe,””anticipate,””expect,””intend,””plan,””will,””may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins’ early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers’ willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins’ filings with Canadian securities regulatory authorities, as well as Miraculins’ ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins’ forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

 Contacts: Miraculins Inc. Christopher J. Moreau President and CEO (204) 477-7599 (204) 453-1546 (FAX) Email: [email protected] Website: www.miraculins.com

SOURCE: Miraculins Inc.

Rat Brain Robot Helps With Alzheimer’s Studies

University of Reading scientists say an unlikely source – a blob of rat brain cells – controls a robot, a process that could provide clues into diseases like Alzheimer’s.

Meet Gordon, the world’s first robot controlled exclusively by living brain tissue.

The groundbreaking experiment of the neuron-powered machine explores the vanishing boundary between natural and artificial intelligence. One of the lead researchers said it sheds light on the fundamental building blocks of memory and learning. 

The project marries 300,000 rat neurons to a robot that navigates via sonar.

The neurons are now being taught to steer the robot around obstacles and avoid the walls of the small pen in which it is kept. By studying what happens to the neurons as they learn, its creators hope to reveal how memories are laid down.

“The purpose is to figure out how memories are actually stored in a biological brain,” said Kevin Warwick, a professor at the University of Reading and one of the robot’s principle architects.

Observing how the nerve cells turn into a network as they fire off electrical impulses may also help scientists combat neurodegenerative diseases that attack the brain such as Alzheimer’s and Parkinson’s.

“If we can understand some of the basics of what is going on in our little model brain, it could have enormous medical spin-offs,” he said.

Gordon looks like the garbage-compacting hero of the blockbuster animation “Wall-E”; his brain is composed of 50,000 to 100,000 active neurons.

Once removed from rat fetuses and disentangled from each other with an enzyme bath, the specialized nerve cells are laid out in a nutrient-rich medium across a five-by-five inch array of 60 electrodes.

This “multi-electrode array” (MEA) serves as the connection between living tissue and machine. The brain sends electrical impulses to drive the wheels of the robots, and receiving impulses delivered by sensors reacting to the environment.

The cells are living tissue, and are therefore kept separate from the robot in a temperature-controlled cabinet in a container pitted with electrodes.

Scientists transmit signals to the robot via Bluetooth short-range radio.

Once the robot can learn to steer, researchers plan to disrupt the memories in an effort to recreate the gradual loss of mental faculties seen in diseases such as Alzheimer’s and Parkinson’s.

They want to know how neural tissue is degraded or copes with the disruption.

“One of the fundamental questions that neuroscientists are facing today is how we link the activity of individual neurons to the complex behaviors that we see in whole organisms and whole animals,” said Dr Ben Whalley, a neuroscientist at Reading.

“This project gives us a really useful and unique opportunity to look at something that may exhibit whole behaviors but still remains closely tied to the activity of individual neurons,” he said.

The Reading team is not the first to use living tissue to control robots.

Dr. Steve Potter at the Georgia Institute of Technology pioneered work in 2003 on what he dubbed “hybrots” that connected neural tissue and robots.

On the Net:

Rice Aroma and Flavor: A Literature Review

By Champagne, Elaine T

ABSTRACT Descriptive sensory analysis has identified over a dozen different aromas and flavors in rice. Instrumental analyses have found over 200 volatile compounds present in rice. However, after over 30 years of research, little is known about the relationships between the numerous volatile compounds and aroma/flavor. A number of oxidation products have been tagged as likely causing stale flavor. However, the amounts of oxidation products, singly or collectively, that need to be present for rice to have stale or rancid flavor have not been established. Only one compound, 2- acetyl-l-pyrroline (2-AP; popcorn aroma) has been confirmed to contribute a characteristic aroma. Furthermore, 2-AP is the only volatile compound in which the relationship between its concentration in rice and sensory intensity has been established. This article discusses the challenges of measuring aroma and flavor instrumentally and by human sensory panels and reviews research examining the effects of genetic, preharvest, and postharvest factors on volatile compound profiles and the aroma and flavor of cooked rice.

Rice is an important provider of nourishment for the world’s population. Unlike most food crops, rice is generally eaten whole without seasoning, making the sensory properties of the rice grain itself important. Small variations in sensory properties, especially aroma, can make rice highly desired by or unacceptable to consumers (Yau and Liu 1999). Consequently, aroma and flavor have been rated as the major criteria for preference among consumers (Del Mundo and Juliano 1981).

There has been a quest for >30 years to understand how genetic, preharvest (e.g., environment, cultural methods), and postharvest (e.g., drying, milling, storage, cooking method) factors affect the aroma and flavor of cooked rice and to relate these effects to the numerous volatile compounds in rice. The desired outcome is to identify important marker compounds that will allow preharvest and postharvest strategies to be enacted to assure that cooked rice will have the expected aroma and flavor. Most researchers have taken the approach of correlating preharvest and postharvest variables with changes in volatile compounds and have drawn conclusions as to which compounds possibly affect aroma and flavor based on concentration or aroma value (AV). Few have conducted preference or descriptive sensory analyses with concurrent volatile analyses. The result is that, with the exception of 2-acetyl-l-pyrroline (popcorn aroma), no single marker compound has been identified to allow monitoring and control of preharvest and postharvest factors that affect aroma and flavor. This article will focus on the challenges of measuring rice aroma and flavor and using these measures to understand what effects these sensory properties in cooked rice.

ISOLATING AND QUANTIFYING VOLATILE COMPOUNDS

Methods for the determination of the volatile compounds in rice have schemes for collection, concentration, separation, and quantification. Traditional methods have involved static headspace, purge and trap, steam distillation-solvent extraction (including simultaneous distillation/extraction), and direct solvent extraction for collection/concentration (Reineccius 2006). Separation is by gas chromatography (GC) with flame ionization or mass spectrometer (MS) as detector. The GC effluent to the MS can be split with a portion going to a sniffer port for human detection. Vogue since introduction in the mid 1990s (Yang et al 1994; Steffen et al 1996) has been collection of rice volatile compounds using solid-phase microextraction (SPME) followed by GC-MS (Grimm et al 2001; Lam and Proctor 2003; Wongpornchai et al 2004; Champagne et al 2004b, 2005; Zheng et al 2007). In this technique, an inert fiber coated with an adsorbent is placed in the headspace above a rice sample and allowed to adsorb volatile compounds. The fiber containing the adsorbed volatile compounds is then thermally desorbed into a GC carrier gas flow.

The number and amount of volatile compounds isolated from rice are method dependent. In static headspace analyses using a gas- tight syringe for collection, only the most abundant volatile compounds (>10^sup -7^ g/L) are detectable. In purge and trap methods, the compounds with the highest vapor pressure are preferentially removed and, of these, the compounds trapped on Tenax depend on their polarity. Tenax has low adsorption capacity and a low affinity for polar compounds and a high affinity for nonpolar compounds (Reineccius 2006). In steam distillation-solvent extraction, the volatile profile obtained is influenced by volatility of the aroma compounds (initial isolation), solubility during solvent extraction of the distillate, and volatility again during the concentration of the solvent extract (Reineccius 2006). In simultaneous distillation/extraction, the prepared aroma isolate contains nearly all the volatile compounds in rice; however, their proportions may poorly represent the true profile. In direct solvent extraction, recoveries of volatile compounds depend on the solvent chosen.

The number and amount of volatile compounds isolated from rice also depend on how the sample is prepared. The volatile profile of cooked rice differs from that of uncooked rice; the profile of flour differs from that of intact grains. Higher amounts of lipid oxidation products are observed in flour compared with intact grains. This may be a matrix effect or due to accelerated oxidation. The composition of the headspace of rice can be readily changed by the addition of water and temperature. For targeted analysis, such as 2-acetyl-l-pyrroline (2-AP), the addition of a small amount of water is advantageous, whereas for other compounds the addition of water may suppress recovery (Grimm et al 2002). The addition of water can further complicate analysis because it can induce enzymatic action, leading to increases in volatile compounds.

Quantification is difficult with the described methods. In headspace methods, the data obtained reflects the amount of volatile compounds in the headspace which is influenced by the food matrix. Interactions between volatile compounds and starch matrices may increase retention (Arvisenet et al 2002; Boutboul et al 2002; Jouquand et al 2006). In particular, the linear amylose of starch is able to form inclusion complexes with a wide variety of volatile compounds that may affect the intensity of perceived aromas. Interactions of aroma compounds with lipids and proteins also affect their volatility.

Quantifying 2-AP and Distinguishing Fragrant and Nonfragrant Cultivars

The high demand for fragrant rice cultivars in markets worldwide has driven the development of methods for quantifying 2-AP and distinguishing fragrant and nonfragrant cultivars. Fragrant rice cultivars contain

Purge and trap (Buttery et al 1988), simultaneous steam distillation-solvent extraction (Buttery et al 1986; Lin et al 1990; Petrov et al 1996; Widjaja et al 1996; Tava and Bocchi 1999; Mahatheeranont et al 2001), microsteam distillation-solvent extraction (Tanchotikul and Hsieh 1991), direct solvent extraction (Fushimi et al 1996; Bergman et al 2000; Mahatheeranont et al 2001; Itani et al 2004), SPME (Grimm et al 2001; Wongpornchai et al 2004), and static headspace (Sriseadka et al 2006) have been used for the isolation and concentration of 2-AP from rice samples. The long extraction time in steam distillation-solvent extraction methods, and thus low sample throughput per day, makes them impractical for use in breeding programs. The extraction method developed by Bergman et al (2000) requires only 0.3 g of brown or milled rice, a 2.5 hr extraction in methylene chloride at 850C, and a 25-min GC run allowing 50 samples to be analyzed per day. One extraction solubilized

Identification of the fragrance gene and a molecular marker for detecting it led to the development of a PCR assay for fragrance genotyping (Bradbury et al 2005). The allele specific amplification (ASA) technique allows discrimination between fragrant cultivars that carry the 8-bp deletion and those without. An alternative method for rapid discrimination of fragrant and nonfragrant cultivars is by SPME/MS coupled with SIMCA statistical analysis (Laguerre et al 2007). 2-AP, pyridine, 2-acetylpyrrole, and an unidentified fragment (145 m/z) contributed to the discriminating fingerprint. Laguerre et al (2007) concluded that pyridine and 2- acetyl-pyrrole may serve as indirect indicators of aroma. The odor thresholds for these compounds are too high to play significant roles in rice aroma.

Identifying Volatile Compounds Affecting Rice Aroma and Flavor

A large number of compounds contribute to the aroma and flavor of rice. However, of the >200 volatile compounds observed in rice, only a few have been identified as affecting the aroma and flavor of cooked rice. Determining which volatile compounds are responsible for the perceived aroma/flavor of rice is a difficult task. With the exception of 2-AP (popcorn aroma), no one single compound can be said to contribute a characteristic aroma. Additionally, perceived aroma/flavor is not strictly additive but may result from interactions of several volatile compounds. Several researchers (Buttery et al 1988; Jezussek et al 2002; Lam and Proctor 2003) have taken methodical approaches to determining which of the numerous volatile compounds in rice are candidates as important contributors to its aroma and flavor. Buttery et al (1988) and Lam and Proctor (2003) calculated and compared aroma values (AV) to determine which lipid oxidation products are likely contributors to off-flavor. The higher the ratio of a volatile compound concentration to its odor threshold (AV), the more probable that the compound will contribute to the overall aroma or flavor of rice. Buttery et al (1988) found that the aldehydes (E)2-nonenal (threshold [T] = 0.08 ppb) and (E,E)- 2,4-decadienal (T = 0.07 ppb) had the lowest odor threshold and, considering the amounts in rice, were considered to likely contribute to the aroma. Other aldehydes with relatively low thresholds that are also likely to contribute were (E)-2-decenal (T = 0.4 ppb), octanal (T ? 0.7 ppb), nonanal (T = 1 ppb), and decanal (T = 2 ppb). Lam and Proctor (2003) concluded, based on AV, that hexanal (grassy flavor) and 2-pentylfuran (beany) probably contributed more to flavor change in milled rice early in storage rather than later. 2Nonenal (rancid flavor) and octanal (fatty flavor) contributed more to the overall flavor of milled rice during long-term storage.

The approach of calculating and comparing AV has been extended to a screening method referred to as aroma extract dilution analysis (AEDA) in which the volatile components in serial dilutions of a rice extract are evaluated by gas chromatography/ olfactometry. The greater the number of dilutions a volatile compound is sensed, the higher its dilution value (DV), which would correspond with AV. Jezussek et al (2002) used this method to identify 41 odor-active compounds in cooked brown rice. Among newly identified constituents, 2-amino acetophenone (medicinal, phenolic) had the highest DV and was concluded to be an important odorant. The previously unknown rice aroma compound 3-hydroxy4,5-dimethyl-2(5H) furanone (Sotolon; seasoning-like) differed in DV among the cultivars. Table I lists olfactory-active volatile compounds identified in rice that may affect aroma and flavor.

Another approach for determining which volatile compounds are important contributors to aroma and flavor or serve as markers for sensory quality has been through examining how genetic, preharvest, and postharvest factors affect formation and concentration and subsequently the aroma and flavor of the rice. Following this approach, a degree of success has been achieved in determining which lipid oxidation products may be likely contributors to the off- flavor of stale rice. As discussed above, Buttery et al (1988) and Lam and Proctor (2003) identified key oxidation products based on the increase during storage and AV. However, researchers have not discerned at what level particular lipid oxidation products need to be present to result in stale aromas and flavor.

A side-by-side comparison of odor-active compounds in rice with those in other grains has not been published. Hougen et al ( 1 97 1 ) noted that different grains commonly have similar volatile compound profiles but in different concentrations. This is observed particularly for oxidation products, which, as in rice, are also important contributors to aroma and flavor in other grains. For example, oxidation products l-octen-3-ol, 3-methylbutanal, 2- methylbutanal, hexanal, 2-hexenal, 2-heptenal, 2-nonenal, and decanal were identified as key aroma compounds in 12 barley cultivars based on odor thresholds in water (Cramer et al 2005). In wholemeal and white wheat flour, (E)-2-nonenal, (E,Z)-and (E,E)-2,4- decadienal, 4,5-epoxy-(E)-2-decenal, and 3-hydroxy-4,5-dimethyl- 2(5H)-furanone were odor-active based on AEDA (Czerny and Schieberle 2002). Most of these compounds are also odor-active in rice. Of interest would be to determine the qualitative and quantitative composition differences in odor-active compounds that differentiate the sensory properties of rice from other grains. Such a comparison has been reported for the rye and wheat flour (Czemy and Schieberle 2002; Kirchhoff and Scieberle 2002).

The search for understanding the composition of fragrant rices and how it differs from nonfragrant cultivars has been through comparisons of volatile profiles. Buttery et al (1982, 1983) reported 2-AP to be the volatile compound defining the characteristic popcorn aroma of fragrant rice. Only fragrant rice cultivars possess the genetic potential (Lorieux et al 1996; Bradbury et al 2005) for accumulating 2-AP. Hussain et al (1987) compared the volatile profiles of an aromatic Basmati rice with a nonfragrant rice. More pentadecan-2-one, hexanol, and 2-pentylfuran were found in the Basmati rice. In another comparison, Petrov et al (1996) found nine compounds to discriminate fragrant and nonfragrant rice: pentanol, hexanol, 2-AP, (E)-hept-2-enal, benzaldehyde, octanal, pentadecan-2-one, 6, 10, 14-trimethyl-pentadecan-2-one, and hexadecanol. However, based on AV, only 2-AP would be olfactory- discriminant. Widjaja et al (1996), in a comparative study of nonfragrant and fragrant rice, found nonfragrant rice contained much more n-hexanal, (E)-2-heptenal, l-octen-3-ol, n-nonanal, (E)-2- octenal, (E)-2, (E)-4-decadienal, 2-pentylfuran, 4-vinylguaiacol, and 4-vinylphenol, than the four fragrant rices. In these three studies, oxidation products were identified as discriminants. However, the preharvest and postharvest growing/handling of nonfragrant and fragrant rices were not the same for the two rice types in these studies. Therefore, the predominance of lipid oxidation products in one type may have been due to growing/ handling differences and not whether or not it was fragrant. Comparison studies need to be conducted on larger sets of fragrant and nonfragrant cultivars grown under identical conditions and handled identically postharvest.

TABLE I

Olfactory-Active (AV or FD > 1) Volatile Compounds Identified in Rice That May Affect Aroma and Flavor”

A new approach was taken by Laguerre et al (2007) to identify volatile compounds that differentiate the aroma of 61 rice cultivars (29 fragrant and 32 nonfragrant). Of particular interest, was determining compounds contributing to the diversity of aroma encountered in fragrant rices. It is unlikely that 2-AP is the only compound that contributes to the unique aroma of these rices. Their method used SPME for volatile collection coupled directly with mass spectrometry with no chromatography for selection. No differentiating compounds, other than 2-AP, were found in the fingerprints with odor thresholds low enough to contribute to rice aroma.

Tava and Bocchi (1999) also observed through a comparison of fragrant cultivars that the only differences were in contents of 2AP and lipid oxidation products, with the latter being ascribed to differences in postharvest handling.

In conclusion, other than lipid oxidation products and 2-AP, researchers have not been successful in conclusively identifying specific volatile compounds or classes of compounds that contribute to other desirable or undesirable aroma or flavor attributes in rice.

SENSORY ANALYSIS OF AROMA AND FLAVOR

The aroma of rice is detected when its volatile compounds enter the nasal passage and are perceived by the millions of tiny, hair- like cilia that cover the epithelium located in the roof of the nasal cavity (Meilgaard et al 2007). The sensitivity of receptors to different volatile compounds varies over a range of >10^sup 12^ (Harper 1972; Meilgaard 1975). Generally there is only a 100-fold difference between the threshold (minimum detectable level) and concentration that produces saturation of the receptors. A good perfumer can differentiate 150-200 odorous qualities (Meilgaard et al 2007). Rice aroma is typically described by trained panelists using a lexicon with 10-12 descriptors.

Flavor is the impression perceived through the chemical senses from a product in the mouth (Caul 1957). According to Meilgaard et al (2007), when defined in this manner, flavor includes aromatics (olfactory perceptions caused by volatile substances released from a product in the mouth through the posterior nares); tastes (gustatory perceptions [salty, sweet, sour, bitter] caused by soluble substances in the mouth); chemical feeling factors that stimulate nerve ends in the soft membranes of the buccal and nasal cavities (astringency, spice heat, cooling, bite, metallic flavor, umami taste).

The aroma and flavor of rice can be characterized and analytically measured by panelists trained in descriptive sensory analysis (Meilgaard et al 2007). Descriptive analysis is useful in evaluating sensory changes over time with respect to preharvest and postharvest conditions and shelf life (Meilgaard et al 2007). Combined use of descriptive and preference sensory panels can provide accurate assessment and identify quality characteristics desired by various markets. Descriptive scores can also be correlated to volatile compound concentrations using various statistical methods to determine which compounds are responsible for perceived aroma and flavor or serve as markers for these attributes. Some researchers have developed statistical correlations based primarily on linear regression (Bett and Boylston 1992), while others have used multivariate statistics to correlate two sets (or more) of measurements. Multivariate statistical analysis (multiple linear regression, principle component analysis, and partial least squares) allows for the integration of all the individual volatile compounds in a mixture to be related to sensory responses (Meilgaard et al 2007). The advantage of this approach is that it more accurately models the synergistic and interactive nature of flavor and nonflavor active components that produce the total sensory impression. The disadvantage is that some components may be chosen for the flavor model only because they were highly correlated but not causative agents (Nobler and Ebler 2002). To eliminate this problem, researchers have developed models from only those compounds shown to be flavor active from gas chromatography-olfactometry (GC- O) (Luning et al 1994; van Ruth and Roozen 1994).

Following the principles and concepts of descriptive sensory analysis, lexicons for aroma and flavor are developed by having a panel rigorously evaluate various rice samples to identify and describe the aroma and flavor. References are established and the panel uses them to come to consensus on the definitions of the descriptors. As described by Goodwin et al (1996), a rice aroma/ flavor lexicon was developed in the early 1990s by panelists at the Sensory Analysis Center of Kansas State University. The trained descriptive panel at the USDA ARS Southern Regional Research Center uses this lexicon to evaluate rice aroma and flavor. Similar rice lexicons were developed by Meullenet et al (1999, 2000) and Park et al (2001). Figure 1 lists the aroma and flavor descriptors, the definitions, and references as developed by Goodwin et al (1996), Meullenet et al (1999, 2000), and Park et al (2001). Other groups have developed lexicons that contain these and other descriptors. Piggott et al (1991) recruited 18 Malyasian students to develop descriptors for aroma and flavor of undermilled and well-milled rice. The resulting descriptors developed were fragrant, pungent, sour, smooth, sweet, sulphury, muddy, earthy, bread-like, hay-like, buttery, nutty, coconut, oily grassy, mouldy, and musty. The descriptive panelists trained by Yau and Liu (1999) described 11 attributes in cooked rice defined by raw and cooked grains: cold- steam bread aroma, hot-steam-bread aroma, raw-dough aroma, rice- milk aroma, corn aroma, corn-leaf aroma, pear-barley aroma, burnt aroma (dried baked rice), stale aroma (raw flour), fermented-sour aroma (fermented dough), and brown rice aroma.

Using descriptive analysis, the intensity of each descriptor is scored by the panelists. The choice of scale and references used to rate intensities is particularly important in rice, where aroma and flavor differences can be small. The spectrum descriptive analysis method uses a universal scale for all foods (Meilgaard et al 2007). Champagne et al (2004, 2005) and Meullenet et al (1999) have employed this scale in their research programs. The scale is 0-15 with flavor components of U.S. name brand products with defined intensities. For example, the soda flavor in Nabisco saltine crackers has an intensity rating of 2; the grape flavor of Kool-Aid has a rating of 4.5. With the absolute values on this scale, sensory intensities can be compared even if testing dates are spread over a long period of time. The maximum rating for rice aroma/flavor descriptors is generally >>5 when this scale is used. Most rice descriptors, however, have intensity ratings in the 1-3 range. This is problematic if panelist use integers (whole numbers) to rate the intensities. This leads to large standard deviations, and therefore significant differences are not observed. The established universal scale does not have enough reference points between integers to allow panelists to be more precise with their ratings. Of value for the world rice community would be to develop additional low intensity references for the universal scale.

FACTORS AFFECTING RICE AROMA AND FLAVOR

Genetics

Fragrance in rice has been shown to be due to an eight-base pair deletion in exon 7 of a gene on chromosome 8 (Lorieux et al 1996; Jin et al 2003; Chen et al 2006) that encodes a putative betaine aldehyde dehydrogenase 2 (BAD2) (Bradbury et al 2005). This deletion results in a loss of function of the encoded enzyme and, consequently, 2-AP accumulates in fragrant cultivars.

Recently, Fitzgerald et al (2008) analyzed 464 samples recorded as fragrant from the Genetic Resources Center of the International Rice Research Institute (IRRI). A number of these cultivars, primarily from South and Southeast Asia, did not carry the 8-bp deletion even though they contained 2-AP. After eliminating the possibility of a Maillard reaction product, the authors concluded that the 8-bp deletion in the fragrance allele is not the only cause of aroma, and that at least one other mutation drives the accumulation of 2-AP.

Preharvest

Environment, fertilization, and cultural practices affect the amylose and protein contents of rice cultivars which in turn may influence the aroma and flavor of the cooked rice. Low protein rice samples of the same cultivar are reported to be more flavorful than those with higher protein (Juliano et al 1965). This observation was corroborated by two descriptive sensory panels (Park et al 200 1 ; Champagne et al 2004), who found rice with lower protein content to have higher levels of desirable sweet aroma/taste and lower levels of undesirable flavor attributes. In 17 diverse cultivars grown over two crop years in one location, hay-like and sweet aromatic flavors were significantly (P

Other studies did not find a relationship between protein content and aroma or flavor. In a recent study by Champagne et al (2007), the aroma and flavor of five diverse cultivars grown conventionally with 50 and 100% of the typically used nitrogen rate and with chicken litter using organic management were compared. The low protein (mean 7.7% with organic management; 7.5% with 50% N rate) rice samples did not differ in aroma or flavor from those with higher protein (mean 9.2% with 100% N rate). In support of this finding, Terao et al (2005) found that growing the rice cultivar Akitakomachi under elevated CO2 concentration decreased the protein content but did not change the sensory properties to a level the could be detected by taste panel evaluation.

Fig. 1. Descriptive sensory analysis attributes and definitions used to evaluate cooked rice aroma and flavor.

Amylose content, the most important determinant of cooked rice texture, correlated highly and negatively (P

The concentration of 2-AP varies with environmental conditions. The 2-AP concentration was higher in brown rice ripened at a low temperature (day 250C; night 2O0C) than that ripened at a high temperature (day 35 0C; night 30[degrees]C) in both short-grain cultivar Hieri and long-grain cultivar Sari (Itani et al 2004).

Drain and Harvest Dates

Timing of field draining and harvesting of rice with consideration of physiological maturity, moisture content, and meteorological conditions can allow growers to foster conditions for high head rice yield. However, there may be a trade-off in flavor. Draining fields early may cause moisture stress in grains before they are physiologically mature, affecting metabolic processes and, in turn, volatile flavor compounds. Harvesting early at higher moisture contents, while improving head rice yield (Kester et al 1963), may lead to problematic microbial growth with associated off- flavor metabolites if drying is delayed (Champagne et al 2004b). In a study to determine the effects of varying drain and harvest dates on rice sensory properties, M-202, the predominant cultivar produced in California, demonstrated stable flavor with timing of field draining (14-day span) and harvesting (32-48 days after flowering) (Champagne et al 2005). The lowest levels of lipid oxidation products 1-pentanol, hexanal, and nonanal occurred in rice with the lowest harvest moisture content. However, differences in levels of lipid oxidation products did not lead to significant (P > 0.05) differences in flavor.

Rice cultivar IR42 was harvested at seven times 20-38 days after 50% flowering (Marzempi et al 1990). With increase in harvesting time, amylose and protein content increased. Aroma and flavor decreased with maturity, with the best flavor found at 20 days after 50% flowering. Arai and Itani (2000) found that when rice was harvested 10 days before the ordinary time of harvesting (42 days after heading), the cooked rice was sweeter and more “delicious.” Tamaki et al (1989) also found flavor declined with maturity. Playing a role in the flavor of rice, the amount of free amino acids in the exterior of cooked rice declined continuously with maturation. Flavor was considered to be rich in immature rice but poor in over-ripened rice. The influence of harvest time during ripening on the 2-AP concentration in two cultivars was examined (Itani et al 2004). During grain development in an early-heading cultivar, the 2-AP concentration in the brown rice reached a peak at four or five weeks after heading (WAH) and then decreased rapidly to 20% of the maximum at seven or eight WAH. In a late-heading cultivar, the 2-AP concentration peaked at four WAH then gradually decreased to 40% of the maximum at eight WAH.

Harvest Moisture Content

Between harvest and the start of drying, paddy may be held for more than 24 hr at moisture contents from 16 to >26%. Microbes found on the freshly harvested rice grow under these conditions and may produce volatile compounds that affect the flavor or aroma of the white rice obtained after drying and milling. A comparison was made of the contents of 10 volatile microbial metabolites in white rice obtained from paddy (cvs. M-202 and Akitakomachi) harvested at differing moisture contents and immediately dried or held for 48 hr before drying (Champagne et al 2005). No increases in volatile microbial metabolite levels were observed in white rice obtained from paddy rice that was stored at 17-21% moisture contents for 48 hr. No changes in the intensities of the flavor attributes were observed. This was in agreement with the observations of Meullenet et al (1999). Wet holding of rice harvested at 20.5% moisture for 86 hr did not significantly affect starch note (grain flavor), cardboard note (stale), sulfur note (off-note), or overall flavor impact. In white rice from paddy rice stored at >24% moisture content, 3-methyl-butanol, 2-methylbutanol, acetic acid, 2,3- butandiol, and ethyl hexadecanoate increased markedly with time (Champagne et al 2005). Also, in these samples, as determined by a descriptive panel, sour/silage and alfalfa/grassy/green bean flavors significantly increased (P

Rough Rice Drying Conditions, Final Moisture Content, and Storage Conditions

Meullenet et al (1999) examined the effects of rough rice drying conditions on the starch note (grain flavor), cardboard note (stale), sulfur note (off-note), and overall flavor impact. Drying treatment (high 54.3[degrees]C and 21.9%rh and low 33[degrees]C and 67.8% rh) did not significantly affect these flavor notes in cooked rice before storage. Likewise, Champagne et al (1997) observed no trends indicating an increase or decrease in flavor attributes with increased drying temperatures (18-600C). Higher levels of the aroma compound 2-AP and lower levels of off-flavor compounds, such as 2- pentylfuran and n-hexanal, were obtained at lower drying temperatures when rice was dried by sun, in modified air (at 30- 40[degrees]C), and in hot air (at 40, 50, and 700C) (Wongpornchai et al 2004). In contrast, Sunthonvit et al (2005) reported that 2-AP tended to increase in concentration with increasing drying temperature from 100 to 1500C.

Intensities of desirable and undesirable flavor attributes were higher in rice dried to 15% moisture compared with 12% moisture (Champagne et al 1997).

The temperature and time rough rice is stored can affect the aroma and flavor of the white rice obtained from it upon milling. Rice dried at 43.40C and 38.2% rh was allowed to equilibrate in air- controlled chambers until reaching moisture contents of 10, 13, and 14% and stored at 4, 21, and 380C for 0, 6, 12, 24, and 36 weeks (Meullenet et al 2000). At each storage temperature, sulfur notes increased with storage time; the increase was slight at the highest storage temperature (Meullenet et al 2000). In an earlier study, however, Meullenet et al (1999) observed a significant decrease in sulfury notes after 20 weeks over the same storage temperatures (4, 21, 38[degrees]C). In both studies, sulfur notes significantly decreased as storage temperature increased from 4 to 38[degrees]C. Sulfur compounds were probably volatilized at a higher rate as temperature increased (Meullenet et al 1999). Cardboard notes, an indicator of slightly oxidized fats and oils, increased with storage duration and storage temperature (Meullenet et al 1999, 2000). Starchy aroma notes decreased with increasing storage duration (Meullenet et al 2000). Grainy notes consistently decreased with time for the first 25 weeks of storage and increased during subsequent storage (Meullenet et al 2000). The panelists may have perceived off-flavors developing during storage as grainy notes. Cardboard notes, an indicator of slightly oxidized fats and oils, increased with storage duration and storage temperature.

Drying rice at high temperature lowered 2-AP concentrations (Itani and Fushimi 1996). Regardless of drying method (sundried, modified air at 30 or 400C, hot air at 40, 50, or 700C), 2-AP decreased during 10 months storage for rough rice, with the highest rate of decrease at the beginning of storage (Wongpornchai et al 2004). The average concentration of 2-AP of all of the rice samples subjected to the six different drying methods after one month storage (4.02 + 0.60 ppm) was slightly more than double that after four months (1.88 + 0.27 ppm) and more than four times that after 10 months of storage (0.89 + 0.12 ppm). In another study, 2-AP in stored rice was about half that of a fresh rice sample (Laksanalamai and Ilangantileke 1993).

Degree of Milling

The aroma of milled rice differs with the degree of milling. Four types of rice milled to different degrees (92, 85, 75, and 50% milled rice) were subjected to odor evaluation. Significant differences in odor of cooked rice and in quantity of volatile components between 92% milled rice and 85, 75, and 50% of milling were observed (Tsugita et al 1980). Higher concentrations of lipid oxidation products in the 92% milled rice compared with levels in deeper milled rice was probably because these products were contained in residual bran on the surface of the 92% milled rice.

Puffed corn flavor, raw rice flavor, wet cardboard flavor, hay- like flavor, and bitter taste were lower, while sweet taste was higher with increased milling from 8 to 14% (Park et al 2001). Samples milled 6% were more sour, less smooth (mouthfeel), more pungent, less smooth (aroma), and had less sweet taste than those milled at 8.8% (Piggott et al 1991). Champagne et al (1997) found the effects of degree of milling on flavor attribute intensities to be dependent on moisture content and cultivar or location.

Milled Rice Storage Temperature and Time

Milled rice develops stale or “komai-shu” flavor during storage. During storage, surface lipids undergo hydrolysis to form free fatty acids that are susceptible to oxidation (Yasumatsu and Moritaka 1964). Lipase of residual bran on the surface of the milled rice will contribute to the formation of these free fatty acids. Additionally, oxidation of unsaturated fatty acids, particularly linoleic and linolenic acids, proceeds with the eventual formation of various secondary oxidation products such as aldehydes, ketones, alcohols, furanones, acids, lactones, and hydrocarbons that are ultimately responsible for the development of off-flavors and odors (Yamamatsu et al 1966; Grosch 1987). The milling process accelerates the process by disrupting cells, releasing lipoxygenase.

Numerous researchers (Tsugita et al 1983; Piggott et al 1991; Tsrai 1995; Widjaja et al 1996; Lam and Proctor 2003; Tran et al 2005) have examined the effects of different storage conditions on volatile components and flavor properties. GC analyses of the volatiles of cooked rice showed that a larger amount of pentanal, hexanal, heptanal, alkenals, ketones, 2-pentylfuran, 4-vinylphenol, and a smaller amount of 1-pentanol and 1-hexanol was found in milled rice stored for 60 days at 4O0C compared with rice stored 4[degrees]C (Tsugita et al 1983). These authors found that 4- vinylphenol has a characteristic off-flavor and may partly contribute to the offflavor of cooked old rice (Fujimaki et al 1977). Widjaja et al (1996) found an increase in levels of most of the carbonyl compounds and in n-pentanol, 2-pentylfuran, l-octen-3- ol, and 4 vinylguaiacol in milled rice stored for three months at 30[degrees]C. (E)-22, (E)-4-Decadienal, identified earlier by the authors as an important contributor to the character of fragrant rice flavor, also increased in concentration with storage. This compound imparts a desirable flavor at relatively low levels and a distinct rancid aroma at higher concentrations. In a more recent study (Lam and Proctor 2003), the concentrations of 2-nonenal, hexanal, and octanal increased during storage (370C, 70% rh) and remained high during the 50day time frame. The concentrations of heptanal, 2-pentylfuran, and 3-penten-2-one remained low. As discussed earlier, the authors concluded, based on aroma values (AV) that hexanal (grassy flavor) and 2-pentylfuran (beany) probably contributed more to flavor change in milled rice early in storage rather than later. 2Nonenal (rancid flavor) and octanal (fatty flavor) contributed more to the overall flavor of milled rice during long-term storage.

Hydrogen disulfide (H2S) is an indispensable component of cooked rice aroma and it is thought that H2S is generated from the sulphydryl groups of proteins. The amount of H2S in the volatiles of cooked rice was higher in rice stored at 50C than in rice stored at 4O0C (Moritaka and Yasumatsu 1972). Sugars such as glucose and sucrose, and amino acids such as glutamic acid and aspartic acid, are the main components that affect the sweetness and umami tastes of rice (Fukui and Nikuni 1959; Tajima et al 1992; Saikusa et al 1994; Kasai et al 2001). The sweetness (sucrose) and umami tastes of rice were reduced during storage, whereas glucose and fructose increased (Tran et al 2005). Rice content of 2-AP decreased 40-50% in all forms of rice (paddy, brown, white), irrespective of whether three-month storage was in air or under partial vacuum (Widjaja et al 1996). 2-AP content decreased faster at higher storage temperature (Yoshihashi et al 2005). Fat acidity of rice increased during storage and was inversely correlated with 2-AP content at an early stage of storage. Packaging material moderately affected preservation of 2-AP.

The effects of storage on the flavor of undermilled and wellmilled rice were determined by a descriptive panel (Piggott et al 1991). Samples stored at 30[degrees]C had higher scores for pungent, oily, moldy/musty, sour (taste), bitter, sour (aroma), and muddy/ earthy, while those stored at -20[degrees]C had higher scores for sweet (taste), fragrant, smooth (aroma), sweet (aroma), grassy, and smooth (mouthfeel). Scores for oily and starchy (mouthfeel), fragrant, smooth (aroma), and muddy/earthy increased with storage time. Both the under-milled and well-milled samples underwent these changes during storage at 30[degrees]C but they were greater for the under-milled rice. Free fatty acids (FFA) formed a greater proportion of the total surface lipid in the under-milled than in the wellmilled samples for the high-temperature stored samples. Storage at -20[degrees]C completely suppressed this increase in FFA. Hexanal and carbonyls followed the same trend as the FFA.

Washing

Rice that had been washed three times showed less deterioration in flavor during holding of the cooked rice for up to 24 hr than for rice washed once (Fukai and Tukada 2006). Monsoor and Proctor (2002) demonstrated that >>60-80% of total surface lipids were removed by water washing, with a reduction of free fatty acid and conjugated dienes relative to unwashed control samples. The total surface free fatty acid content of first-, second-, and third-break milled rice was reduced by >50% of the original value by washing. Increases in free fatty acids and conjugated dienes in washed rice after seven days storage at 37[degrees]C and 70% rh were much lower than those of unwashed controls. Water washing may be a practical means of reducing off-flavor development in milled rice (Monsoor and Proctor 2002).

Soaking

Water soaking for >30 min before cooking is a traditional practice in Japan, Korea, and other Asian countries. Soaking facilitates uniform cooking and shortens gelatinization time. Soaking also leads to chemical changes in the grain that could affect the aroma and flavor of the rice. A considerable amount of oligosaccharides are formed through activation of amylases in the outer layers (510% of the milled kernel) during soaking (Tajima et al 1992). Water soaking of flours prepared from outer layers of milled kernels also led to increases in most free amino acids (Saikusa et al 1994). Contents of free sugars and free amino acids are believed to play a role in the flavor of cooked rice by influencing sweetness and umami (Matuzaki et al 1992; Tajima et al 1992; Tamaki et al 1993; Saikusa et al 1994; Tran et al 2005).

Recently a study was undertaken to determine the effects of presoaking on the flavor of cooked rice and whether flavor differences are associated with textural changes that could influence retention of the aroma compounds (Champagne et al, in press). Eleven samples of short-, medium-, and long-grain milled rice representing scented and nonscented rice and a wide range of amylose contents were presented to a descriptive sensory panel. For the set of all rice samples, undesirable sewer/animal flavor significantly increased and sweet taste significantly decreased with presoaking for 30 min. Presoaking also resulted in significant increases in summed negative flavor attributes and significant decreases in summed positive flavor attributes for the set of all rice samples. The effects of presoaking on texture, as measured by TPA hardness and chewiness, did not explain the observed increases in negative flavor attributes. An increase in free-sulfurcontaining free amino acids with presoaking could have resulted in an increase of their breakdown products, thereby contributing to the increase in sewer/animal flavor. The decreases in sweet taste and summed positive flavor attributes were likely the result of masking caused by the increases in sewer/animal and summed negative flavor attributes.

Cooking Method

Methods for cooking rice include the excess water to optimum cooking time method (Excess method), rice cooker optimum water method (Pilaff method), and steaming (Juliano 2003). In a comparison of the Excess and Pilaff methods, a consumer panel found rice cooked by the Pilaf method had more acceptable flavor than excess cooking (Crowhurst and Creed 2001). Possibly flavor compounds were lost during draining following cooking using the Excess method.

Influence of Water-to-Rice Ratio on Cooked Rice Flavor

The water-to-rice ratio used in the Pilaff method did not significantly affect flavor attributes across all cultivars (Bett- Garber et al 2007).

Serving Temperature of Cooked Rice

Yau and Huang (1996) found that the aroma of cooked rice would change with serving temperatures and that aroma should be the summation or mixture of specific attributes. In a follow-up study, Yau and Liu (1999) found that there was no clear temperature effect trend for all rice samples. In terms of total volatile content (TVC), TC Sen 10 contained higher TVC at 60[degrees]C, TNu 67 at 25[degrees]C, and TC 189 and TNu 70 at 18[degrees]C. Temperature affected the contents of certain compounds of individual cultivars differently. Aromas for samples held at 60[degrees]C were higher for hot steam bread, corn, corn-leaf, and brown rice, while 18[degrees]C samples were higher in cold-steam bread and fermented-sour aromas. In another study (Liu et al 1996), aroma of cooked samples of four cultivars was evaluated at 18 and 60[degrees]C using modified descriptive analysis. Sweet, earthy, burnt rice, rancid, acid, moldy, and sulfur attributes were assessed. Samples evaluated at 18[degrees]C rated higher in sweetness, while samples evaluated at 60[degrees]C scored higher in earthy, burnt rice, rancid, moldy, and sulfur.

CONCLUSIONS

Descriptive sensory analysis has identified over a dozen different aromas and flavors in rice. Instrumental analyses have found over 200 volatile compounds present in rice. Among these compounds, possible contributors to rice aroma and flavor have been identified through determination of AV or DV. A number of oxidation products have thus been tagged as likely causing stale flavor. However, the amounts of oxidation products, singly or collectively, that need to be present for rice to have stale or rancid flavor have not been established. Only one compound, 2-AP (popcorn aroma) has been confirmed to contribute a characteristic aroma. Furthermore, 2- AP is the only volatile compound in which the relationship between its concentration in rice and sensory intensity has been established (Itani et al 2004).

Despite 30 years of research, still little is known about the relationships between the numerous volatile compounds and aroma/ flavor. A knowledge-base for predicting how preharvest and postharvest factors will affect the levels of these volatile compounds and consequently aroma and flavor is lacking. Research is still needed to identify important marker compounds that will allow preharvest and postharvest strategies to be enacted to assure that cooked rice will have desired aroma and flavor.

Cereal Chem. 85(4):445-454

LITERATURE CITED

Akbar, A., Arshed, K., Liaquat, A., Shahid, A. S., and Abdul, M. 1993. Effect of transplanting date on grain quality in fine-grain varieties/ strains. Pakistan. J. Sci. 45:64-69.

Arai, E., and Itani, T. 2000. Effects of early harvesting of grains on taste characteristics of cooked rice. Food Sci. Technol. Res. 6:252-256.

Arvisenet, G, Le Bail, P., Voilley, A., and Cayot, N. 2002. Influence of physicochemical interactions between amylose and aroma compounds on the retention of aroma in food-like matrices. J. Agrie. Food Chem. 50:7088-7093.

Bergman, C. J., Delgado, J. T., Bryant, R., Grimm, C, Cadwallader, K. R., and Webb, B. D. 2000. Rapid gas chromatographic technique for quantifying 2-acetyl-l-pyrroline and hexanal in rice (Oryza sativa, L.) Cereal Chem. 77:454-458.

Bett, K. L., and Boylston, T. D. 1992. Effect of storage on roasted peanut quality. Pages 322-343 in: Lipid Oxidation in Foods. A. J. St. Angel, ed. ACS: Washington, DC.

Bett-Garber, K. L., Champagne, E. T, Ingram, D. A., and McClung, A. M. 2007. Influence of water to rice ratio on cooked rice flavor and texture. Cereal Chem. 84:614-619.

Boutboul, A., Giampaoli, P., Feigenbaum, ?., and Ducruet, V. 2002. Influence of the nature and treatment of starch on aroma retention. Carbohydr. Polym. 47:73-82.

Bradbury, L. M. T., Henry, R. J., Qingsheng, J., Reinke, R. F, and Waters, D. L. E. 2005. A perfect marker for fragrance genotyping rice. MoI Breeding 16:279-283.

Buttery, R., Ling, L., and Juliano, B. O. 1982. 2-acetyl-l- pyrroline: An important aroma compound in cooked rice. Chem. Ind. Dec:958.

Buttery, R., Ling, L. C, Juliano, B. O., and Turnbaugh, J. G. 1983. Cooked rice aroma and 2-acetyl-l-pyrroline. J. Agrie. Food Chem. 31:823-826.

Buttery, R. G., Ling, L. C, and Mon, T. R. 1986. Quantitative analysis of 2-acetyl-l-pyrroline in rice. J. Agrie. Food Chem. 34:112-1 14.

Buttery, R., Turnbaugh, J., and Ling, L. 1988. Contributions of volatiles to rice aroma. J. Agrie. Food Chem. 36:1006-1009.

Callier, P. 1996. La cartographie des preferences. Son application en milieu industriel et son extension aux plans incomplets. These de l’Universite de Montpellier: Montpellier, France.

Caul, J. F. 1957. The profile method of flavor analysis. Adv. Food Res. 7:1

Champagne, E. T., Bett, K. L., Vinyard, B. T., Webb, B. D., McClung, A. M., Barton, II, F. E., Lyon, B. G, Moldenhauer, K., Linscombe, S., and Kohywey, D. 1997. Effects of drying conditions, final moisture content, and degree of milling on rice flavor. Cereal Chem. 74:566-570. Champagne, E. T, Bett-Garber, K. L., McClung, A. M., and Bergman, C. 2004a. Sensory characteristics of diverse rice cultivars as influenced by genetic and environmental factors. Cereal Chem. 81:237-243.

Champagne, E. T., Thompson, J. F, Bett-Garber, K. L., Mutters, R., Miller, J. A., and Tan, E. 2004b. Impact of storage of freshly harvested paddy rice on milled white rice flavor. Cereal Chem. 8 1 : 444-449.

Champagne, E. T., Bett-Garber, K. L., Thompson, J., Mutters, R., Grimm, C. C, and McClung, A. M. 2005. Effects of drain and harvest dates on rice sensory and physicochemical properties. Cereal Chem. 82:369374.

Champagne, E. T., Bett-Garber, K. L., Grimm, C. C, and McClung, A. M. 2007. Effects of organic fertility management on physicochemical properties and sensory quality of diverse rice cultivars. Cereal Chem. 84:320-327.

Champagne, E. T, Bett-Garber, K. L., Thomson, J. L., Shih, F. F, Lea, J., and Daigle, K. 2008. Impact of presoaking on the flavor of cooked rice. Cereal Chem.: in press.

Chen, S. H., Wu, J., Yang, Y., Shi, W. W., and Xu, M. L. 2006. The fgr gene responsible for rice fragrance was restricted within 69 kb. Plant Sci. 171:505-514.

Cramer, A. C. J., Mattinson, D. S., Fellman, J. K., and Baik, B. K. 2005. Analysis of volatile compounds from various types of barley cultivars. J. Agrie. Food Chem. 53:7526-7531.

Crowhurst, D. G, and Creed, P. G. 2001. Effect of cooking method and variety on the sensory quality of rice. Food Serv. Technol. 1 : 133-140.

Del Mundo, A. M., and Juliano, B. O. 1981. Consumer preference and properties of raw and cooked milled rice. J. Texture Stud. 12:107-120.

Dutta, R. K., Lahiri, B. P., Khanam, S., and Rahman, S. 1999. Aroma synthesis in Basmati rice in relation to temperature and nitrogen. Indian J. Plant Physiol. 4:215-218.

Fitzgerald, M. A., Hamilton, N. R. S., Calingacion, M. N., Verhoeven, H. A., and Butardo, V. M. 2008. Is there a second fragrance gene in rice? Plant Biotechnol. J. 6:416-423.

Fukai, Y, and Tukada, K. 2006. Influence of pre-washing on quality of cooked rice maintained at a constant temperature. 1. Influence of cooking conditions on quality of cooked rice. Nippon Shokuhin Kagaku KogakuKaishi 53:587-591.

Fukui, T., and Nikuni, Z. 1959. Changes in sugar contents during the germination of rice seed. Application of the ion exchange resin chromatography. Nippon Nogel Kagaku Kaishi 33:72-78.

Fujimaki, M., Tsugita, T., and Kurata, T. 1977. Fractionation and identification of volatile acids and phenols in the steam distillate of rice bran. Agrie. Biol. Chem. 41:1721-1725.

Fushimi, T, Itani, T, Kohyama, N., and Sekiya, K. 1996. Variation of 2acetyl-1-pyrroline concentration of the aromatic rice (cv. Hieri) cultivated at Kubokawa-area in Kochi Prefecture. Pages 738- 739 in: Crop Research in Asia, 1996: Achievements and Perspective. Proc. 2nd Asia Crop Sci. Conf. R. Ishii and T. Horie, eds. Fukui: Japan.

Goodwin, Jr., H. L., Koop, L. A., Rister, M. E., Miller, R. K., Maca, J. V, Chambers, E., Hollingsworth, M., Bett, K., Webb, B. D., and McClung, A. M. 1996. Developing a common language for the U.S. rice industry: Linkages among breeders, producers, processors and consumers. TAMRC Consumer Product Market Research CP2-96. Texas A&M: College Station, TX.

Grimm, C. C, Bergman, C. J., Delgado, J. T., and Bryant, R. 2001. Screening for 2-acetyl-l-pyrroline in the headspace of rice using SPME/GC/MS. J. Agrie. Food Chem. 49:245-249.

Grimm, C, Champagne, E. T., and Ohtsubo, K. 2002. Analysis of volatile compounds in the headspace of rice using SPME/GC/MS. Pages 229248 in: Flavor, Fragrance, and Odor Analysis. R. Marsili, ed. Marcel Dekker: New York.

Grosch, W. 1987. Reactions of hydroperoxides – Products of low molecular weight. Pages 95-140 in: Autoxidation of Unsaturated Lipids. 1st ed. H. W. S. Chan, ed. Academic Press: London.

Guadagni, D. G., Buttery, R. G., and Harris, J. 1966. Odor intensities of hop oil components. J. Sci Food Agrie. 17:142-144.

Harper, R. 1972. Human Senses in Action. Churchill Livingstone: London.

Hougen, F. W., Quilliam, M. A., and Curran, W. A. 1971. Headspace vapors from cereal grains. J. Agrie. Food Chem. 19: 182-183.

Hussain, A., Mujtaba-Naqvi, S. H., and Hammerschmidt, F. J. 1987. The isolation and identification of volatile components from basmati rice (Oryza sativa L.). Flavor Science and Technology: Proc. 5th Weurman Flavour Res. Symp. Wiley: New York.

Itani, T, and Fushimi, T. 1996. Influence of pre- and post- harvest conditions on 2-acetyl-l-pyrroline concentration in aromatic rice. Crop Research in Asia: Achievements and Perspective. ACSA: 728- 729.

Itani, T, Tamaki, M., Hayata, Y, Fushimi, T, and Hashizume, K. 2004. Variation of 2-acetyl-l-pyrroline concentration in aromatic rice grains collected in the same region in Japan and factors affecting its concentration. Plant Prod. Sci. 7:178-183.

Jezussek, M., Juliano, B. O., and Schieberle, P. 2002. Comparison of key aroma compounds in cooked brown rice varieties based on aroma extract dilution analyses. J. Agrie. Food Chem. 50:1101-1105.

Jin, Q. S., Waters, D., Cordeiro, G. M., Henry, R. J., and Reinke, R. F. 2003. A single nucleotide polymorphism (SNP) marker linked to the fragrance gene in rice (Oryza sativa L.). Plant Sci. 165:359-364.

Jouquand, C, Ducruet, V, and Le Bail, P. 2006. Formation of amylose complexes with C6-aroma compounds in starch dispersions and its impact on retention. Food Chem. 96:461-470.

Juliano, B. O., Onate, L. U., and del Mundo, A. M. 1965. Relation of starch composition, protein content, and gelatinization temperature to cooking and eating qualities of milled rice. Food Technol. 19:10061011.

Kasai, M., Ohishi, K., Shimada, A., and Hatae, K. 2001. Taste properties of cooked rice based on an analysis of the cooked rice extracts. J. Cook. Jpn. 34:373-379.

Kato, H., Ohta, T, Tsugita, T., and Hosaka, Y 1983. Effect of parboiling on texture and flavor components of cooked rice. J. Agrie. Food Chem. 31:818-823.

Kester, E. B., Lukens, H. C, Ferrei, R. E., Mohammad, A., and Finrock, D. C. 1963. Influence of maturity on properties of Western rices. Cereal Chem. 40:323-336.

Kirchhoff, E., and Schieberle, P. 2002. Quantitation of odor- active compounds in rye flour and rye sourdough using stable isotope dilution assays. J. Agrie. Food Chem. 50:5378-5385.

Laguerre, M., Mestres, C, Davrieux, F, Ringuet, J., and Boulanger, R. 2007. Rapid discrimination of fragrant rice by solid- phase microextraction, mass spectrometry, and multivariate analysis used as a mass sensor. J. Agrie. Food Chem. 55:1077-1083.

Laksanalamai, V, and Ilangantileke, S. 1993. Comparison of aroma compound (2-acetyl-l-pyrroline) on leaves from pandan (Pandanum amaryllifolius) and Thai fragrant rice (Khao Dawk Mali-1 05) Cereal Chem. 70:381-384.

Lam, H. S. and Proctor, A. 2003. Milled rice oxidation volatiles and odor development. J. Food Sci. 68:2676-2681.

Lin, C, Hsieh, T, and Hoff, B. 1990. Identification and quantification of the “popcorn”-like aroma in Louisiana Aromatic Delia Rice (Oryza sativa L.). J. Food Sci. 55:1466-1467.

Liu, T. T, Wu, C. M., andYau, N. J. N. 1996. Descriptive analysis of odor of cooked rice maintained at 18[degrees]C and 60[degrees]C. Food Sci. 23:761-766.

Lorieux, M., Petrov, M., Huang, N., Guiderdoni, E., and Ghesquiere, A. 1996. Aroma in rice: Genetic analysis of a quantitative trait. Theor. Appi. Gen. 93:1145-1151.

Luning, P. A., de Rijk, T, Wichers, J. J., and Roozen, J. P. 1994. Gas chromatography, mass spectrometry, and sniffing port analyses of volatile compounds of fresh bell peppers (Capsium annuum) at different ripening stages. J. Agrie. Food Chem. 42:977- 988.

Lyman, W. J., Reehl, W. P., and Rosenblatt, D. H. 1982. Handbook of Chemical Property Estimation Methods, Section 14. McGraw-Hill: New York.

MacLeod, A. J., and Cave, S. J. 1975. Volatile flavour components of eggs. J. Sci. Food Agrie. 26:351-360.

Mahatheeranont, S., Keawsaard, S., and Dumri, K. 2001. Quantification of the rice aroma compound, 2-acetyl-l-pyrroline, in uncooked Khao Dawk Mali 105 brown rice. J. Agrie. Food Chem. 49:773- 779.

Marzempi, Sastrodipuro, D., and Edi, S. 1990. Effect of harvesting time on the cooling and eating quality of rice. Pemberitaan Penelitian Sukarami. 17:19-22.

Meilgaard, M. C. 1975. Flavor chemistry of beer. II. Flavor and threshold of 239 aroma volatiles. Tech. Q. Master Brew. Assoc. Am. 12:151.

Meilgaard, M., Civille, G. V, and Carr, B. T. 2007. Sensory Evaluation Techniques. CRC Press: Boca Raton, FL.

Meullenet, J. F, Marks, B. P, Griffin, K., and Daniels, M. J. 1999. Effects of rough rice drying and storage conditions on sensory profiles of cooked rice. Cereal Chem. 76:438-486.

Meullenet, J. F, Marks, B. P., Hankins, J. A., Griffin, V. K., and Daniels, M. J. 2000. Sensory quality of cooked long-grain rice as affected by rough rice moisture content, storage temperature, and storage duration. Cereal Chem. 77:259-263.

Mitsuda, H., Yamamoto, A., Ominami, H., and Nakamura, T. 1999. Methods for improving the quality of aged and imported rice. J. Jpn. Soc. Nutr. Food Sci. 52:91-96.

Monsoor, M. A., and Proctor, A. 2002. Effect of water washing on the reduction of surface total lipids and FFA on milled rice. J. AOCS 79:867-870.

Moritaka, S., and Yasumatsu, K. 1972. Studies on cereals. X. The effect of sulphydryl groups on deterioration of milled rice during storage. J. Jpn. Soc. Food Nutr. 25:59-62.

Nobler, A., and Ebler, S. 2002. Use of multivariate statistics in understanding wine flavor. Food Rev. Int. 18:1-21.

Park, J. K., Kim, S. S., and Kim, K. O. 2001. Effect of milling ratio on sensory properties of cooked rice and on physicochemical properties of milled and cooked rice. Cereal Chem. 78: 151-156.

Petrov, M., Danzart, M., Giampaoli, P., Faure, J., and Richard, H. 1996. Rice aroma analysis: Discrimination between a scented and a nonscented rice. Sci. AHm. 16:347-360. Piggott, J. R., Morrison, W. R., and Clyne, J. 1991. Changes in lipids and in sensory attributes on storage of rice milled to different degrees. Int. J. Food Sci Technol. 26:615-628.

Reineccius, G. 2006. Flavor Chemistry and Technology. Taylor & Francis: Boca Raton, FL.

Rothe, M. 1976. Aroma values – A useful concept? Die Nahrung 20:259266.

Rousset, S., and Martin, J.-F. 2001. An effective hedonic analysis tool: Weak/strong points. J. Sensory Stud. 16:643-661.

Saikusa, T, Horino, T, and Mori, Y. 1994. Distribution of free amino acids in the rice kernel and kernel fractions and the effect of water soaking on the distribution. J. Agrie. Food Chem. 42:1122- 1125.

Srisawas, W., and Jindal, V. K. 2007. Sensory evaluation of cooked rice in relation to water-to-rice ratio and physicochemical properties. J. Texture Stud. 38:21-41.

Sriseadka, T, Wongpornchai, S., and Kitsawatpaiboon, P. 2006. Rapid method for quantitative analysis of the aroma impact compound, 2-acetyl-1 -pyrroline, in fragrant rice using automated headspace gas chromatography. J. Agrie. Food Chem. 54:8183-8189,

Steffen, A., and Pawliszyn, J. 1996. Analysis of flavor volatiles using headspace solid-phase microextraction. J. Agrie. Food Chem. 44:21872193.

Sunthonvit, N., Srzednicki, G. S., and Craske, J. 2005. Effects of hightemperature drying on the flavor components in Thai fragrant rice. Drying Technol. 23:1407-1418.

Tajima, M., Horino, T, Maeda, M., and Rok Son, J. 1992. Maltooligosaccharides extracted from outer-layer of rice grain. Nippon Shokuhin Kogyo Gakkaishi. 39:857-861.

Tamaki, M., Ebata, M., Tashiro, T, and Ishikawa, M. 1989. Physicoecological studies on quality formation of rice kernel. II. Effects of ripening stage and some ripening conditions on free amino acids in milled rice kernel and in the exterior of cooked rice. Jpn. J. Crop Sci. 58:695703.

Tanchotikul, U., and Hsieh, T. C. Y. 1991. An improved method for quantification of 2-acetyl-l-pyrroline, a “popcorn”-like aroma, in aromatic rice by high-resolution gas chromatography/mass spectrometry/selected ion monitoring. J. Agrie. Food Chem. 39:944- 947.

Tava, A., and Bocchi, S. 1999. Aroma of cooked rice (Oryza sativa): Comparison between commercial Basmati and Italian line B5- 3. Cereal Chem. 76:526-529.

Terao, T, Miura, S., Yanagihara, T, Hirose, T, Nagata, K., Tabuchi, H., Kim, H. Y., Lieffering, M., Okada, M., and Kobayashi, K. 2005. Influence of free-air CO2 enrichment (FACE) on the eating quality of rice. J. Sci Food Agrie. 85:1861-1868.

Tran, T. U., Suzuki, K., Okadome, H., Ikezaki, H., Homma, S., and Ohtsubo, K. 2005. Detection of changes in taste of japonica and indica brown and milled rice (Oryza sativa L.) during storage using physicochemical analyses and a taste sensing system. J. Agrie. Food Chem. 53:1108-1118.

Tsrai, K. Y. 1995. A review of studies in volatile components of cooked rice. Food Sci. (China) 16:7-9.

Tsugita, T, Ohta, T., and Kato, H. 1983. Cooking flavor and texture of rice stored under different conditions. Agrie. Biol. Chem. 47:543-549.

Tsugita, T, Kurata, T., and Kato, H. 1980. Volatile components after cooking rice milled to different degrees. Agrie. Biol. Chem. 44:835-840.

Weast, R. C, ed. 1985. Handbook of Chemistry and Physics, Section D, 66th Ed. CRC Press: Boca Raton, FL.

Widjaja, R., Craske, J. D., and Wootton, M. 1996. Changes in volatile components of paddy, brown, and white fragrant rice during storage. J. Sci. Food Agrie. 71:218-224.

Williams, A. A. 1978. Interpretation of the sensory significance of chemical data in flavor research. III. Sensory analysis. Int. Flav. Food Addit. 9:171-175.

Wongpornchai, S., Dumri, K., Jongkaewwattana, S., and Siri, B. 2004. Effects of drying methods and storage time on the aroma and milling quality of rice (Oryza sativa L.) cv. Khao Dawk Mali 105. Food Chem. 87:407-414.

van Ruth, S. M., and Roozen, J. P. 1994. Gas chromatographic/ sniffing port analysis and sensory evaluation of commercially-dried bell peppers (Capsium annuum) after rehydration. Food Chem. 51:165- 170.

Yamamatsu, K., Moritaka, S., and Wada, S. 1966. Stale flavour of stored rice. Agrie. Biol. Chem. 30:483-486.

Yang, X., and Peppard, T. 1994. Solid-phase microextraction for flavor analysis. J. Agrie. Food Chem. 42:1925-1930.

Yasumatsu, K., Moritaka, S., and Wada, S. 1966. Studies on cereals. V. Stale flavor of stored rice. Agrie. Biol. Chem. 30:483- 486.

Yau, N. J. N., and Huang, J. J. 1996. Sensory analysis of cooked rice. Food Qual. Pref. 7:263-270.

Yau, N. J. N. and Liu, T. T. 1999. Instrumental and sensory analysis of volatile aroma of cooked rice. J. Sens. Stud. 14:209- 233.

Yoshihashi, T. Huong, N. T. T., Surojanametakul, V, Tungtrakul, P., and Varanyanond, W. 2005. Effect of storage conditions on 2- acetyl-lpyrroline content in aromatic rice variety. Khao Dawk Mali 105. J. Food Sci. 70:S34-S37.

Zheng, Z., and Zhang, H. 2007. Direct extraction of volatiles of rice during cooking using SPME. Cereal Chem. 84:423-427.

[Received October 2, 2007. Accepted January 27, 2008.]

Elaine T. Champagne1

1 USDA ARS Southern Regional Research Center, New Orleans, LA 70124. Fax: 504-286-4430. E-mail: [email protected]

doi:10.1094/CCHEM-85-4-0445

This article is in the public domain and not copyrightable. It may be freely reprinted with customary crediting of the source. AACC Internatio

Shake-Up ‘Threatens the Lives of Patients’

By Liz Perkins

Lives could be placed at risk if plans go ahead to axe a Swansea minor casualty unit in favour of a 24-hour GP-led service, angry staff have warned.

They say they have major concerns over the shake-up at Singleton Hospital, which bosses have told them could take place as early as September.

But hospital bosses insist patients are their top priority, and they are working hard to offer a safe service at the site, in the wake of problems in recruiting doctors.

One Singleton health worker said trust chiefs were keeping the public in the dark over the controversial plan to downgrade the service because of fears it would be opposed.

She said: “We have been told the closure of Singleton’s minor casualty unit is imminent – it may be in September or October.

“We have been told it’s going to become a GP-led service 24 hours a day.

“We can stay and work with the GPs if we want at Singleton, but we have all been offered jobs in Morriston Hospital.

“If we do not want to go to Morriston, we could be redeployed anywhere in the trust – we are all gutted.”

The worker also accused Calum Campbell, assistant chief executive (west) of ABM University NHS Trust, of keeping the public in dark over the plans, following battles faced by the trust over proposals for Fairwood Hospital and ward one at Hill House.

And the health worker issued a warning that extra patients at Morriston Hospital would have an impact on ambulance waiting times.

Bosses at Swansea Local Health Board (LHB) have already said an urgent care centre will remain in place at Singleton Hospital, which sees 38,000 patients every year.

But the health worker says the unit is now regularly closed overnight and at weekends, after a doctor left and was not replaced.

The staffing problem was said to relate to a Wales-wide shortage of locum doctors to cover emergency units.

But the Assembly previously said the problem in attracting doctors was unique to Singleton Hospital.

Staff have now claimed the service is being deliberately run down to ensure the changes go ahead.

Mr Campbell said: “The safety of our patients is the trust’s first priority.

“We are working hard to determine the safest, most effective and most sustainable way of managing the service at Singleton, which is experiencing major problems recruiting junior and middle-grade doctors.

“This issue has been well documented in recent months and is a national problem, with Singleton’s minor injuries casualty unit being particularly badly affected.

“As a result, we are regularly left with no choice but to close the unit at night, because no doctor is available, and that situation cannot be allowed to continue indefinitely.

“We are committed to providing a service at Singleton, and we are continuing to work with other partner agencies as thoroughly and quickly as possible to find a solution.

“We are talking to local GPs and the LHB about how they could support us, and one option being looked at is working with the GPs to provide a safe, effective and regular service at Singleton.

“There are currently no set timescales for completing this piece of work, but whichever option is chosen, it will be more expensive to provide than the current service – so this is not about saving money, but is about getting the best service we can.”

(c) 2008 South Wales Evening Post. Provided by ProQuest LLC. All rights Reserved.

Central Oregon Occupational Safety and Health Conference to Focus on Safety in Workplace

A conference focusing on the improvement of workplace safety is coming to Central Oregon next month.

The Central Oregon Occupational Safety and Health Conference will be held September 17 and 18 at Eagle Crest Resort in Redmond. The event is for workers and employers who wish to improve the safety and health performance of their workplace. The conference is a joint effort of the Central Oregon Safety and Health Association and Oregon OSHA. Exhibits showing new safety and health products and services will be on display.

A keynote address will be given by organizational consultant Dan Miller, who will talk about making small changes to improve safety in the workplace and beyond.

Registration for the conference is $150; single-day attendance is $80. To register, visit www.orosha.org/conferences.

Originally published by DJC Staff.

(c) 2008 Daily Journal of Commerce (Portland, OR). Provided by ProQuest LLC. All rights Reserved.

Measles Plea to All Parents

MERSEYSIDE parents have been urged to help avoid a measles epidemic.

Primary care trusts hope parents of children about to start school or playgroup will add the MMR vaccination to their checklist.

In 2006-7, there were 1,726 confirmed measles cases in England and Wales, more than in the previous 10 years put together.

Sefton PCT is urging parents to ensure children are vaccinated against measles as well as tetanus, polio, mumps and rubella.

Rod Thomson, Sefton PCT consultant in public health, said: “When you are putting your child’s school check list together of uniform, gymkit,maths set, make sure you have a pre-school booster and that MMR is on it.”

(c) 2008 Liverpool Echo. Provided by ProQuest LLC. All rights Reserved.

Man Saved By 58 Electric Shocks

By TOM McTAGUE

A MIRACLE dad lived after having 58 electric shocks to restart his heart during a dramatic dash to save his life.

John McCarthy, who is in his 60s, suffered five massive heart attacks before his three-hour transfer from Wexford General Hospital to St Vincent’s Hospital in Dublin.

Amazingly just two weeks later, John – who is still seriously ill – walked from his hospital bed and went home where he is being cared for by devoted family. John’s wife was still very emotional about the ordeal and said the family now just wanted some time to be together and hopefully get back to normal.

The heroic paramedics who saved John’s life were praised last night for their skilful work.

A HSE spokesman said: “The HSE’s emergency services are staffed by a dedicated and skilled team of professionals who, on a daily basis, provide a valued service.

“The pre-hospital management of heart attacks by the ambulance service has undergone dramatic changes in recent years.”

Now all ambulances have defibrillators which have saved hundreds of lives.

Even so, the number of electric shocks given to John as he battled for his life is a medical first in Ireland.

Wexford paramedics used the defibrillator on John 38 times in the ambulance early last month.

And when he got to the Dublin hospital the battling dad was given 20 more shocks.

The miracle man, who lives near Enniscorthy, checked into Wexford General Hospital on July 1 and suffered five heart attacks.

The medical team at the hospital decided he urgently needed be taken to Dublin for specialist treatment and a Garda escort made sure the trip was not delayed.

Just 15 minutes into the journey, John suffered another heart attack and the series of powerful electric shocks began.

Astonishingly John was conscious for many of the life-saving blows to his chest.

As soon as they arrived at St Vincent’s Hospital, the dad was taken straight to the operating theatre.

(c) 2008 Daily Mirror. Provided by ProQuest LLC. All rights Reserved.

Froedtert Leads in Kidney and Liver Transplant Survival Rates

MILWAUKEE, Aug. 13 /PRNewswire/ — According to data recently released by the Scientific Registry of Transplant Recipients, for the second consecutive reporting period, Froedtert & The Medical College of Wisconsin Transplant Center leads Region 7, which includes Michigan, Illinois, Wisconsin and Minnesota, in kidney and liver transplant survival rates. The one-year survival rate for a patient who received a kidney transplant at Froedtert is 98.7 percent, about 2.5 percent higher than the national average. The one-year survival rate for a patient who received a liver transplant at Froedtert is 93.2 percent, about six percent higher than the national average.

Froedtert & The Medical College of Wisconsin Transplant Center also lead in one-year graft survival rate of the 15 largest renal transplant centers in the Midwest. The 15 largest renal transplant centers in the Midwest includes Froedtert & The Medical College of Wisconsin, Barnes Jewish, University of Indiana, University of Minnesota, University of Illinois, Mayo, University of Nebraska, University of Michigan, Cleveland Clinic, The Ohio State University, University of Wisconsin, Rush and Henry Ford.

Froedtert performs about 120 kidney transplants and 40 liver transplants a year. “In transplant medicine, having a medium size program like ours that performs between 70-150 kidney transplants a year is conducive to having good outcomes,” said Christopher Johnson, MD, Medical College of Wisconsin transplant surgeon and director of the Froedtert & The Medical College Transplant Center. “If your program is too small, it’s challenging to develop the expertise and if your program is too large, you can easily lose quality control.”

With more than two decades of experience, Froedtert & The Medical College of Wisconsin hepatologists and other physicians have the expertise to better recognize and treat complications of cirrhosis and other liver diseases, which means patients undergo transplant surgery in overall better health.

“The key is also having an experienced, dedicated team to manage both pre- and post- transplant patients,” said Johnson. “Our transplant programs have provided high-quality, innovative transplant services for people in Wisconsin and northern Illinois for more than 30 years.”

The multidisciplinary approach taken by Froedtert & The Medical College of Wisconsin Transplant Center draws upon the broad range of resources and expertise available through a variety of specialties within our campus. “As an academic medical center, we are at the forefront of new developments and information, and we can help patients explore all available treatment options,” said Johnson.

About Froedtert & The Medical College of Wisconsin

Froedtert Hospital is a 450-bed academic medical center staffed by faculty of The Medical College of Wisconsin. The hospital employs more than 1,400 registered nurses and is one of just 230 hospitals in the country to receive the prestigious Magnet designation by the American Nurses Credentialing Center. It serves as an eastern Wisconsin referral center for advanced medical practice care in 37 specialties and subspecialties. It is a major training and research facility with more than 1,000 medical, nursing and health technical students in training and over 2,000 active clinical trials each year. Froedtert, part of Froedtert & Community Health, operates the region’s only adult Level One Trauma Center.

Froedtert Memorial Lutheran Hospital

CONTACT: Kim Wick of Froedtert Memorial Lutheran Hospital,+1-414-805-3057, [email protected]

Web site: http://www.froedtert.com/

Fifth Young Stanford Scientist Gets Stem Cell Funding From State Institute

A fifth young scientist from the Stanford University School of Medicine has received funding from the California Institute of Regenerative Medicine through its efforts to foster the next generation of stem cell researchers.

Ching-Pin Chang, MD, PhD, assistant professor of cardiovascular medicine, was awarded $3.1 million over a five-year period for his proposal to investigate the role of stem cells in the restenosis, or narrowing, of coronary arteries enlarged by angioplasty.

The award brings to five the total number of new faculty awards received by investigators at the School of Medicine. Four others were awarded during the first round of funding in December 2007. Institutions were limited to a maximum of five recipients between the two rounds of funding. Stanford has now received nearly $94 million from CIRM in research and facilities grants, $13.8 million of which are from the new faculty awards.

Chang’s grant was approved at the Aug. 13 meeting of CIRM’s 29-member governing board, the Independent Citizen’s Oversight Committee. During the meeting, which was held on the Stanford campus, $59 million was awarded to 23 researchers in the second round of new faculty awards. The awards are intended to support young physician-scientists in the early stages of establishing careers in stem cell research–a point at which it can be difficult to obtain funding from other research agencies.

“There are two major pressures impacting the development of physician-scientists,” Philip Pizzo, MD, dean of the School of Medicine, said during the meeting (Pizzo abstained from voting on Chang’s award). “Decreased funding by the National Institutes of Health has created enormous pressure on young researchers, and the marketplace of current medicine, with its increased demands to be clinically productive, further constrains the time they can devote to research.”

Each applicant was assessed on three points: the significance, innovation, design and feasibility of their research plan; the qualifications, leadership potential, career development and mentoring plans of the potential principal investigator; and the commitment, track records and future plans of the applicant’s institution.

The awards complement the 22 new faculty awards totaling more than $54 million announced last December. The additional 23 grants announced Aug. 13 reflect CIRM’s commitment to supporting the recruitment of new faculty into the stem cell field in California.

“We expect these awards to play a significant role in changing the career trajectory of funded researchers, encouraging talented young investigators to pursue careers in stem cell research,” CIRM president Alan Trounson said in a press release. “I’m pleased that great research has the opportunity for funding.”

CIRM was established in early 2005 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure provided $3 billion in funding for stem cell research at California universities and research institutions. To date, the CIRM governing board has approved 229 research and facility grants totaling more than $614 million, making CIRM the largest source of funding for embryonic and pluripotent stem cell research in the world.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions — Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

More Than 400-Mile Victory Walk to Conclude Aug. 14, at Campus Martius

To: STATE EDITORS

Contact: Patricia A. Ellis of the Barbara Karmanos Cancer Institute, +1-313-576-8629, +1-313-410-3417 (cell)

Sean Shearon raises awareness and donations for breast cancer research/programs

DETROIT, Aug. 13 /PRNewswire-USNewswire/ — Sean Shearon wanted to make a difference and do his part to end cancer, as well as honor the victims and survivors of this horrific disease. He set a goal of walking 18 marathons in 18 days — The Victory Walk –to raise awareness and dollars for breast cancer research and programs at the Barbara Ann Karmanos Cancer Institute, in Detroit. He began his journey in Sault Saint Marie, Michigan, on July 27 and will conclude his Victory Walk Thursday, Aug. 14, at approximately 6 p.m., at Campus Martius, in Detroit.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/ KARMANOSCANCERINSTITUTELOGO)

Shearon, age 43, is a resident of Windsor, Ontario, and teaches at the Roberto Clemente Learning Academy in southwest Detroit. Shearon’s mom Bette was originally from Michigan and worked many years at the J.L. Hudson’s Company in downtown Detroit. Shearon saw his mom battle breast cancer and he himself was only 12 years old when he was diagnosed with rhabdomyosarcoma, a cancer that formed in the soft tissue and muscle of his shoulder. He underwent extensive chemotherapy and radiation treatments. In 1984, his mother lost her battle with breast cancer.

“I can’t stand by and watch more people go through what my mother and I went through,” said Shearon. “I’m walking to make a statement and to show that it’s not beyond us to do all that we can to raise awareness and funds for a cure. I challenge everyone in Michigan and elsewhere to join me in support of cancer research so we can help end this despicable disease.”

Shearon was hoping to raise at least $1 from everyone in Michigan. To date, approximately $3,200 has been raised in online donations.

“The Karmanos Cancer Institute is honored to be the recipient of The Victory Walk,” said Nick Karmanos, vice president of development. Sean Shearon’s commitment in the fight against cancer, specifically to further breast cancer research and programs that may one day eliminate this horrendous disease, is unprecedented. Having lost my mother to breast cancer, it is both personally and professionally gratifying to know that one person’s determination to make a difference can touch so many lives. Sean’s Victory Walk and his compassion to help others sets an example for all of us.

Media and the public are invited to cheer Sean on as he concludes his victorious Victory Walk.

WHAT:The Victory Walk Finale

WHEN: Thursday, Aug. 14, at approximately 6 p.m. Brief program at 6:10 p.m.

WHERE: Campus Martius Park, on Woodward, in downtown Detroit

WHO:Sean Shearon, cancer survivor and creator of the Victory Walk; Nick Karmanos, vice president, Development, Karmanos Cancer Institute; and family, friends and supporters.

Here are some other Aug. 14 locations where the public can help show their support and encourage Sean on his victory lap. (Approximate times)

6 a.m.: Sean will begin his walk going east on 12 Mile near Drake Rd., in Farmington Hills, by William Tyndale College

9:30 a.m.: 12 Mile, just east of Evergreen, in Southfield

11:30 a.m.: Main Street at 12 Mile, in Royal Oak

1:15 p.m.: Woodward Ave. south of 9 Mile, in Ferndale

3 p.m.: Woodward Ave. south of McNichols, in Highland Park

5:30 p.m.: Woodward in front of the FOX Theatre, in Detroit

6 p.m.: Approximate arrival time at Campus Martius, in downtown Detroit

Visit www.thevictorywalk.comfor more information or to make a donation.

About The Victory Walk

The Victory Walk is dedicated to raising awareness about breast cancer prevention and money for a cure. Thanks to generous donations of services and supplies, 100% of all money donated will go toward breast cancer research at the Karmanos Cancer Institute, a nationally recognized cancer research facility.

About The Barbara Ann Karmanos Cancer Institute

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 41 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nations best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D., is the Institutes president and chief executive officer. For more information call 1-800-KARMANOS or go towww.karmanos.org.

SOURCE Barbara Ann Karmanos Cancer Institute

(c) 2008 U.S. Newswire. Provided by ProQuest LLC. All rights Reserved.

Fluorescent Genetic Barcodes

By Luntz, Stephen

The capacity to track gene expression has been one of the biotechnology revolution’s driving forces, so a technology that gives researchers more accuracy and sensitivity has the potential to lead to even more rapid progress. Dr Krassen Dimitrov of the Australasian Institute of Bioengineering and Nanotechnology at the University of Queensland has created what he calls “nanostrings”. These are fluorescent pieces of nucleic acid that act like barcodes, binding to RNA molecules and providing researchers with an easy-to- read measure of the presence of biomolecules.

The technology has several advantages over the microarrays used currently. It provides a digital count, recording the exact number of RNA molecules, rather than an analogue result, where the correspondence between luminosity and the amount of molecules breaks down at high and low values. “Because this system can count the exact number of biomolecules present we can get an extremely accurate and sensitive picture of gene expression at a particular point in time,” Dimitrov says.

Another advantage is that the nanostrings do not require the conversion of RNA to DNA, followed by enzyme conversion to fluorescing DNA. “Enzymes are finicky and don’t work if the conditions are dirty,” Dimitrov says.

“The nanostringis an important technological development in both clinical and research settings. We will be able to more accurately detect molecules associated with particular diseases, and in the research arena we will be able to identify new molecules associated with diseases and trace these back to the genes responsible.”

The nanostrings are being commercialised by a company that Dimitrov founded for the purpose in 2003. Technical obstacles prevented the nanostrings from reaching the market until now. Although patents were awarded years ago, business interests were not keen for the technology to be publicised until a product was ready for market. The splash was significant, with the invention making the March cover of Nature Biotechnology.

Meanwhile Dimitrov is working on a new generation of nanostrings capable of emitting electronic signals rather than light, which he says will make them “easier to count and much smaller”.

These fluorescent markers provide an exact record of the RNA molecules expressed.

Copyright Control Publications Pty Ltd Jul 2008

(c) 2008 Australasian Science. Provided by ProQuest LLC. All rights Reserved.

Miscellaneous Occupational Lung Diseases

By Erdogan, M Sarper Martin, Christopher J

ABSTRACT. A case is presented of a rare occupational lung disease for which the workplace etiology may have been overlooked. The authors review 4 such diseases, which are important to recognize not only because cessation of exposure can lead to clinical improvement, but also because other cases of these conditions may be identified in the workplace. KEYWORDS: occupational exposure, occupational lung disease

CASE PRESENTATION

A 33-year-old woman presents with repeated episodes of nonproductive cough, fever, fatigue, and night sweats. She has been hospitalized on several occasions and received multiple courses of antibiotics and corticosteroids without improvement. Her chest radiograph shows diffuse patchy infiltrates. An open-lung biopsy reveals findings consistent with bronchiolitis obliterons organizing pneumonia.

An occupational history reveals that the patient is employed in a cabinet manufacturing facility. Identifiable exposures include sawdust, paint and oil mists containing refined castor oil, petroleum, and linseed oil. After re-examining the biopsy specimen, the attending physician notes that lipidladen macrophages are filling the alveolar spaces. The patient improves after removal from the workplace.1

BACKGROUND

A variety of occupational lung conditions are less wellrecognized than are the classic diseases of pneumoconioses, asthma, byssinosis, and hypersensitivity pneumonitis. Frequently, these rare conditions present along the spectrum of bronchiolitis obliterans organizing pneumonia. Because this disease is often considered idiopathic, clinicians should always bear in mind the possibility of an occupational cause.

Table I summarizes the conditions we will discuss in this article. We emphasize acute diseases resulting from relatively high- level exposures; however, many of these exposure settings can also result in chronic diseases from more prolonged, lower-level exposures.

ORGANIZING PNEUMONIA IN TEXTILE PRINTING SPRAYERS

In 1992 in Valencia, Spain, an outbreak of severe interstitial lung disease occurred among factory workers employed in 8 textile- printing factories, resulting in 6 deaths.2 Because a majority of these patients were employed at a factory named Ardystil, the condition has become known as Ardystil syndrome. Among 27 heavily exposed workers, symptoms at presentation included cough (n = 21 ), shortness of breath (n = 18), and epistaxis (n = 17).3 In the total workforce of 257,71 were considered affected on the basis of at least 1 of the following criteria: respiratory symptoms not accounted for by another disease, abnormal chest radiograph, or lung biopsy. Imaging studies showed either widespread small nodular opacities or confluent patchy consolidation in 22 workers.1 Pulmonary function testing revealed findings consistent with a restrictive pattern, including reduction in total lung capacity and in diffusing capacity.

A similar disease occurred in an Algerian textile facility whose workers used the same painting process.4 In this outbreak, 6 employees out of a total of 12 developed disease, and 1 worker died. After 1 year, most patients in the Spanish cohort had significantly improved; a similar trend occurred after 5 years in 3 of the Algerian patients.2,5

Workers have used this painting technique since the early 1950s without recognized adverse health effects. The paint itself consisted of a 3-component substance that workers mixed with water and applied as a paste using a brush or sponge. Material safety data sheets indicated that all components were nonirritating polymers with low oral and dermal toxicity.6 However, in both the Spanish and Algerian factories, workers substituted white spirits for water as the carrier and applied the paint as an aerosolized spray.1 Furthermore, working conditions were described as poor in both outbreaks, and some exposed employees became symptomatic within I month of exposure.

Table 1.-Summary of 4 Rare Occupational Lung Diseases

After the outbreaks, Oottens et al7 conducted intratracheal investigations of all components of the painting system in hamsters and found that LD50 (ie, the lethal dose required to kill half of test subjects) was 10 to 1,250 times more toxic by this route of administration. However, for 2 of the components (Acramin FWR and Acramin FWN), the researchers observed no appreciable difference in toxicity by this route. Therefore, the precise cause of Ardystil syndrome remains unknown. In vitro studies in human cells have shown that toxicity is greatest in polycationic paint components.8 This cytotoxicity is greatly reduced when cells are co-incubated with polyanions.9

Ardystil syndrome presents several important and interrelated lessons. First, this outbreak is yet another demonstration of the limitations of animal studies in predicting toxicology in humans. In this case, substances that were believed to be nonirritating through a mucocutaneous exposure route were found to be profoundly irritating to the lung. second, reformulations and changes in practices may always present new risks of diseases arising in established work settings in ways that may not be easily predicted. Last, our understanding of the mechanisms of pulmonary toxicity remains limited. As one group of authors summarized, “The subacute time course, the unusual presentation, and the extreme severity of the disease are puzzling, particularly because these polymers would not be expected, from a toxicological viewpoint, to cause such spectacular pulmonary damage, even when inhaled as aerosols.”8lp209)

LIPOID PNEUMONIA

Lipoid pneumonia may result from either endogenous or exogenous causes. The most common exogenous causes include aspiration of fatty foods, oils, or petroleum medicinal preparations, frequently by debilitated patients. In a retrospective, nationwide study of 44 cases of lipoid pneumonia in France, Gondouin et al10 found that 4 cases had an occupational basis. The authors described the occupational exposure as “chronic inhalation of cutting mist or oily vapour either in a metallurgy plant (three cases) or a cable factory (one case).”10

Table 2,-Occupational Causes of Lipoid Pneumonia

Lipoid pneumonia has been documented in diverse occupational settings. Based on early pathologic studies, animal oils are believed to be the most powerful causes of lipoid pneumonia, followed by vegetable and mineral oils12 (see Table 2). However, the method of diagnosis is disputed. Some authorities state that bronchoalveolar lavage with transbronchial biopsy is sufficient; however, this technique has limitations both with respect to sensitivity and specificity, and an open biopsy may be required. The latter approach will also provide information about the extent of fibrosis.13

POPCORN WORKER’S LUNG

In 2000, an occupational medicine physician reported 8 former workers of a microwave popcorn factory with fixed obstructive lung disease to public health authorities in Missouri (USA).23 Four of these patients had sufficiently severe disease to warrant consideration for lung transplantation. The respiratory illness resembled bronchiolitis obliterans, with symptoms of cough and dyspnea on exertion, and spirometric findings showing obstruction without a bronchodilator response. In 2 of 3 cases for which tissue samples were available from open-lung biopsy, findings were consistent with bronchiolitis obliterans.24 Four of the patients had worked in a room where microwave popcorn flavoring agents were mixed, and 4 had worked only in microwave-popcorn packaging areas,25 A cross-sectional survey of current employees revealed a more widespread excess of respiratory morbidity: a 2.6-fold increase in workers’ symptoms of chronic cough and shortness of breath and a 3.3- fold increase in airway obstruction.24 Among never smoking workers, researchers observed a 10.8-fold increase in respiratory symptoms. At follow-up, most patients appeared to have an irreverisible yet stable pattern of fixed obstruction of the lung with partial improvement in symtpoms.23

Researchers singled out diacetyl, a butter-flavored ketone, as the likely cause of disease, given that high levels of the substance were found in the mixing room and that researchers observed a strong correlation between worker exposure to the substance and severity and frequency of airway obstruction. Findings from subsequent toxicity studies in rats have supported this association.26 Additional case reports are consistent with this hypothesis. For example, at another microwave popcorn packaging plant, a worker exposed to butter flavorings supplied by a different manufacturer developed fixed-airway obstruction.27 Researchers28″30 have also reported bronchiolitis obliterans in workers in other food manufacturing and flavouring industries.

Symptoms of Popcorn Worker’s Lung can extend beyond the lung to include eye, nose, and skin irritation, which may act as warning symptoms.23 Protective measures include installing isolated ventilation systems for flavor-mixing areas of food manufacturing facilities and requiring workers exposed to flavorings to wear air- purifying and paniculate respirators with organic vapor cartridges.24 FLOCK WORKER’S LUNG

Flock consists of short fibers cut from thin continuous strands (called tow) by means of rotary or guillotine cutters. Nylon and rayon are most frequently used to make flock, although other synthetic and natural fibers are used in certain applications. A variety of substances-such as titanium dioxide, ammonium ether, potato starch, tannic acid, and fatty alcohol derivatives-may be applied to the tow prior to cutting. After cutting, the flock is dried, screened, and bagged. Ultimately, flock fibers are applied to an adhesivecoated surface using an electrostatic process to produce a velvet-like coating. This application may be used to coat an object, such as a toy, or as a backing to generate upholstery material. Flock without adhesion is also used as a filler material; first, heating cures the adhesive, and the flocked product may then be subjected to finishing, embossing, and printing. Demand for flocked fabric has increased in recent years. In the United States, an estimated 2,500 workers are employed at 12 flock manufacturing companies, with an additional 100 companies applying flock.31

Pimentel et al32 reported the first documented outbreak of lung disease associated with exposure to nylon fibers in 1975 in 7 patients who developed a variety of lung diseases and 2 of whom had biopsy-proven interstitial lung fibrosis. The investigators also reproduced an impressive inflammatory response in guinea pigs exposed to nylon dust. However, these findings went largely unnoticed.

Between 1990 and 1991, 5 cases of interstitial lung disease were diagnosed among 88 workers in a plant manufacturing nylon flock upholstery in Ontario, Canada.13 Biopsies from the first 3 cases revealed desquamative interstitial pneumonias with diffuse alveolar damage. The investigators, unable to identify a chemical exposure with known pulmonary toxicity in the workplace, suspected that the cause was aflatoxin produced by mold growing on the surface of barrels of adhesive.

When 2 additional cases of interstitial lung disease were diagnosed at another plant owned by the same company in Rhode Island (USA), the employer requested an investigation by a local university in conjunction with the National Institute for Occupational Safety and Health (NIOSH). The investigators identified 7 cases of “flock worker’s lung” in a cohort of 165 current or former workers at the Rhode Island facility on the basis of findings either at biopsy or of bronchoalveolar lavage together with a restrictive lung defect and high-resolution computed tomography showing micronodularity or diffuse ground-glass appearance.34

The median time of onset from time of hire to symptoms (dyspnea and progressive dry cough) was 6 years (range = 9 months-31 years). At the time, the researchers reported pathological findings as nonspecific interstitial pneumonia in 5 patients and bronchiolitis obliterons organizing pneumonia in I patient. Although environmental investigations failed to identify the specific cause, researchers began to doubt the role of a microbial-related agent. First, 2 additional cases of interstitial lung disease had developed in the Canadian plant in spite of remediation measures for mold. second, air sampling at the Rhode Island facility showed only modest concentrations of fungal spores and endoloxin. However, these investigators did find high levels of dust overall, and high levels of respirable nylon fragments specifically.33 Subsequent animal studies demonstrated that respirable nylon flock fragments, even without a finish, could provoke an impressive acute inflammatory response.35 Eventually, a total of 8 cases were reported at the Rhode Island plant.31 All improved after leaving work at the facility.

At a workshop hosted by NIOSH in which attendees reviewed lung biopsy material from 15 available cases (including a revaluation of the Canadian cases), a consensus was reached that the characteristic lesion for this dis ease was, “a lymphocytic bronchiolitis and peribronchiolitis with lymphoid hyperplasia represented by lympho
id aggregates.”^sup 36(p2005)^ Therefore, we regard Flock Worker’s Lung as a new occupational lung disease.

Bear in mind that initial criteria for a diagnosis of Flock Worker’s Lung were relatively stringent, as is appropriate for research purposes. However, when more liberal criteria were applied, more potentially affected workers were identified. In a group of 32 symptomatic flock workers who did not fulfill previously established criteria, high-resolution computed tomography revealed that 19 exhibited groundglass or micronodular patterns.37 Because flock fragments cut from tow are large, what remained to be explained was the origin of the respirable nylon dust. Eventually, researchers discovered that workers frequently cut tow incompletely, leaving a frayed end. This frayed end can subsequently break off, generating respirable fragments.38

References

1. Brown CD, Hewan-Lowe K, Kseibi SA, Huang YY. Exogenous lipoid pneumonia secondary to an occupational exposure in a furniture factory (abstract]. Chest. 2004;126:997S.

2. Moya C, AnIo JM, Taylor AJ. Outbreak of organising pneumonia in textile printing sprayers. Lancet. 1994;344:498-502.

3. Sole A. Cordero PJ, Morales P, Martinez ME, Vera F, Moya C. Epidemic outbreak of interstitial lung disease in aerographics textile workers. The “Ardystil syndrome”: a first-year follow up. Thorax. 19%;51:94-95.

4. Ould Kadi F, Mohammed-Brahim B, Fyad A, Lellou S, Nemery B. Outbreak of pulmonary disease in textile dye sprayers in Algeria. Lancet. 1994; 344:962-963.

5. Ould Kadi F, Abdesslam T, Nemery B. Five-year follow-up of Algerian victims of the “Ardystil syndrome.” Ear Respir J. 1999; 13:940-941.

6. Camus P, Nemery B. A novel cause for bronchiolitis obliterans organizing pneumonia: exposure to paint aerosols in textile workshops. Ear Respir J. 1998; [1:259-262.

7. Clottens FL, Verbeken EK, Demedts M, Nemery B. Pulmonary toxicity of components of textile paint linked to the Ardystil syndrome: intratracheal administration in hamsters. Occup Environ Med. 1997:54:376-387.

8. Hoet PH, Gilissen LP, Leyva M, Nemery B. In vitro cytotoxicity of textile paint components linked to the “Ardystil syndrome.” Toxicol Sci. 1999;52:209-216.

9. Hoet PH, Gilissen LP, Leyva M, Nemery B. Polyanions protect against the in vitro pulmonary toxicity of polycationic paint components associated with the Ardystil syndrome. Toxicol Appl Pharmacol. 2001:175:184-190.

10. Gondouin A, Manzoni P, Ranfaing E, et al. Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France. Ear Respir J. 1996;9:1463-1469.

11. National Institute of Occupational and Safety and Health. National Occupational Exposare Survey (1981-1983). http://www.cdc. gov/noes. Accessed May 12, 2008.

12. Pinkerton H. The reaction to oils and fais in the lung. Arch Palhol. 1928;5:380-401.

13. Pujol JL, Barneon G, Bousquet J, Michel FB. Godard P. Interstitial pulmonary disease induced by occupational exposure to paraffin. Chest. 1990:97:234-236.

14. Oldenburger D, Maurer WJ, Beltaos E, Magnin GE. Inhalation lipoid pneumonia from burning fats. A newly recognized industrial hazard. JAMA. 1972:222:1288-1289. 15. Carby M, Smith SR. A hazard of paint spraying. Lancet. 2000:355:896.

16. Kizer KW, Golden JA. Lipoid pneumonitis in a commercial abalone diver. Undersea Biomcd Res. 1987:14:545-552.

17. Yokohori N, Homma S, Tanaka S, et al. Exogenous lipoid pneumonia induced by inhalation of insecticide [in Japanese]. Nihon Kokyuki Gakkai Zasshi. E999;37:583-588.

18. Perol M, Vallon C, Vallon JJ, Guerin JC. Lipid pneumopathy caused by occupational exposure to cutting oil. Rev Mal Respir. 1989:6:271-274.

19. Beermann B, Christensson T. Moller P, Stillstrorti A. Lipoid pneumonia: an occupational hazard of fire eaters. Br Med J (Clin Res Ed). 1984:289:1728-1729.

20. Cullen MR, Balmes JR. Robins JM, Smith GJ. Lipoid pneumonia caused by oil mist exposure from a steel-rolling tandem mill. Am J lnd Med. 1981;2:51-58.

21. Skorodin MS, Chandrasekhar AJ. An occupational cause of exogenous lipoid pneumonia. Arch Pathol Lab Med. 1983:107:610-611.

22. Weissman H. Lipoid pneumonia: report of two cases. Am Rev Tuberc. 1951:64:572-576.

23. Simoes E, Maley R, Kreiss K, Malone J, Kanwa! R. Fixed obstructive lung disease in workers at a microwave popcorn factory: Missouri, 2000-2002. MMWR. 2002:51:345-347.

24. Akpinar-Elci M, Travis WD, Lynch DA, Kreiss K. Bronchiolitis obliterans syndrome in popcorn production plant workers. Ear Rspir J. 2004:24:298-302.

25. Kreiss K, Gomaa A, Kullman G, Fedan K, Simoes EJ, Enright PL. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N Engl J Med. 2002:347:330-338.

26. Hubbs AF. Battelli LA, Goldsmith WT, et al. Necrosis of nasal and airway epithelium in rats inhaling vapors of artificial butter flavoring. To-iicol Appl Pharmacol. 2002; 185:128-135.

27. Parmet AJ, Von Essen S. Rapidly progressive, fixed airway obstructive disease in popcorn workers: a new occupational pulmonary illness? J Occup Environ Med. 2002;44:216-218.

28. Alleman T, Darcey DJ. case report: Bronchiolitis obliterans organizing pneumonia in a spice process technician. J Occup Environ Med. 2002:44:215-216.

29. National Institute for Occupational Safety and Health. Health Hazard Evaluation and Technical Assistance Report. International Bakers Services, Inc.. South Bend, Indiana. Washington, DC: Department of Health and Health Services; 1986. DHHS publication no. 85-171-1710.

30. Lockey J, McKay R, Barth E, Dahlsten J, Baughman R. Bronchiolitis obliterans in the food flavoring manufacturing industry [abstract). Am J Respir CHr Care Med. 2002; 165: A461. 31. Kern DG, Crausman RS, Durand KTH, Nayer A. Kuhn C 3rd. Flock worker’s lung: chronic interstitial lung disease in the nylon flocking industry. Ann Intern Med. 1998; 129:261-272 [erratum: 1999: 130:246],

32. Pimentel JC, Avila R, Lourenco AG. Respiratory disease caused by synthetic fibres: a new occupational disease. Thorax. 1975;30: 204-219.

33. Lougheed MD, Roos JO, Waddell WR, Munt PW. Desquamative interstitial pneumonitis and diffuse alveolar damage in textile workers. Potential role of mycotoxins. Chest. 1995;108:1196-2000.

34. Kem DG, Durand KTH, Crausman RS, et al. Chronic interstitial lung disease in nylon flocking industry workers: Rhode Island, 1992- 1996. JWWWA Morh Mortal WkIy Rep. 1997:46:897-901.

35. Porter DW, Castranova V, Robinson VA, et al. Acute inflammatory reaction in rats after intratracheal instillation of material collected from a nylon flocking plant. J Toxicol Environ Health A. !999:57: 25-45.

36. Eschenbacher WL, Kreiss K. Lougheed MD, Pransky GS, Day B, Castellan RM. Nylon flock-associated interstitial lung disease. Am J Respir Crit Care Med. 1999;159:2003-2008.

37. Weiland DA, Lynch DA, Jensen SP, et al. Thin-section CT findings in flock worker’s lung, a work-related interstitial lung disease. Radiologv. 2003:227:222-231.

38. Burkhart J. Piacitelli C, Schwegler-Berry D, Jones W. Environmental study of nylon flocking process. J Toxicol Environ Health Part A. 1999:57:1-23.

M. Sarper Erdogan, MD, PhD; Christopher J. Martin, MD, MSc

M. Sarper Erdogan is with Istanbul University in Turkey. Christopher J. Martin is with West Virginia University in Morgantown.

For comments and further information, address correspondence to Dr Christopher J. Martin, Institute of Occupational and Environmental Health, Department of Community Medicine, West Virginia University School of Medicine. PO Box 9091. Morgantown, WV 26506-9190, USA. E-mail: [email protected]

Copyright Heldref Publications Summer 2008

(c) 2008 Archives of Environmental Health. Provided by ProQuest LLC. All rights Reserved.

Spontaneous Alternans in Brugada ST-Segment Morphology Within Minutes

By Ariyarajah, Vignendra Smith, Hugh; Hodge, Steve; Khadem, Aliasghar

Abstract Brugada syndrome is an inherited, life-threatening, cardiac channelopathy where the electrocardiogram (ECG) characteristically depicts a classic pattern of complete or incomplete right bundlebranch block with ST-segment elevation in the right precordial leads V^sub 1^ to V^sub 3^. These, almost inalienable, ECG patterns may be dynamic, where changes may resolve to baseline or one particular type may evolve into another. Such alternans has been described with fever, electrolyte imbalances, atrial pacing, glucose and/or insulin administration, psychotropic drugs, beta-adrenergic blocker use, class IA and IC antiarrhythmic provocation testing, such as with ajmaline, procainamide, or flecainide, and even large meals, that is, “full stomach sign.” However, spontaneous alternans between the different types of Brugada ECG patterns (types) have not been reported within minutes, in the absence of previously described precipitating factors. We present a novel case where classic, type 2, Brugada-like ECG pattern evolved spontaneously to type 1 before returning to type 2 within minutes of presentation.

(c) 2008 Elsevier Inc. All rights reserved.

Keywords: Brugada syndrome; Type 1; Type 2; Spontaneous alternans

Introduction

Brugada syndrome, first described in 1992 by Pedro and Josep Brugada,1 is an autosomal dominant, life-threatening, cardiac channelopathy where the electrocardiogram (ECG) characteristically depicts a classic pattern of complete or incomplete right bundle- branch block with ST-segment elevation in the right precordial leads V^sub 1^ to V^sub 3^ (Fig. 1). Three distinct types of Brugada-like ECG patterns have been described. In type 1, the ST-segment elevation is 2 mm and descends with an upward convexity to an inverted T wave (Fig. IA).2 This is the classic Brugada type and is often referred to as the “coved-type” Brugada pattern. The type 2 and type 3 patterns demonstrate J-point elevation and have a “saddleback-type” Brugada ST-T wave configuration where the elevated ST segment descends toward the baseline, then rises again to an upright or biphasic T wave. The ST segment is elevated 1 mm in type 2 and less than 1 mm in type 3 (Fig. IB and C).2 These, almost inalienable, ECG patterns may be dynamic, where changes may resolve to baseline or one particular type may evolve into another. Such altemans has been described with fever,3 electrolyte imbalances,4 atrial pacing,5 glucose and/ or insulin administration,5 psychotropic drugs,6 beta-adrenergic blocker use,7’8 class IA and IC antiarrhythmic provocation testing, such as with ajmaline, procainamide, or flecainide,9’10 and even large meals, that is, “full stomach sign.”11 However, spontaneous alternans between the different types of Brugada ECG patterns (types) have not been reported within minutes, in the absence of previously described precipitating factors. We present a novel case where classic type 2 Brugada-like ECG pattern evolved spontaneously to type 1 before returning to type 2 within minutes of presentation.

Case scenario

A previously healthy, 43-year-old, afebrile, Filipino male, who was not on any medications, presented to the emergency department of a peripheral community hospital with chest discomfort. The Brugada- like ST-segment elevations on his ECG (Fig. 2) were misdiagnosed as acute myocardial infarction, and he was given thrombolytic therapy. However, his symptoms did not resolve. Despite negative cardiac enzyme markers and normal serum biochemistry, he then underwent coronary artery angiography. Only when the coronary angiogram showed nonocclusive normal coronary anatomy, a potential arrhythmogenic conduction abnormality was considered.

Fig. 1. Types of Brugada-type ECG patterns.

When the patient’s medical information was reviewed by the arrhythmia service, in the absence of other potential causes for such ECG findings (Table I),2 Brugada syndrome was diagnosed. Interestingly, this patient’s serial ECGs demonstrated spontaneous alternans between the different types of Brugada-like ECG patterns within minutes of each other (Fig. 2). Classic “saddleback-type” patterns of type 2 Brugada-like ECG pattern changed spontaneously to “coved-type” type 1 and subsequently reverted to type 2 within minutes, without drug provocation and in the absence of known factors that could induce change. These spontaneous changes occurred repeatedly, even before beta-adrenergic blocker administration. The patient has been scheduled for electrophysiologic assessment.12

Fig. 2. Evolution from type 2 to type 1 Brugada-type ECG pattern in our patient. A, August 14, 2007, 1840 hours-after administration of sublingual nitroglycerine. B, August 14, 2007, 1853 hours-after administration of aspirin and more sublingual nitroglycerine. C, August 14, 2007, 1923 hours-after administration of more sublingual nitroglycerine and thrombolytic therapy. D, August 14, 2007, 2019 hours-after administration of intravenous beta-adrenergic blocker.

Table 1

Differential diagnosis for the ECG pattern (ie, ST-segment elevation in the right precordial leads)

Discussion

Chest pain is an unusual presentation of Brugada syndrome.2 Syncope and cardiac arrest are, by far, the most common clinical manifestations associated with this disease.2 Because sudden unexplained nocturnal death syndrome or “SUNOS”13 is similarly associated with nocturnal death and can be preceded by nightmares with nocturnal thrashing, these syndromes that are sometimes mistaken for seizures are thought to be phenotypically, genetically, and functionally the same entity.13 Indeed, in several Southeast Asian populations, where it is endemic, it is known by various names such as Bangungut (to rise and moan in sleep) in the Philippines, Lai Tai (death during sleep) in Thailand, and Pokkuri (unexpected sudden death at night) in Japan.14

Brugada syndrome has a male preponderance and usually affects men aged 30 to 50 years.2 Commonly, patients have a structurally normal heart. However, in 30% of patients and families with Brugada syndrome, mutations in the SCN5A gene, which encodes for the voltage- gated cardiac fast sodium channel, have been thought to be the culprit abnormality.2 The resultant inhomogeneities in epicardial and endocardia! action potentials from reduced sodium current flow allows the transient outward current to predominate, primarily in the superior portion of the anterior right ventricular myocytes, where this phenomenon is most strongly expressed.2 This manifests as ST-segment elevation in precordial leads V^sub 1^ to V^sub 3^ in the setting of a complete or incomplete right bundle-branch block pattern.

Fazelifar et al15 reported spontaneous alternans in Brugada-type ECG patterns between type 1 (coved type) and type 2 (saddleback type), particularly in lead V^sub 2^, after permanent implantable pacemaker failure. However, these changes did not occur within minutes. Moreover, in that case, such ECG changes were only noted when the R-R interval changed. They noted the saddleback pattern with decreased R-R interval and coved type pattern with increased R- R interval. Our patient clearly did not have significant change in the R-R interval. During a 40 +- 19-month followup, where 124 consecutive patients with Brugada-type ECG patterns were studied, Ikeda et al16 showed that spontaneous ST-segment change was noted in 41 patients (33%); 28 had manifestation, augmentation, or normalization of ST-segment elevation, 12 had a change from saddleback type to coved type, or vice versa, and 9 had visible alternans on continuous ECG monitoring. However, these observations did not occur within minutes as noted with our patient. The authors however showed that spontaneous change in STsegment elevation was most significant (relative hazard, 9.2; P = .036) among the risk indices for subsequent events that were evaluated such as family history of sudden death, syncopal episodes, spontaneous coved-type ST-segment elevation, and late potentials. Because such changes occurred frequently after a large meal, Ikeda et al11 also later demonstrated that the “full stomach test” could be used to identify high-risk Brugada syndrome patients.

T-wave alternans in Brugada syndrome has also been shown to occur with administration of sodium channel blockers, glucose, and atrial pacing.5 Miyazaki et al7 observed that intravenous isoproterenol consistently reduced ST-segment elevation by >/=0.1 mV or greater for 80 milliseconds after the J point in their patients with Brugada syndrome. They also observed that selective alpha-adrenoceptor stimulation by intravenous norepinephrine in the presence of propranolol or by intravenous methoxamine consistently augmented the ST-segment elevation, whereas alpha-adrenoceptor blockade reduced the ST-segment elevation. Aouate et al8 also presented a case where intentional propranolol overdose resulted in unmasking of the typical coved-type Brugada ECG pattern. Our patient, however, did not receive beta- or alpha-adrenergic blocker therapy while the ST- segment elevations evolved. It is also unknown what the exact role of sublingual nitroglycerine would be in this scenario, although alteration in Brugada ECG pattern after nitroglycerine has been described.17 In addition, there have been no known reports of such ECG change induced by thrombolytic therapy. Although it is unlikely that thrombolytic therapy had any effect on these ECG changes, interestingly, these changes occurred only after or at the time of its administration. Further study is certainly warranted to perhaps ascertain novel factors that may contribute to this phenomenon. Acknowledgment

We thank Maureen Kuppe, CAS, for preparing the figures.

References

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographie syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391.

2. Wilde AA, Antzelevitch C, Borggrefe M, et al. Study Group on the Molecular Basis of Arrhythmias of the European Society of Cardiology. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002; 106:2514.

3. Saura D, Garcia-Alberola A, Carrillo P, Pascual D, Martinez- Sanchez J, Valde M. Brugada-like electrocardiographic pattern induced by fever. PACE 2002;25:856.

4. Kovacic JC, Kuchar DN. Brugada pattern electrocardiographic changed associated with profound electrolyte disturbance. PACE 2004;27:1020.

5. Nishizaki M, Fujii H, Sakurada H, Kimura A, Hiraoka M. Spontaneous T wave altemans in a patient with Brugada syndrome- responses to intravenous administration of class 1 antiarrhythmic drug, glucose tolerance test, and atrial pacing. J Cardiovasc Electrophysiol 2005;16: 217.

6. Rouleau F, Asfar P, Boulet S, et al. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J Cardiovasc Electrophysiol 2001;12:61.

7. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Ogawa S. Autonomie and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996;27:1061.

8. Aouate P, Clerc J, Viard P, Seoud J. Propranolol intoxication revealing a Brugada syndrome. J Cardiovasc Electrophysiol 2005;16:348.

9. Brugada R, Brugada P, Brugada J. Electrocardiogram interpretation and class I blocker challenge in Brugada syndrome. J Electrocardiol 2006; 39(Suppl4):S115.

10. Hong K, Brugada J, Oliva A, et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 2004; 110:3023.

11. Ikeda T, Abe A, Yusu S, et al. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. J Cardiovasc Electrophysiol 2006; 17:602.

12. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST- segment elevation in precordial leads Vl to V3. Circulation 2002;105:73.

13. Vatta M, Dumaine R, Varghese G, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNOS), a disease allelic to Brugada syndrome. Hum MoI Genet 2002;! 1:337.

14. Di Grande A, Tomaselli V, Massarelli L, Amico S, Bellanuova I, Barbera A. Brugada-like electrocardiographic pattern: a challenge for the clinician. Eur J Intern Med 2006; 17:3.

15. Fazelifar AF, Haghjoo M, Arya A, et al. Spontaneous alternans in Brugada ECG morphology. J Interv Card Electrophysiol 2006;!5: 131.

16. Ikeda T, Takami M, Sugi K, Mizusawa Y, Sakurada H, Yoshino H. Noninvasive risk stratification of subjects with a Brugada-type electrocardiogram and no history of cardiac arrest. Ann Noninvasive Electrocardiol 2005;10:396.

17. Matsuo K, Shimizu W, Kurita T, Inagaki M, Aihara N, Kamakura S. Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 1998;9:508.

Vignendra Ariyarajah, MD,* Hugh Smith, MD, Steve Hodge, MD, Aliasghar Khadem, MD

Division of Cardiology, Department of Medicine, St Boniface General Hospital, University of Manitoba, Winnipeg, Manitoba, USA

Received 29 August 2007; accepted 15 November 2007

* Corresponding author. WRHA/SBGH Cardiac Sciences Program, Bergen Cardiac Care Centre, Winnipeg, MB R2H 2A6, USA. Tel: +1 204 510 2235; fax: +1 204233 9162.

E-mail address: [email protected]

Copyright Churchill Livingstone Inc., Medical Publishers Jul/Aug 2008

(c) 2008 Journal of Electrocardiology. Provided by ProQuest LLC. All rights Reserved.

Oral Verapamil Effectively Suppressed Complex Ventricular Arrhythmias and Unmasked U Waves in a Patient With Andersen-Tawil Syndrome

By Erdogan, Okan Aksoy, Alper; Turgut, Nilda; Durusoy, Elcim; Samsa, Murat; Altun, Armagan

Abstract Andersen-Tawil syndrome (ATS) is a rare, heterogeneous, autosomal dominant, or sporadic disorder characterized by the clinical triad of periodic paralysis, dysmorphic features, and ventricular arrhythmias such as bidirectional ventricular tachycardia (BVT). We present a case of an elderly patient with ATS whose symptomatic ventricular arrhythmias including BVT were effectively suppressed by oral verapamil therapy. (c) 2008 Elsevier Inc. All rights reserved.

Keywords: Andersen-Tawil; Verapamil; Bidirectional VT; U wave; Long QT; Therapy; Sudden death

Introduction

Andersen-Tawil syndrome (ATS) is a rare, heterogeneous, autosomal dominant, or sporadic disorder characterized by the clinical triad of periodic paralysis, dysmorphic features, and ventricular arrhythmias.’ One gene, KCNJ2, has been identified so far and more than 20 mutations have been reported. Reduced IKl resulting from KCNJ2 mutations alters late cardiac repolarization by increasing its duration and leads to both distinctive T-U wave morphology and an increased propensity to ventricular arrhythmias.2 Although the frequency and pattern of ventricular arrhythmias vary considerably among affected subjects, it is a common finding and includes frequent premature ventricular complexes (PVCs), bigeminy, polymorphic ventricular tachycardia (PVT), and bidirectional VT (BVT). Despite frequent VT burden, most ATS patients are remarkably asymptomatic, and sudden cardiac death is exceedingly rare.1-8 However, management of complex ventricular arrhythmias and prevention of cardiac arrest still remain elusive given the lack of large comparative clinical studies. We present here a case of an elderly lady who incidentally was diagnosed with ATS and successfully treated with oral verapamil for symptomatic complex ventricular arrhythmias including BVT.

Case presentation

A 65-year-old woman with a history of hypertension and abdominal surgery for hydatid cyst in the liver presented to the emergency department with presyncope, palpitation, and generalized muscle weakness associated with nausea and vomiting. Surface electrocardiogram (ECG) demonstrated that the rhythm was nonsustained VT (12 beats) consisting of polymorphic PVCs that originate late after T wave from prominent U waves and a short run of BVT preceded by sinus complex (Fig. 1). During previous admissions for symptomatic ventricular arrhythmias, both beta- blocker and propafenone as well as sotalol, whose first dose (40 mg) once elicited torsades de pointes according to past medical records, were ineffective for suppression of arrhythmias. Family history revealed that her brother suddenly died of unknown cause at a young age. Coronary angiography and transthoracic echocardiography performed during last admission showed normal findings. Her physical examination revealed short stature (height, 1 m 40 cm; weight, 40 kg), micrognathia, small hands and feet, and clinodactyly of fifth fingers in both hands. Her blood potassium level on admission was 3.5 mmol/L, although successive values on subsequent days showed slight variations (range, 3.84.7 mmol/L). Neurological evaluation revealed that she was having recurrent episodes of mild proximal muscle weakness beginning from childhood. She also referred difficulty releasing her hand grip. Her global cognitive status was impaired. Standardized mini-mental test (SMMT-E) score was calculated as 15 (normal, >24). Suggesting intracellular calcium overload and triggered activity as the probable mechanisms, we speculated that empiric therapy with verapamil might be effective in suppressing frequent BVT episodes. On the third day of oral verapamil (40 mg TID) therapy, BVTs were suppressed before the rhythm initially converted to bigeminy and then to sinus rhythm with interspersed PVCs every other third or fourth beat. We were then able to reliably measure the baseline ECG intervals (Fig. 2). The PR interval and QRS duration were normal. On precordial leads, there were prominent U waves maximally measured in amplitude as 0.3 mV, with a maximal duration of 200 milliseconds in lead V5. The interval between T peak and U peak was significantly prolonged and measured 240 milliseconds. Both QU and QUc intervals were prolonged and maximally measured 720 milliseconds, whereas QT and QTc intervals remained normal and were measured as 440 milliseconds at a heart rate of 60 beats per minute, respectively. T-wave amplitude and duration were 0.15 mV and 120 milliseconds, respectively. The QU dispersion measured in all leads including limb leads was calculated to be 60 milliseconds, which was mainly related to prolongation of QU intervals between right and left precordial leads. Prolonged repolarization times including prominent U waves, high ventricular arrhythmia burden associated with typical BVT episodes, and symptoms suggestive of periodic muscle paralysis and typical dysmorphic features mentioned previously suggested a high clinical probability of ATS. Treadmill exercise test performed during verapamil therapy induced bigeminy, which gradually subsided during recovery phase (Fig. 3, A and B). The QT and QU intervals during and after exercise were not significantly changed. Holter ECG recorded on the 12th day after oral verapamil therapy revealed that the high burden of complex ventricular arrhythmias such as BVT, couplets and triplets, were completely suppressed. There were no significant changes in U- wave amplitude and duration after verapamil therapy. At follow-up 7 months later, while the patient was still on verapamil therapy, Holter ECG revealed absence of BVT and nonsustained VT with frequent episodes of bigeminy, which however could not be effectively suppressed by oral verapamil. In addition, symptoms related to arrhythmias disappeared, and the patient’s quality of life significantly improved during follow-up.

Fig. 1. Nonsustained VT episode (12 beats) consisting of polymorphic PVCs and a short run of BVT preceded by sinus complex.

Fig. 2. Surface ECG was recorded after verapamil therapy was started, and complex ventricular arrhythmias were suppressed.

Fig. 3. Recovery phase of treadmill exercise test during oral verapamil therapy. A, Bigeminy induced with exercise gradually subsided during recovery. B, Note prominent U waves on precordial leads.

Discussion

Andersen-Tawil syndrome is a rare autosomal dominantly inherited disorder that demonstrates high clinical variability and nonpenetrance. Specific ventricular arrhythmias such as BVT, although rare, have been described extensively in association with ATS.1 In the absence of other causes such as digitalis toxicity and catecholaminergic PVT, occurrence of BVT should prompt a thorough search for other features of ATS in a given individual. It is associated with intracellular calcium overload and sodium/calcium- mediated triggered activity in ATS.3 Verapamil given intravenously at a dose of 2.5 mg effectively terminated BVT and suppressed further episodes of BVT in a young patient with ATS.7 Similar to that reported case, oral verapamil effectively suppressed BVT and decreased the frequency of polymorphic PVCs in our patient. It also unmasked underlying prominent U waves that are now considered as markers of delayed afterdepolarizations and promoters of BVT/ polymorphic VT by triggering delayed afterdepolarizations at multiple shifting sites.3 Amiodarone, beta blockers, and other class 1 antiarrhythmic drugs including mexiletine and propafenone have been described ineffective in select patients.8 A recent study demonstrated genotype-specific T-U-wave patterns that included prolonged terminal T-wave downslope, a wide T-U junction, and biphasic enlarged U waves. These T-U-wave patterns were not seen in the ATS non-KCNJ2 patients or normal subjects and could therefore be used to distinguish carriers of KCNJ2 mutations from normal subjects or ATS patients without KCNJ2 mutations and long QT syndrome, with excellent sensitivity and specificity.2 Our patient interestingly demonstrated similar ECG features observed in patients with KCNJ2 mutation and accordingly could be inferred to be an ATS1 genotype- positive individual. In conclusion, verapamil seems to be an effective agent for treating BVT and suppressing VT episodes in patients with ATS.

References

1. Venance SL, Cannon SC, Failho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 2006;129:8.

2. Zhang L, Benson DW, Tristani-Firouzi M, et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation 2005;111:2720.

3. Tristani-Firouzi M, Jensen JL, Donaldson MR, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002;110:381.

4. Chun TO, Epstein MR, Dick M, et al. Polymorphic ventricular tachycardia and KCNJ2 mutations. Heart Rhythm 2004;1:235.

5. Peters S, Schulze-Bahr E, Etheridge SP, Tristani-Firouzi M. Sudden cardiac death in Andersen-Tawil syndrome. Europace 2007;9:162.

6. Efremidis M, Pappas LK., Sideris A, Letsas KP, Gavrielatos GD, Kardaras F. Swimming-triggered aborted sudden cardiac death in a patient with Andersen-Tawil syndrome. Int J Cardiol 2006;112:e45. 7. Kannankeril PJ, Roden DM, Fish FA. Suppression of bidirectional ventricular tachycardia and unmasking of prolonged QT interval with verapamil in Andersen’s syndrome. J Cardiovasc Electrophysiol 2004; 15:119.

8. Smith AH, Fish FA, Kannankeril PJ. Andersen-Tawil syndrome. Indian Pacing Electrophysiol J 2006;6:32.

Okan Erdogan, MD,a,* Alper Aksoy, MD,b Nilda Turgut, MD,b Elcim Durusoy, MD,b Murat Samsa, MD,b Armagan Altun, MD(b)

a Department of Cardiology, School of Medicine, Marmara University, Istanbul, Turkey

b Department of Cardiology, School of Medicine, Trakya University, Edirne, Turkey

Received 29 September 2007

* Corresponding author. Marmara Universitesi Tip Fakutesi Hastanesi, Altunizade, Istanbul, Turkey. Tel.: +90 216 327 10 10; fax: +90 212 327 60 35.

E-mail address: [email protected]

Copyright Churchill Livingstone Inc., Medical Publishers Jul/Aug 2008

(c) 2008 Journal of Electrocardiology. Provided by ProQuest LLC. All rights Reserved.

Orbis Education Expands Nursing Education Program to Glendale, California

INDIANAPOLIS, Aug. 13 /PRNewswire/ — Orbis Education has announced the launch of a new collaborative accelerated nursing program in the city of Glendale, California, in conjunction with the University of Oklahoma, San Diego State University and Glendale Adventist Medical Center. This is the second program of its kind from Orbis, with the first being launched a year ago in San Diego, California. The expansion of the program to Glendale allows students in the Los Angeles area to earn an Accelerated Second Degree BSN from the University of Oklahoma College of Nursing.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080813/LAW528LOGO)

This innovative program blends tradition and technology, offering leading-edge online education and traditional on-site clinical education. Orbis works transparently to manage logistics from the beginning to the end of this process, including developing relationships with potential college affiliates, scouting clinical locations, conducting all marketing and public relations student recruitment efforts and managing the day-to-day operations. In establishing the new program, Orbis works diligently to meet the highest standards in education and health care set forth by all affiliates and regulatory bodies.

“The San Diego program has proven to be a success, with the first Accelerated BSN class scheduled to graduate this December,” said Daniel Briggs, CEO of Orbis Education. “We are looking forward to having the nursing program running simultaneously at two locations and plan to continue implementing similar solutions with additional hospitals throughout the country.”

In Glendale, students without previous healthcare experience and a degree in another field can become a nurse in as few as 14 months. The theory portion of the program is taught completely online by the faculty of OU, and the clinical education component is taught at Glendale Adventist Medical Center by adjunct appointed faculty.

“In California, it’s estimated that over 10,000 new registered nurses will be needed each year for the next six years,” Briggs said. “Hospitals today are being proactive in searching for ways to efficiently meet the high demand for nurses and our program is the solution they’ve been looking for.”

According to a PricewaterhouseCoopers’ report(1), the “use of temporary nurses is no longer a stop-gap measure but has become a way of life for many hospitals.” Also noted in the report, hospital executives are challenged by the overhead associated with attracting and retaining quality nurses. Current efforts to control the nursing shortage are taking away resources better spent on patient care. With the new collaboration in Glendale, dramatic cost reductions are expected to be seen in approximately 15 to 20 months, with cost savings increasing each year.

“Orbis Education provided us with a transparent solution to help educate the nurses our community needs,” said Gwen Matthews, Senior Vice President of Clinical Services and Chief Nursing Officer of Glendale Adventist Medical Center. “We now host a fully accredited nursing program on premise without having to manage, recruit or administer anything.”

Graduates of the program will earn a Bachelor of Science in Nursing degree through a 14-month curriculum, provided they already hold a baccalaureate degree in another field. The curriculum is comprehensive, encompassing more than 600 hours of online course work and more than 900 hours of hands-on clinical preparation. Theory courses will be taught by University of Oklahoma nursing faculty via interactive online classes that include threaded discussions, real-time web casts, projects, assignments and proctored examinations. Students have the flexibility of completing the online courses during day or evening hours. Hands-on clinical preparation is taught by appointed adjunct University of Oklahoma faculty assigned to work directly with students at Glendale Adventist Medical Center.

About Orbis Education

Founded in 2003, Orbis Education leverages opportunities in nursing education by affiliating existing nursing education programs with major hospitals. Orbis works to help solve the nursing shortage problem across the country, improve patient care and improve the cash flow and bottom line for affiliate hospitals. For more information visit http://www.orbiseducation.com/.

(1) “What works: Healing the healthcare staffing shortage” by

PricewaterhouseCoopers’ Health Research Institute; 2007.

Photo: http://www.newscom.com/cgi-bin/prnh/20080813/LAW528LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]

Orbis Education

CONTACT: Mairim Martinez, +1-949-833-3822, [email protected], forOrbis Education

Web site: http://www.orbiseducation.com/

Plan to Improve Sex Ratio Gets CM’s Nod

By Surender Dhiman

Chandigarh: To boost the falling sex ratio in Haryana the health department has formulated a new scheme, Jacha Bacha Yojna, under which if a female child is born in a health institution then the doctor and multipurpose health worker will get an incentive of Rs 600 each. For a male child it is Rs 400. The staff nurse will get Rs 100, laboratory technician and cleaner Rs 50 for every delivery. Chief minister Bhupinder Singh Hooda has given his nod to the scheme.

Presently, 5.25 lakh deliveries take place in a year in the state, of which 3.75 lakh are reported in rural areas. Of these only 18% are done in government institutions. The National Rural Health Mission has made it mandatory to reduce the MMR, IMR and skewed sex ratio.

“There is a need to substantially enhance institutional deliveries by converting all sub-centres , primary health and community health centres as preferred ones for institutional deliveries,” said Anuradha Gupta, financial commissioner and principal secretary, health department, Haryana. A system of regular ante-natal check up and measures to reduce anemia and ensure health of pregnant women had also been worked out, she added.

Anuradha said, “High risk pregnancies will be identified well in advance to tie up proper referral.” She added that the chief minister would launch the new scheme in the state on Independence Day.

Health centre docs to work in rural areas

Doctors, multi-purpose health worker will have to go to the rural areas for a fixed tenure. Anuradha Gupta said, “Every doctor of a public health and community health centre will have to go to rural areas as per roster. The fixed day visit schedule is being notified to all sarpanches, headmaster/principal in schools and angarwaris.”

(c) 2008 The Times of India. Provided by ProQuest LLC. All rights Reserved.

Readers Dash to Rescue for Sick Dylan ; Greg Tindle Health Correspondent

ECHO readers have come to the aid of a family who needed a vital piece of equipment for their sick son.

Paul and Claire Bethell have been overwhelmed by the generosity of readers who we removed by the plight of their son Dylan, who was born with a rare and possibly fatal condition.

Paul, together with three friends, recently endured a full body wax to raise money for a special monitor to help son Dylan, who has a lung disease that sees him regularly admitted to hospital.

His appeal for the pounds 1,200 piece of equipment was highlighted by the Echo two weeks ago and within just a few days, readers ensured they reached their target.

Paul and mum Claire have now raised the full amount for the monitor to be used at their home.

Dylan’s medical problems have been caused by a lung disease called primary pulmonary lymphangiectasia, which is so rare, it’s believed the two-year-old may be the only person in Wales suffering with it.

Dylan is also allergic to the smallest traces of fat, a condition which provides a major shopping headache for 25-year-old Claire with every single purchase – apart from most fruit and vegetables – having to be checked carefully.

Paul, 33, a security guard at Cardiff International Airport, said: “Dylan’s been regularly in and out of hospital almost since the day he was born. When he gets ill with breathing problems he cannot get enough oxygen into his blood. The monitor helps us keep an eye on his blood oxygen levels and gives us peace of mind.”

Paul, of Cornwall Road, Barry, said: “The response from Echo readers was phenomenal.

I had no idea how generous people can be.

We have also received more than pounds 200 from the staff Sports and Social Club at the University Hospital of Wales, in Heath, Cardiff.

“The Echo readers have not only sent us money but some of the stories they had to tell about what their own children went through have been very touching, even humbling.”

Paul said that any extra money collected above their target was being donated to another child who has received regular treatment at the Children’s Hospital for Wales and also needs home monitoring equipment.

[email protected]

(c) 2008 South Wales Echo. Provided by ProQuest LLC. All rights Reserved.

Sacred Heart Hospital in Springfield Opens

By Libby Tucker

After five years under construction, the $500 million Sacred Heart Medical Center in Springfield is complete and open to the public. Owner and developer PeaceHealth began moving patients on Sunday from its 104-bed University District hospital in Eugene to the new 1.2-million-square-foot facility.

General contractor Turner Construction Co. broke ground on the RiverBend development in 2003 and wrapped up the project in July as PeaceHealth conducted mock exercises to prepare patients and staff members for the move.

The massive complex, on 181 acres near the McKenzie River, is the length of two football fields and includes a 150,000-square-foot Oregon Heart and Vascular Institute and 125,000 square feet of medical office buildings connected to the main tower with sky bridges, as well as parking for 1,000 cars. Services at the nonprofit hospital also include a Neurosciences Institute, Gerontology Institute, and Neonatal Intensive Care Unit.

The facility sits on the site like a sprawling estate with architecture meant to evoke a mountain retreat. Health-care architects Anshen + Allen worked with resort designers Wimberly Allison Tong & Goo to create a high-tech hospital with a warm, friendly atmosphere.

“PeaceHealth wanted a state-of-the-art hospital, built and designed for 100 years,” said Terry Shugrue, senior project manager for Turner Construction Co. “They did evidence-based design, on the principle that a patient given a nicer environment will heal quicker and take less medication.”

The concrete structure is terraced and stepped back with concrete- tile roofs typically found on high-end homes. And the facade was finished in brick, unusual for a large building, with each of the 5 million bricks laid by hand.

Inside, a $250,000, three-story stone fireplace graces the entrance alongside a custom hardwood staircase made with Douglas fir trees salvaged from the lot. Patient rooms afford a view of either the mountains or the adjacent river.

“If you walk into a patient room you feel like you’re at a five- star hotel,” said Shugrue. “So if I get sick I definitely want to come to this joint.”

As one of the largest projects in Oregon under construction in a community of about 57,000 residents, the biggest challenge to Turner was finding subcontractors for the job to meet the owner’s request for local labor. No large mechanical and electrical contractors were to be found in the area, for example, according to Turner.

So the typically all-union shop turned to local non-union subcontractors with the condition that they pay their workers prevailing wage. Mechanical and electrical contracts were also divided into smaller pieces to accommodate local companies. In the end, Turner issued about 400 contracts with local contractors completing about 40 percent of the total hours spent on the project, according to Turner.

To keep up with the labor-intensive project, Turner spread shorter work shifts over more days for a consistent workforce of 650 to 700 workers. At its peak, the project could have employed 1,200 workers at once, but instead the labor was distributed evenly, said Shugrue.

“This building, when you see it,” he said, “it’s just amazing.”

Originally published by Libby Tucker.

(c) 2008 Daily Journal of Commerce (Portland, OR). Provided by ProQuest LLC. All rights Reserved.

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures

AUSTIN, Texas, Aug. 13 /PRNewswire/ — This week, doctors at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center became the first in the nation to implement the CoHesion(TM) 3D Visualization Module — an enhancement to the state-of-the art Hansen Robotic system used to treat cardiac arrhythmias. With the visualization module, patients undergoing the ablation treatment for heart arrhythmias are exposed to about 30 percent less radiation than without the new technology, among other benefits.

Heart arrhythmias are problems that affect the electrical system, or “wiring,” of the heart muscle. Heart arrhythmias are very common. Experts say that millions of people will experience an abnormal heart rhythm some time during their lives.

During cardiac ablation, doctors destroy, or ablate, a small spot of heart tissue to create an electrical block along the pathway that causes a heart arrhythmia. The new CoHesion(TM) module can help reduce potentially fatal complications during treatment. The improved accuracy of allowing physicians to more precisely control the robotic catheter can also reduce the time it takes to perform the procedure, cutting the amount of radiation exposure for patients by about 30 percent.

The new CoHesion(TM) module combines the EnSite System’s 3D cardiac chamber model with anatomic labeling with the Sensei system’s main navigation window, allowing physicians to see the location of Hansen Medical’s Artisan(TM) Control Catheters within the heart in 3D. This allows doctors to augment their ability to move a catheter throughout the heart, as well as increase control over placement of the catheter in specific locations in patients with heart arrhythmias. Previously, physicians used 3D imaging as a reference only.

Hansen Medical, Inc. received FDA approval for using the CoHesion(TM) 3D Visualization Module in complex electrophysiology mapping procedures in July, 2008.

TCAI — an international treatment, training and research center specializing in heart rhythm disorders — formally opened in April, 2008, under the direction of internationally renowned cardiac electrophysiologist Andrea Natale, M.D.

Texas Cardiac Arrhythmia/Texas Cardiovascular Consultants

Founded in 1996 by Rodney P. Horton, M.D., Texas Cardiac Arrhythmia, now a division of Texas Cardiovascular Consultants, has performed thousands of electrophysiology procedures and cared for thousands of patients, providing state-of-the-art care in Texas as well as in Central and South America. The team participates in clinical research, offering patients the latest technology while ensuring that physicians remain on the cutting edge. For more information about clinics throughout Austin and surrounding countries, as well as in Waco, Bryan, College Station, San Angelo, Temple, Killeen, Corpus Christi, Laredo and Odessa — please visit http://www.tcaheart.com/.

Founded in 1995, Texas Cardiovascular believes the successful delivery of effective cardiovascular care and health management depends on the establishment of a close working relationship with the patient, the availability of all of the latest diagnostic technologies, and physicians trained in all state-of-the-art techniques to prevent and treat cardiovascular disease. With more than 35 physicians and seven full-time offices, Texas Cardiovascular cares for patients throughout Central Texas and statewide.

St. David’s HealthCare

St. David’s HealthCare’s total capital investment related to the Texas Cardiac Arrhythmia Institute is approximately $36 million. The initial capital investment is $8 million for new technology and Institute infrastructure, $6 million for a hospital renovation project on the second floor where Institute patients receive care and another $22 million for a critical care patient tower that is currently in the planning stages. With the $36 million capital investment in TCAI, St. David’s HealthCare will have invested more than $680 million in Central Texas in the last 10 years.

St. David’s HealthCare is the fourth-largest private employer in the Austin area, with more than 6,200 employees and $2.3 billion in annual gross revenues. In 2007, St. David’s HealthCare was voted one of Austin’s “Best Places to Work” by the Austin Business Journal. For more information about St. David’s HealthCare or its hospitals: St. David’s North Austin Medical Center, St. David’s Round Rock Medical Center, St. David’s South Austin Hospital, St. David’s Medical Center, St. David’s Georgetown Hospital, and St. David’s Rehabilitation Hospital, please visit http://www.stdavids.com/.

    Media Contacts:    Kristin Marcum or Erin Ochoa    Elizabeth Christian & Associates Public Relations    512.472.9599  

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center

CONTACT: Kristin Marcum or Erin Ochoa, both of Elizabeth Christian &Associates Public Relations, +1-512-472-9599, for Texas Cardiac ArrhythmiaInstitute at St. David’s Medical Center

Web site: http://www.tcaheart.com/http://www.stdavids.com/

Train Like an Olympic Champion at Fitness First

Train like an Olympic Champion at Fitness First

Fitness First Middle East clubs will be equipped by Technogym, the Official Supplier for Fitness equipment and services at the Beijing 2008 Olympic Games.

Fitness First, a world leader in operating Commercial Health Clubs and Technogym, a world leader in developing and manufacturing Fitness and Wellness equipment and related services, have just signed a partnership agreement for the Middle East Region and Northern Africa.

This agreement presently includes over 20 clubs in 7 countries. Technogym will supply all clubs with their latest range of equipment, the same currently being used in the Olympic Village at the Beijing Olympics where Technogym are the exclusive official equipment supplier.

Fitness First Middle East will order over 1500 state of the art pieces of Cardio equipment from the Excite range, around 1000 Selection strength training machines, as well as the brand new FLEXability range of stretch machines. For their specialist work out zones Fitness First will order Kinesis, a platform for free movement; hiding the technology behind a beautifully designed wooden wall and offering a real body & mind experience, and Easy Line, a stylish circuit training line to develop specific programs for weight loss, – fantastic for ladies only facilities.

As well as innovative equipment, Technogym have created a personalized service solution including educational programs for Fitness First trainers and members.

In order to capitalize on the involvement of Technogym at the Olympics, one trainer from Fitness First will be a member of the Technogym Fitness team at Beijing 2008. In addition, Technogym have offered a hospitality package to “LIVE” the Olympic experience in Beijing for the promotion “Join Fitness First and fly to Beijing” which ran last May.

“We are very excited about this agreement” declared Gary Knill, CEO of Fitness First Middle East- “Technogym is the ideal partner to work with in this relatively young and fast growing market. We are looking forward to growing this business and being part of the many social responsibilities arising from the expansion of fitness and wellness in the Middle East and North Africa. When it comes to products and technology we really appreciate the unique Italian design which makes the equipment attractive and non intimidating. The Technogym commitment to innovation is fundamental for us at Fitness First because we always want to offer our members the cutting edge products and services. I recently visited Technogym Headquarters in Italy and I was amazed by the manufacturing plant and Research & Development Center: they are by far the most sophisticated and advanced in the industry; for us this is an additional value for our business”.

“We are very proud and happy of what we have achieved with Fitness First- states Nerio Alessandri, Technogym President In the last 3 years in the region, helping them launch a new era of fitness and wellness in the region. Points of reference for Fitness and Wellness have been to open in Dubai and all around Middle East, like the first club in Ibn Battuta Mall, DIFC and Burjuman in Dubai, the one in Mecca Mall, Jordan or WTC in Bahrain and many more. We are proud about the new stage of our relationship with Fitness First and are really excited about the future with new countries, new concepts, more people will enjoy a better lifestyle thanks to the perfect combination of Fitness First Clubs and Technogym equipment and services”.

Alongside the business focus, we also share with Fitness First the responsibility of spreading the concept and philosophy of wellness as a new and healthier lifestyle around the region”. 2008 Al Bawaba (www.albawaba.com)

Originally published by By Al-Bawaba Reporters.

(c) 2008 Al Bawaba. Provided by ProQuest LLC. All rights Reserved.

Two Girls Found Slain Were Shot 13 Times

By MANNY GAMALLO

OKLAHOMA CITY — Two young girls murdered near Weleetka on June 8 were shot a total of 13 times, according to autopsy reports released Friday by the state Medical Examiner’s Office.

Those reports, which go into graphic detail, noted that the youngest of the two — 11-year-old Skyla Jade Whitaker — was shot eight times. Her best friend, Taylor Paschal-Placker, 13, was shot five times, the reports noted.

Both were shot in the legs, torso, neck and base of the skull. The bodies of the girls were found in a shallow ditch about four miles northeast of Weleetka.

The girls had gone for a walk on that sunny Sunday afternoon to the Bad Creek bridge, half a mile north of Taylor’s home.

Authorities said the girls made it to the bridge and were returning to the Placker home when they were gunned down. They were less than 1,000 feet from Taylor’s home when shot.

No arrests have been made yet, though authorities are looking for possibly two killers, because each of the girls was shot with two different caliber bullets. Bullets recovered from the bodies of the girls also show two different sizes, the medical examiner’s reports state.

The Oklahoma State Bureau of Investigation believes the killers are from the Weleetka area, given the remote location of the crime scene.

From the autopsy reports, it was evident both girls were facing their killer or killers when gunned down. Authorities said the girls were not sexually molested.

So far, the OSBI has received nearly 600 leads in the case, half of which have been checked.

Agents have also questioned more than 100 people in the hopes of nabbing the killers.

The OSBI knows what caliber bullets and types of guns were used in the slayings, but authorities won’t divulge that information.

They also recovered spent shell casings from the crime scene. They’re not saying whether the casings yielded any fingerprints.

Manny Gamallo 581-8386

[email protected]

Originally published by MANNY GAMALLO World Staff Writer.

(c) 2008 Tulsa World. Provided by ProQuest Information and Learning. All rights Reserved.

IMS Sets Global Standard for Patient-Centered Metrics

IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced significant enhancements to its global suite of patient-centered longitudinal disease and treatment insights. Drawing from information on more than 250 million anonymized patients, the IMS LifeLink(TM) portfolio of information, analytics and consulting offerings delivers expanded, more relevant metrics for understanding healthcare market dynamics and shaping effective commercial strategies. IMS LifeLink enables pharmaceutical and biotech companies, medical researchers, government agencies, payers and other stakeholders to define appropriate clinical requirements, understand treatment patterns, and gauge disease progression for improving healthcare outcomes.

“The pharmaceutical landscape has changed dramatically in recent years, and a patient-centered perspective is essential to understanding the market environment,” said David Carlucci, chairman and CEO, IMS. “Our anonymized patient-level insights set the standard for demonstrating the value of medicines and optimizing commercial effectiveness – both at a portfolio and product level. Only IMS has made the extensive global investments needed to bring together a full range of capabilities to help healthcare stakeholders assess and respond to patient needs.”

IMS LifeLink enhancements seamlessly integrate the company’s comprehensive longitudinal prescription information and sub-national anonymized patient-level metrics with its provider-level prescription databases. With more granular information, clients can make informed decisions earlier in the product lifecycle, and realize meaningful performance and productivity gains. In addition, they can define patient populations that will derive the greatest clinical benefits from the right products, and engage prescribers with more timely, relevant information about treatments and therapies.

Recent IMS LifeLink offerings enhancements include:

— IMS Xponent Prescribing Dynamics(TM)- Expanded prescriber-level coverage in the U.S. extends anonymized patient-level analytics. As a result, clients can more precisely define patient segments that would benefit from their products, and better educate physicians about treatment variability.

— IMS NPA Market Dynamics(TM) – New views by diagnosis, ethnicity and treatment adherence enable clients to more effectively measure therapy use by patient type, as well as monitor overall compliance in the drive to improve patient outcomes.

— IMS Disease Dynamics On-Line(TM) – A recently launched Web-enabled tool in the U.K. supports fast access to information and guided analyses. Clients can more readily understand the true market potential of new medications and define patient populations based on current treatment patterns.

— IMS New-to-Brand – A new patient-based offering in Canada provides greater visibility into the volume of anonymized first-time prescriptions for retail brands treating chronic diseases.

— Consulting Studies – A broad range of custom studies leverages IMS’s disease and treatment information for insights across all major therapeutic areas and multiple geographies. By bringing together the company’s extensive information, analytics and consulting capabilities, IMS addresses critical client issues related to commercial effectiveness, product and portfolio strategy, and the value of medicines.

“Our team of experts applies real-world information to both anticipate and address evolving market and treatment dynamics,” said Ray Hill, general manager, Consulting and Services, IMS. “With IMS LifeLink, anonymized patient-level insights are at the forefront of clinical and commercial decisions – strengthening the link between specific diseases and available therapies. We’re uniquely qualified to help move the industry to a more unified approach to improving treatment of patients, measuring quality of care and managing costs.”

About IMS

Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries. With $2.2 billion in 2007 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com.

As a global leader in protecting individual patient privacy, IMS uses de-identified healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes.

Pennsylvania Governor Rendell Names Joseph Torsella State Board of Education Chairman

HARRISBURG, Pa., Aug. 13 /PRNewswire-USNewswire/ — Governor Edward G. Rendell today said he has named Joseph M. Torsella as chairman of the State Board of Education.

Torsella, who joined the board earlier this year, was among 12 board members unanimously confirmed by the state Senate in April.

“The State Board of Education is embarking on major initiatives that will impact students for years to come,” said Governor Rendell. “For example, it recently made changes to require the state’s colleges and universities to better prepare students to be the next generation of teachers; updated state academic standards; and improved state policies that address educational programs and services for students with disabilities.

“Joe will be terrific in implementing the new changes. Additionally, I cannot think of a more qualified individual who can facilitate the discussion about guaranteeing that our students graduate with the skills they need to be successful in the global workforce upon high school graduation,” the Governor said.

“I am excited and honored to have this opportunity to serve the commonwealth. No issue is more important to our common future, both economic and civic, than education in Pennsylvania,” said Torsella.

Torsella has served as president and CEO of the National Constitution Center since June 2006, securing and advancing the museum’s place as one of America’s most vital and dynamic institutions. He previously served as president and CEO from 1997 through 2003 and was the driving force behind the National Constitution Center’s concept, construction, and opening as a new tourism anchor on Independence Mall.

“Mr. Torsella’s education credentials and leadership at the National Constitution Center make him the ideal board chair,” said secretary of Education Gerald L. Zahorchak. “Under his leadership, the facility has become a hub of civic education and developer of curriculum and materials by working in cooperation with school District of Philadelphia to train classroom teachers and engage students. I look forward to his ideas and leadership benefiting all of Pennsylvania’s children.”

Torsella graduated Phi Beta Kappa with an honors degree in economics and history from the University of Pennsylvania. As a Rhodes Scholar, he did graduate work in American history at New College, Oxford. He is active in community and public affairs. He is a former director of Admiral Merchants Motor Freight and Young Scholars Charter School, and a current trustee of Pennsylvanians for Modern Courts, and Historic Philadelphia Inc. Torsella also served as volunteer board co-chair of Philadelphia 2016, the bi-partisan regional group that is leading the effort to bring the Olympics to Philadelphia He, his wife, Carolyn Short Torsella, a partner at the Reed Smith law firm, and their four children live in Flourtown, Montgomery County.

Torsella succeeds Karl Girton, who resigned as State Board of Education chair last month. Girton spent 17 years as the State Board of Education chair.

“Karl tirelessly worked on behalf of Pennsylvania’s children and worked on major policy changes during his tenure that positively affected all children of the commonwealth. His efforts are appreciated by all those in the educational community and by all those students whose lives he made better.

“I applaud Karl for his exceptional service to the students and schools of the commonwealth and thank him for his hard work and dedication,” said Governor Rendell.

The State Board of Education is the principal administrative regulatory body for elementary/secondary and higher education in Pennsylvania. Its recent duties have included the compilation of a statewide costing-out study, which was requested by the General Assembly, to determine the finances necessary to provide all students with a quality education.

For more information about the board, visit http://www.pde.state.pa.us/.

The Rendell administration is committed to creating a first-rate public education system, protecting our most vulnerable citizens and continuing economic investment to support our communities and businesses. To find out more about Governor Rendell’s initiatives and to sign up for his weekly newsletter, visit http://www.governor.state.pa.us/.

CONTACT: Michael Race of PDE, +1-717-783-9802, or Gary Miller of Pennsylvania Office of the Governor, +1-717-783-1116

Pennsylvania Office of the Governor

CONTACT: Michael Race of PDE, +1-717-783-9802, or Gary Miller ofPennsylvania Office of the Governor, +1-717-783-1116

Web Site: http://www.governor.state.pa.us/http://www.pde.state.pa.us/

Certain Nutrients Can Help Ease Symptoms of Autoimmune Disorders

By SUZY COHEN

Q: I have MS and I’ve taken the medicine Copaxone. Last year, you said not to rev up my immune system with vitamins. Can you explain why and tell me what kinds of supplements are safe? — R.T., Decatur,Ill.

A: Imagine looking into the mirror, but instead of seeing your sweet self, you see a creepy robber and then start punching yourself — and it hurts. That’s autoimmune disease — your immune system perceives its own tissue as an invader, then seeks to destroy it, little by little.

With rheumatoid arthritis, the joints are primarily affected; with Hashimoto’s, it’s the thyroid; with MS, it’s the brain and spinal cord nerves, and so on.

Avoid high doses of vitamin C, beta carotene, cat’s claw, echinacea and ginseng, among others. Why add fuel to the fire? Doing so may cause you to slip out of remission.

Copaxone has become a popular prescription drug choice for MS sufferers because it seems to spark some relief in patients, plus its side effects are reportedly less disabling. .

I’ll share some tips in the space provided, but there are so many other nutrients.

For now, consider a gluten-free diet and any of these nutrients:

DHA: A type of essential fatty acid found in fish oils that helps nourish nerve cells and balance angry inflammatory chemicals.

Vitamin D: The sunlight vitamin seems to help with MS.

Melatonin: It’s your sleep hormone, and people with MS seem to lack it.

Methylcobalamin: It’s a form of vitamin B12 that helps you remyelinate.

Padma Basic: This centuries-old formula was handed down from Tibet. It’s sold without a prescription in the United States, but overseas, it is called “Padma 28.” It’s all-natural, with 20 herbs and spices that balance your immune system and squash inflammation. It helps autoimmune sufferers because it’s “cooling” to an immune system that’s on fire. It’s also great for the blood circulation and heart.

Originally published by SUZY COHEN Dear Pharmacist.

(c) 2008 Tulsa World. Provided by ProQuest Information and Learning. All rights Reserved.

Parents Affect Child’s Eating Habits

Providing fruits for snacks and serving vegetables at dinner can shape a preschooler’s eating patterns for his or her lifetime.

To combat the increasing problem of childhood obesity, researchers are studying how to get preschoolers to eat more fruits and vegetables. According to researchers at Washington University in St. Louis, one way is early home interventions “” teaching parents how to create an environment where children reach for a banana instead of potato chips.

“We know that parents have tremendous influence over how many fruits and vegetables their children eat,” says Debra Haire-Joshu, Ph.D., a professor at the George Warren Brown School of Social Work. “When parents eat more fruits and vegetables, so do their children. When parents eat and give their children high fat snacks or soft drinks, children learn these eating patterns instead.”

Haire-Joshu and researchers at Saint Louis University School of Public Health tested a program that taught parents in their homes how to provide preschool children easy access to more fruits and vegetables and examined whether changes in what the parents ate affected what their children consumed. The study was published in the July issue of the journal Preventive Medicine.

“This research shows that it’s important to communicate with parents in real world settings,” Haire-Joshu says. “They control the food environment for their young child. This environment is key to not only what children eat today but how they will eat in the future.”

Past research has shown that diets high in fruits and vegetables are associated with a lower risk of obesity. Previous studies also have established that children learn to like and eat vegetables at a young age “” before they turn five years old.

In this five-year study in rural, southeast Missouri, 1,306 parents and children between the ages of two and five participating in Parents As Teachers, a national parent education program, were randomly assigned to two groups. One group enrolled in the High 5 for Kids program, and the other group received standard visits from Parents as Teachers. In the High 5 for Kids group, parents first completed a pretest interview about fruit and vegetable consumption.

Parent educators then visited the home four times, providing examples of parent-child activities designed around nutrition, such as teaching the child the names and colors of various fruits and vegetables and having the child select a variety of fruits and vegetables for breakfast. At each visit, parents also received materials and informational handouts with suggestions for improving feeding practices and the food environment in the home. Many of these materials were tailored to the individual patterns of that parent, with suggestions for how to improve his or her specific intake and that of their child.

Additionally, children were given four High 5 for Kids sing-along-stories with audiocassettes and coloring books.

The same parent interviewed before the intervention completed a telephone survey to determine changes in the number of fruits and vegetables eaten and behaviors of both the preschool children and parent. The average time between the before and after intervention survey was seven months.

Parents in the High 5 for Kids group ate significantly more fruits and vegetables, and a change in the parent’s servings of fruits and vegetables predicted a change in the child’s diet, too. An increase of one fruit or vegetable serving per day in a parent was associated with an increase of half a fruit or vegetable serving per day in his or her child. These parents also reported an increase in fruit and vegetable knowledge and availability of fruits and vegetables in the home.

Although the High 5 for Kids program was effective in improving fruit and vegetable intake in children of normal weight, overweight children in this group did not eat more of these foods. “Overweight children have already been exposed to salty, sweet foods and learned to like them,” says Haire-Joshu, who also holds an appointment at the School of Medicine as a professor. “To keep a child from becoming overweight, parents need to expose them early to a variety of healthy foods and offer the foods many times.”

Haire-Joshu says many children today are taught patterns that lead to obesity. “We want families to provide their child with an environment in which they not only learn how to eat healthy but have the opportunity to practice what they learn,” she says. “And by partnering with Parents As Teachers, we now can disseminate this program to their sites nationwide. This further impacts healthy eating patterns in parents and their preschool children.”

On the Net:

WoundStat Inventors Recognized for Their Outstanding Medical Research Contributions to Combat Casualty Care

Virginia Commonwealth University (VCU) researchers Kevin Ward, MD, Robert Diegelmann, PhD, and Gary Bowlin, PhD, this week received the Award for Excellence in recognition of their outstanding contributions to combat casualty care from the US Army Medical Research and Materiel Command, Combat Casualty Care Research Program. The three invented WoundStat(TM), a ground-breaking hemostatic agent for control of bleeding in high-pressure arterial wounds, which are a common combat injury. The award was given to the group “in recognition of their hemorrhage control research, and the resultant development of WoundStat, a product that will significantly increase survival of the combat wounded.”

The award was given at the Advanced Technology Applications for Combat Casualty Care (ATACCC) 2008 Conference, and this is one of the few times the award has been given to someone who was not a member of the military.

“I’m gratified, and I’m proud of the award,” said Dr. Ward. “Our team did great work in inventing WoundStat. It is rewarding knowing that your work can help save lives of warfighters and other trauma victims, and it is great to be recognized as well.”

After years of research, Ward, Diegelmann, and Bowlin developed a versatile and robust hemostatic material that is specifically suited to treat the tremendously complex wounds of war under very demanding environmental conditions. WoundStat is both very absorbent and adherent, which helps to quickly stop the bleeding while simultaneously facilitating clotting.

The patent-pending technology behind WoundStat is the result of more than three years of medical research and development by VCURES. The university center not only conducts research on life-saving technologies, it plays a key role in training Special Operation Combat Medics in the U.S. military.

“We are proud of these gentlemen — not only for their scientific and medical expertise, but also for their dedication to our collective mission of advancing combat casualty care. WoundStat is now being deployed within the US military and has the potential to dramatically increase the survival rate of warfighters with severe, bleeding injuries,” commented Devinder Bawa, CEO of TraumaCure, which manufactures and markets WoundStat. “Our partnership with VCU and these dedicated scientists has been tremendously productive.”

Four different medical research studies – including the one conducted by the U.S. Army’s Institute for Surgical Research (ISR) – have consistently proven that WoundStat is the most effective hemostat available for high pressure arterial wounds.

About VCU and the VCU Medical Center

Virginia Commonwealth University is the largest university in Virginia and ranks among the top 100 universities in the country in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 30,000 students in nearly 200 certificate and degree programs in the arts, sciences and humanities. Sixty-three of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation’s leading academic medical centers. For more, see www.vcu.edu.

About TraumaCure

TraumaCure, based in Bethesda, Maryland, supplies the most effective, reliable treatments for life-threatening bleeding wounds. TraumaCure’s hemostatic products help stabilize a wounded individual prior to receiving advanced medical treatment. The company’s products are made in the U.S. and are proven to save lives and improve outcomes following traumatic injury. TraumaCure is committed to providing the most trustworthy and innovative hemostasis treatments for the military, emergency responders, and civilians.

Release Summary:

Kevin Ward, Robert Diegelmann, and Gary Bowlin this week received an Award for Excellence for their hemorrhage control research and the development of WoundStat, a hemostatic agent that will significantly increase survival of the combat wounded.

Keyword Tags:

blood coagulation hemostatic products, control bleeding by tourniquet, corpsman tactical combat casualty care, emerging trends in combat casualty care, gateway medical research, hemostatic, hemostatic agents, medical research, medical research studies, new medical research, steps to control bleeding, tactical combat casualty care

Crime and Public Safety 8-10-08

By Staff Reports

SAN BERNARDINO

Crash near Cal State claims life of boy, 17

A teenage boy who died Friday in a traffic collision near Cal State San Bernardino has been identified as Jose Cintron of San Bernardino.

The 17-year-old was driving a 1999 black Honda Civic east on Northpark Boulevard and trying to pass another vehicle about 5:50 p.m. when he lost control of his car. The car went up a curb and struck a tree before it overturned, police and coroner’s officials said.

Cintron was taken to Loma Linda University Medical Center, where he died at 7:36 p.m. His two passengers, an 18-year-old boy and a 15- year-old girl, suffered serious injuries but are expected to survive, authorities said.

BAKER

Man, teen killed when car flips on highway

A man and a 13-year-old boy were killed Friday when the Ford Thunderbird they were riding in veered off Highway 127, became airborne and flipped several times.

Lazarus Landin, 41, of Pahrump, Nev., and Corey Mills, 13, of San Diego were bound for Pahrump, traveling in a 2005 Ford Thunderbird on Highway 127 – about 37 miles north of the 15 Freeway – when the accident occurred about 8:35 a.m.

Landin and Mills were pronounced dead at the scene, coroner’s officials said.

According to the Coroner’s Office, evidence at the scene of the accident indicated the vehicle was southbound on the highway when it drifted to the right for an unknown reason.

Landin overcorrected to the left and the car struck a berm, became airborne, and rolled over before coming to rest in the open desert.

ONTARIO

Authorities identify woman killed in fire

A 91-year-old woman who died in a house fire was identified Saturday as Dorothy Paulsen.

Firefighters found Paulsen’s body in her home in the 12500 block of West Del Grande Street when they responded to a fire there about 12:50 p.m. Friday.

The cause of the fire was under investigation by the Ontario Fire Department.

An autopsy will be conducted.

POMONA

100 cars impounded at police checkpoint

Police impounded 100 vehicles and issued more than 110 citations during a traffic safety checkpoint Friday near Mission Boulevard and Curran Place.

The checkpoint was an effort to reduce alcohol-involved collisions, deaths and injuries, authorities said.

Police screened more than 2,300 vehicles, and impounded vehicles from motorists driving without licenses or on suspended licenses, according to a Pomona Police Department news release.

Five people were arrested – two for having outstanding warrants, one on suspicion of being drunk in public and two on suspicion of driving under the influence of alcohol or drugs.

(c) 2008 The Sun, San Bernardino, Calif.. Provided by ProQuest Information and Learning. All rights Reserved.

Manhattan Diagnostic Radiology First in New York City to Offer Positron Emission Mammography (PEM) Scanner From Naviscan in the Fight Against Breast Cancer

NEW YORK, Aug. 13 /PRNewswire/ — Manhattan Diagnostic Radiology announced today that it will be the first imaging facility in Manhattan to offer Positron Emission Mammography (PEM) in the fight against breast cancer. This installation will provide Manhattan Diagnostic Radiology an increased ability to image and diagnose early-stage breast cancers, positively impacting cancer management. The leading-edge technology provides unprecedented metabolic resolution down to 1.5 millimeters.

“We recently received prestigious designation as a Breast Imaging Center of Excellence from the American College of Radiology acknowledging our commitment to providing the highest level of breast care to our patients,” said Craig H. Sherman, M.D., Senior Partner and Director of PET/CT imaging at Manhattan Diagnostic Radiology. “We have always sought out the very best in diagnostic imaging technology, and PEM will be the latest in a long list of firsts for our center. We expect that PEM will prove indispensable to effective breast cancer management for both our referring physicians and our patient population.”

“Manhattan Diagnostic Radiology is widely respected for its superior diagnostic skills and comprehensive services. We are excited to play a part in what they do best,” said Paul J. Mirabella, Chairman and CEO of Naviscan.

The PEM Flex scanner from Naviscan uses PET technology to produce high-resolution tomographic images of 1.5 millimeters resolution, allowing physicians to visualize breast tumors about the size of a grain of rice. The scanner is the size of a mammography unit and consists of two high-resolution detector heads which are placed in close proximity to the breast. Compared to the higher-force compression necessary for mammography, the PEM Flex scanner uses gentle breast immobilization.

About Naviscan, Inc.

Naviscan(R), founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging, guide radiological and surgical procedures and advance new clinical therapies. The PEM Flex(R) Solo II is currently installed and available in breast centers and imaging centers throughout the U.S. PEM Flex is also utilized in clinical research studies, funded in part by the National Institutes of Health. The Company is headquartered in San Diego, California and is the first company to obtain FDA clearance of a high-resolution PET scanner designed to image small body parts. For more information, visit http://www.naviscan.com/

About Manhattan Diagnostic Radiology (MDR)

As one of the premiere diagnostic radiology centers in New York City and the surrounding Tri-State area, the physicians of Manhattan Diagnostic Radiology have set new standards of excellence in diagnostic expertise, advanced imaging technology, patient care and women’s health. Based in Manhattan, NY, MDR was one of the first centers in New York City to utilize PET technology in a comfortable and friendly outpatient environment. Further, MDR is one of the very few full-service radiology practices to specialize in high field MRI, PET/CT, 64-Slice CT and Coronary Artery CT, Nuclear Medicine, Multimodality Breast Imaging, Ultrasound, General Diagnostic Radiology, and Outpatient Fine Needle Aspiration and Core Biopsy. MDR remains at the forefront of radiologic technology, as one of first centers to offer Breast MRI in an outpatient setting, and one of the only practices in the entire Tri-State area to routinely conduct complex MR studies including secretin MRCP and pelvic floor defecography. With the acquisition of PEM technology, MDR further continues its commitment to excellence and as a pioneer in the area of women’s health. For more information, visit http://www.mdrny.com/.

Naviscan, Inc.

CONTACT: Craig H. Sherman, M.D. of Manhattan Diagnostic Radiology,+1-212-838-4243; or Guillaume Bailliard, VP, Marketing of Naviscan, Inc.,+1-858-332-0941

Web site: http://www.naviscan.com/http://www.mdrny.com/

Power3 Medical Products, Inc. Provides Progress Report – NuroPro(R) Clinical Validation Study of Serum Biomarkers for Alzheimer’s Disease

Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company specializing in the development and commercialization of diagnostic tests for early detection of breast cancer and neurodegenerative diseases, is providing an interim status report of its international validation study of the company’s NuroPro(R) blood serum biomarker test for Alzheimer’s disease.

Power3 is currently conducting a 300-patient clinical validation study of its NuroPro(R) blood serum test for Alzheimer’s and Parkinson’s disease in collaboration with Dr. Marwan Sabbagh, the Director of Clinical Research at the Cleo Roberts Center of Clinical Research at the Sun Health Research Institute in Sun City, Arizona. “The preliminary results of the Power3’s study look very promising. Clinicians around the world look forward to adding a tool to diagnose and treat Alzheimer’s earlier and therefore give the best care to their patients,” says Dr. Sabbagh. To date, 92 Alzheimer and Control patient samples have been analyzed in Power3’s CLIA certified laboratory and have demonstrated high sensitivity and specificity in the diagnosis of Alzheimer’s disease.

“This study confirms Power3’s panel of Neurodegenerative biomarkers’ ability to diagnose Alzheimer’s disease with superior sensitivity and specificity with results in the 95% range. Additionally, the current study validates Power3’s collection, storage, shipping, processing, and biostatistical analysis methods,” says Dr. Essam Sheta, the Director of Power3’s CLIA laboratory. Power3 expects to conclude the initial Alzheimer’s validation study in September 2008 and publish the validation study results soon after.

“Power3 is planning to expand its validation study for NuroPro(R) to include two additional clinical sites within the U.S. Larger patient cohorts of different ethnic and environmental backgrounds will strengthen the validity of NuroPro’s(R) applicability in the diagnosis of neurodegenerative diseases,” Steven B. Rash, Chief Executive Officer, commented. Mr. Rash added “This study confirms that Power3 is rapidly approaching the stage to commercializing the first ever blood serum proteomic tests for the diagnosis of neurodegenerative diseases. These encouraging Alzheimer’s test results, and the numerous validation studies that are currently underway for Parkinson’s disease, ALS, and similar neurological disorders, demonstrates our commitment to bringing these tests to market in late 2008 or early 2009. We believe this test will be a major breakthrough for patients and physicians, as it will offer a means to detect neurodegenerative diseases at their earliest stages, allowing physicians to begin treatment at stages which will produce more positive outcomes.”

In addition to the Alzheimer’s clinical validation study being conducted in collaboration with Dr. Sabbagh, the Company continues its ongoing Parkinson’s validation study under the direction of the principal investigator, Dr. Katerina Markopoulou at the Research Institute at the University of Thessaly, Greece. Power3 expects to conclude this Parkinson’s validation study in September and will publish the results soon after.

About Power3 Medical Products

Power3 Medical Products, Inc. (OTCBB: PWRM, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro(TM) in twelve Middle Eastern countries before the end of 2008. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas. The Company is preparing to commercialize its IP portfolio, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.

About Sun Health Research Institute

For 21 years, Sun Health Research Institute has been a leader nationally and internationally in the effort to find answers to disorders of aging including Alzheimer’s disease, Parkinson’s disease, arthritis and prostate cancer. The institute, together with its Arizona Alzheimer’s Consortium partners, has been designated by the National Institutes of Health as one of just 31 Alzheimer’s Disease Centers in the nation. The institute’s Cleo Roberts Center for Clinical Research takes laboratory discoveries to clinical trials that foster hope for new treatments. Sun Health Research Institute is affiliated with the Sun Health non-profit community healthcare network. For more information visit www.shri.org or call Brian Browne at (623) 875-6500.

BN ImmunoTherapeutics Announces Partnership With National Cancer Institute

MOUNTAIN VIEW, California, August 13 /PRNewswire-FirstCall/ — BN ImmunoTherapeutics, Inc. has entered into a scientific partnership with the National Cancer Institute (NCI) in the United States. Under the Cooperative Research and Development Agreement (CRADA) the NCI and BN ImmunoTherapeutics will jointly develop new immunotherapies for the treatment of prostate cancer. Under the CRADA, BN ImmunoTherapeutics has rights to exclusively license intellectual property that results from this collaboration.

The company plans to in the future explore opportunities for extending this collaboration to further develop its cancer projects. By combining the company’s expertise within cancer vaccine development with one of the world’s leading centres of excellence within cancer research, the company is confident that this collaboration will result in new and innovative solutions to a disease area with high unmet medical needs as well as expand and accelerate the company’s cancer activities.

Through the collaboration and a license agreement with the United States Public Health Service, the company has obtained rights to intellectual property rights covering a prostate cancer vaccine product candidate in late phase II clinical development. Data from key clinical studies with this vaccine candidate are currently being evaluated. Later in 2008 the company will inform the market about how this development project will have a future in the pipeline of the company.

About the NCI

The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH) and is the United States federal government’s leading cancer research organization.

– The National Cancer Institute (NCI) has played an active role in the development of drugs for cancer treatment for over 50 years. This is reflected in the fact that approximately one half of the chemotherapeutic drugs currently used by oncologists for cancer treatment were discovered and/or developed at NCI.

– NCI has supported the research efforts of at least 20 Nobel Prize winners. For approximately half of these Nobel laureates, NCI supported the awarded research.

– According to a 1996 NCI analysis of drugs approved by the FDA, two-thirds of the anti-cancer drugs approved as of the end of 1995 were NCI-sponsored Investigational New Drugs.

Dr. Jeffrey Schlom is the principal investigator at the NCI for this CRADA and is Chief of the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, NCI, NIH. Dr. Schlom is one of the leading figures in the area of cancer vaccine development, and has been improving and refining novel immunotherapeutic approaches for cancer in clinical studies for more than 10 years. The collaborative effort between BN ImmunoTherapeutics and NCI will hopefully provide urgently needed new therapies for patients suffering from prostate cancer.

Reiner Laus, MD, President & CEO of BN ImmunoTherapeutics said: “The NCI relationship opens up for us new and exciting opportunities within the field of cancer and we are proud to join forces with one of the most prestigious and well-established cancer research organisations in the world. In the collaboration with NCI, BN ImmunoTherapeutics benefits from the enormous expertise in cancer therapeutics development that is present in the NCI organisation.”

Located in Mountain View, California, BN ImmunoTherapeutics is a subsidiary of Bavarian Nordic, headquartered in Denmark. BN ImmunoTherapeutics is developing immune based therapies for breast and prostate cancer.

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company’s business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic’s proprietary and patented technology, MVA-BN(R), has been demonstrated in clinical trials to be one of the world’s safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company’s third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbol BAVA.

For more information, please visit: http://www.bavarian-nordic.com/

“Safe Harbour” Statement under the Private Securities Litigation Reform Act of 1995:

Except for the historical information contained herein, this release contains “forward-looking statements” within the meaning of the Private Securities Reform Act of 1995. No “forward-looking statement” can be guaranteed, and actual results may differ materially from those projected. Bavarian Nordic undertakes no obligation to publicly update any “forward-looking statement”, whether as a result of new information, future events, or otherwise. Additional information regarding risks and uncertainties is set forth in the current Annual Report and in Bavarian Nordic’s periodic reports, if any, which we incorporate by reference.

Bavarian Nordic A/S

CONTACT: Contact: Reiner Laus, President & CEO, BN ImmunoTherapeutics,Inc., +1-650-681-4660

TransUnion Partners With CarePayment(R) to Help Healthcare Patients Pay Off Debt While Increasing Hospital Cash Flow

CHICAGO and PORTLAND, Ore., Aug. 13 /PRNewswire/ — TransUnion announced today that users of its patented Revenue Manager(SM) healthcare solution will now have the option of using CarePayment(R), a program offered and managed by Aequitas Capital Management, Inc. that will be accessible through TransUnion’s Revenue Manager. CarePayment improves hospital cash flow and receivable yields by providing patients with a non-discriminatory, interest-free, hospital-branded finance card for their patients.

“According to the American Hospital Association, the total amount of uncompensated care provided by hospitals was more than $31.2 billion in 2006. As patients take on even greater financial responsibility for healthcare costs, offering CarePayment’s unique patient finance solution with TransUnion Revenue Manager makes absolute sense for both patients and hospitals,” said Mike Snitman, vice president of TransUnion’s healthcare group. “Our partnership ensures that patients have greater flexibility to pay off their debt, while helping hospitals significantly increase their cash flow.”

Steve Wright, senior managing director of healthcare markets at Aequitas Capital, indicated that CarePayment is helping hospitals nationwide to achieve significant improvement in their overall patient-pay receivable portfolio yields.

“Hospitals offering CarePayment have experienced average net collection results of 40 percent compared to 20 percent or less prior to implementing the program,” said Wright. “With our zero interest finance card, patients no longer have to use high-interest credit loans to pay for unexpected medical costs. In addition to improving their key financial metrics, our hospital clients are also enhancing their overall mission by helping patients avoid financial hardship.”

Highlights of the fully-automated CarePayment finance card offered by Aequitas Capital include:

— All patients are pre-approved (a valid social security number is required)

— New account process is fully automated, thus no application forms, documentation or approval processes are required

— Provides manageable monthly payments for consumers — 4 percent of the highest balance or $25, whichever is greater

— 0.00 percent interest program provides extended payment terms, accelerated principal reduction, better payment performance and greater patient and community acceptance

The CarePayment finance card is hospital branded and provides monthly statements, inbound/outbound customer service calls, payment processing, reporting, web access and late payment management. At those healthcare customers who opt to use the CarePayment program, a CarePayment finance card will be offered to patients during the TransUnion Revenue Manager pre-qualifying process.

TransUnion’s Revenue Manager instantaneously verifies patient identity and self-reported information at registration, and performs calculations based on patient information and eligibility requirements to pre-qualify applicants and their family members for optimal financial assistance programs. Patient demographic information is pre-populated on all enrollment forms; ready for immediate printing, signature and submission.

About TransUnion

As a global leader in credit and information management, TransUnion creates advantages for millions of people around the world by gathering, analyzing and delivering information. For businesses, TransUnion helps improve efficiency, manage risk, reduce costs and increase revenue by delivering comprehensive data and advanced analytics and decisioning. For consumers, TransUnion provides the tools, resources and education to help manage their credit health and achieve their financial goals. Through these and other efforts, TransUnion is working to build stronger economies worldwide. Founded in 1968 and headquartered in Chicago, TransUnion employs more than 3,600 employees in more than 25 countries on five continents. http://www.transunion.com/healthcare

About Aequitas Capital Management, Inc.

Aequitas Capital is a value oriented alternative investment manager, offering a variety of private equity, mezzanine and secured debt investment strategies, focusing on lower middle market companies, as well as the healthcare and energy sectors. Aequitas Capital also provides financial advisory services through its subsidiaries, Aequitas Investment Management, LLC and Windswept Capital, LLC, including mergers and acquisitions, commercial finance solutions, restructuring, recapitalization and fund placement. For more information, visit Aequitas Capital on the web at http://www.aequitascapital.com/ or call 503-419-3500.

TransUnion

CONTACT: Cliff O’Neal, +1-312-985-2540, [email protected], or DaveBlumberg, +1-312-985-3059, [email protected], both of TransUnion

Web site: http://www.transunion.com/

Wells Fargo Adds Mark Zollitsch to National Health Solutions Program

Wells Fargo Insurance Services, the world’s 5th largest insurance broker, announces the addition of Mark Zollitsch as Corporate Wellness Consultant in the company’s Wells Fargo Health Solutions(SM) group – a Cincinnati, Ohio-based consulting team offering health-preserving strategies and practices to enhance conventional medical care. As the group’s Corporate Wellness Consultant, Zollitsch will be responsible for designing, implementing and managing healthy lifestyle initiatives for Wells Fargo Health Solutions customers across the country. He will be based in Bellingham, WA and report to Gina Di Girolamo, Executive Director of Wells Fargo Health Solutions in Cincinnati, Ohio.

Prior to joining Wells Fargo Health Solutions, Zollitsch founded and built corporate and governmental wellness programs for the Lummi Indian Nation in Washington State. An experienced and effective communicator, Zollitsch works with a variety of media to promote healthy lifestyles and to design recreational and fitness programs that engage and motivate entire communities.

Zollitsch has a Masters in Health & Fitness Education from Western Washington University with research focus on the effects of strength training on seniors. A committed wellness advocate and practitioner personally, Zollitsch has had an impressive athletic career focused on kayaking and canoeing, winning numerous national and world championship and Pan Am medals.

Wells Fargo Health Solutions is a consulting group offering programs that supplement conventional medical care that actually improve day-to-day behaviors around health. By tackling the underlying health of its members the programs control employee benefit related cost. Wells Fargo Health Solutions uses a full spectrum of integrated services in pharmacy & clinical medical management and lifestyle and wellness initiatives – all focused on lowering costs and improving overall health and quality of life.

https://wfis.wellsfargo.com/ProductServices/A+to+Z/ Wells+Fargo+Health+Solutions/ (Due to its length, this URL may need to be copied/pasted into your Internet browser’s address field. Remove the extra space if one exists.)

Wells Fargo Insurance Services, Inc. (wellsfargo.com/wfis) is the fifth-largest insurance brokerage in the world with 171 offices in 37 states. Its 5,200 insurance professionals place $11.5 billion of risk premiums with expertise in property, casualty, benefits, international, personal lines and life products.

Wells Fargo & Company is a diversified financial services company with $609 billion in assets, providing banking, insurance, investments, mortgage and consumer finance through almost 6,000 stores and the internet (wellsfargo.com) across North America and elsewhere internationally. Wells Fargo Bank, N.A. is the only bank in the U.S., and one of only two banks worldwide, to have the highest possible credit rating from both Moody’s Investors Service, “Aaa,” and Standard & Poor’s Ratings Services, “AAA.”

KI NutriCare to Acquire Allergy Research Group

KI NutriCare, a wholly owned subsidiary of soy sauce brewer Kikkoman, and Allergy Research Group have entered into a definitive agreement pursuant to which Allergy Research will be acquired for approximately $19.5 million through an all-cash tender offer of $1.33 per share by Longhorn Acquisition, a wholly owned subsidiary of KI NutriCare formed to effect the transaction.

Upon completion of the acquisition, Allergy Research Group will become a wholly owned subsidiary of KI NutriCare and will continue operations in Alameda, California.

Under the terms of the agreement, Longhorn Acquisition will commence a cash tender offer to acquire all of the outstanding shares of Allergy Research Group common stock for $1.33 per share in cash, to be followed by a cash merger in which each remaining share of Allergy Research Group would be converted into the same $1.33 cash per share paid in the tender offer, except for shares held by stockholders who exercise appraisal rights.

Stephen Levine, founder of Allergy Research Group, will continue to provide services to the combined entity as a consultant. Manfred Salomon, the current president of Allergy Research Group, will also continue to serve the combined entity as its COO.

Talecris Enters into Definitive Merger Agreement With CSL

Talecris Biotherapeutics, Inc. (www.talecris.com) today announced that it has signed a definitive merger agreement with CSL under which CSL has agreed to acquire Talecris for $3.1 billion in cash. This amount includes net debt, which as of June 30, 2008 was approximately $1.2 billion, implying an equity value as of that date of about $1.9 billion.

The combination of Talecris and CSL will result in:

— a combined company with one of the broadest portfolios in the plasma-derived therapeutics industry with key products in each plasma therapeutic area;

— one of the most robust and efficient plasma collection capabilities in the industry, to better assure supply of plasma for manufacturing essential therapies;

— expanded and integrated manufacturing with greater efficiency and improved ability to supply therapies;

— an enhanced R&D pipeline;

— operating efficiencies that will facilitate further investment in R&D, quality, compliance and plasma collection; and

— improved and more reliable supply of therapies to patients and customers through efficiencies, avoidance of capacity constraints and more assured plasma supply.

“We are very pleased to have entered into the merger agreement with CSL,” said Lawrence D. Stern, Chairman and CEO of Talecris. “We at Talecris have long admired CSL. The opportunity for our employees, customers, distributors, suppliers–and most importantly our patients–to benefit from being part of the CSL family is exciting, and is a testament to the quality and strength of Talecris’ relationships with its stakeholders. At the same time, the transaction represents a good return for our shareholders, many of whom are our employees.”

“We believe Talecris has demonstrated a track record of the utmost integrity and ethics, and has some of the most widely used, life-enhancing plasma-derived therapies available,” said Dr. Brian A McNamee, Chief Executive Officer and Managing Director of CSL. “Patients count on Talecris to provide them with the therapies they need. We are committed to growing and enhancing the business to the benefit of all stakeholders.”

Closing of the transaction is subject to receipt of certain regulatory approvals, as well as other customary conditions. If the necessary approvals are not obtained within one year, either CSL or Talecris will have the right to terminate the transaction.

Concurrently with execution of the merger agreement, Talecris and CSL have also entered into a separate plasma supply agreement under which CSL will supply Talecris with a significant amount of plasma through 2013, which will help Talecris assure an uninterrupted flow of products to its customers, distributors and patients and will also facilitate Talecris’ efforts to build its plasma supply platform in a measured, quality-compliant manner. The additional plasma supply should enable Talecris to increase supplies of Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) and other products to the marketplace in the near future.

Morgan Stanley and Goldman, Sachs & Co. served as Talecris’ financial advisors in connection with the transaction, and Sullivan & Cromwell LLP and Arnold & Porter LLP provided legal advice. CSL was advised by Merrill Lynch and Simpson Thacher & Bartlett LLP.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.

Talecris, with revenues of approximately $1.2 billion in 2007, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,000 talented people worldwide.

Talecris was formed in 2005 by affiliates of Cerberus Capital Management, L.P. and Ampersand Ventures, which acquired the former Bayer Plasma business from Bayer A.G.

To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.

About Gamunex

Gamunex is an IGIV therapy that contains antibodies purified from the donated blood plasma of thousands of people. Gamunex is indicated as replacement therapy of primary humoral immunodeficiency disease (PI) and as immunomodulatory therapy for idiopathic thrombocytopenic purpura (ITP).

Important Safety Information

Gamunex is contraindicated in individuals with known anaphylactic or severe systemic response to Immune Globulin (Human). Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis and death. Patients should be instructed to immediately report symptoms of decreased urine output, sudden weight gain, fluid retention/edema, and/or shortness of breath (which may suggest kidney damage) to their physicians. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number. Gamunex does not contain sucrose. Glycine, a natural amino acid, is used as a stabilizer.

There have been reports of noncardiogenic pulmonary edema, rare reports of hemolytic anemia, and very rare reports of aseptic meningitis in patients administered with IGIV. Thrombotic events have been reported in association with IGIV. Patients at risk may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity. The most common side effects noted during clinical trials included headache, vomiting, fever, nausea, rash, and back pain.

As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated.

For additional information about Gamunex, please see www.gamunex.com for Full Prescribing Information.

About Cerberus Capital Management, L.P.

Established in 1992, Cerberus Capital Management, L .P., along with its affiliates, is one of the world’s leading private investment firms with approximately $27 billion under management in funds and accounts. Through its team of more than 275 investment and operations professionals, Cerberus specializes in providing both financial resources and operational expertise to help transform undervalued companies into industry leaders for long-term success and value creation. Cerberus is headquartered in New York City, with affiliate and/or advisory offices in Atlanta, Chicago, Los Angeles, London, Baarn, Frankfurt, Hong Kong, Beijing, Tokyo, Osaka and Taipei. More information on Cerberus can be found at www.cerberuscapital.com.

About Ampersand Ventures

Ampersand is a Boston-based, middle market private equity firm with a focus in two core Sectors: Healthcare and Industrial. Within this Core, Ampersand’s strategy emphasizes later stage, growth equity opportunities where we can be the first institutional investor. Ampersand’s unique blend of venture, private equity and operating skills positions us to take an active teamwork approach in collaborating with the management teams of our portfolio companies. Ampersand’s current portfolio investments include Elmet Techologies, Endeca, Kortec, Magellan Biosciences, RadPharm and Talecris. More information on Ampersand can be found at www.ampersandventures.com.

Leopold Ketel & Partners Begins Search for New Managing Partner

PORTLAND, Ore., Aug. 12 /PRNewswire/ — Portland marketing firm Leopold Ketel & Partners said it has begun a search for a new agency managing director after announcing that current president John Russell has resigned to pursue other opportunities. Russell had been with the 12-year-old agency for the past six years.

Nathan Plowman, who owns his own Portland-based marketing consulting firm has been retained as a strategic advisor during the transition, said Leopold Ketel’s founding partner Jerry Ketel. Plowman was global business director for 180 Amsterdam for six years, growing the small creative hotshop into an international creative powerhouse with more than 200 employees. Among 180’s notable campaigns were “Impossible is Nothing” for adidas and the 2006 World Cup campaign.

In addition to providing strategic business direction, Plowman will assist the agency in a nationwide search for a managing director.

Leopold Ketel & Partners was founded in 1996 and currently has 27 full-time employees and several freelancers. The marketing agency excels in strategic planning, advertising, design, media planning and buying and public relations.

The agency’s client roster includes some of Oregon’s best known companies and organizations including Tillamook Cheese, ODS Companies, Hood River Distillers, Springbrook Properties, Inc., The Allison Inn & Spa, Oregon Public Broadcasting, RadiSys, Kells Irish Restaurant & Pub, Benchmade Knife Co., Castelli cycling apparel, Oregon Health & Science University, Oregon Coast Aquarium, Oregon Humane Society, The Old Mill District in Bend, and Houdini Tool, Inc.

For more information, call 971-244-0661 or visit http://www.leoketel.com/.

Leopold Ketel & Partners

CONTACT: Olga Haley, Managing Director, Public Relations of LeopoldKetel & Partners, +1-971-244-0661, cell, +1-503-860-0848, [email protected]

Web site: http://www.leoketel.com/

Xpention Genetics Announces Plans for Reverse Stock Split and Name Change As Prelude to New Investment

Xpention Genetics, Inc. (OTCBB: XPNG) today announced that a majority of its shareholders approved a proposal to authorize the Board, in its discretion, to effect a reverse split of Xpention’s issued and outstanding common stock at a ratio ranging from one-for-ten to one-for-twenty without further action by shareholders and to change the name of the company to Cancer Detection Corporation. As of the end of business on July 24, 2008, there were approximately 96.5 million shares of Xpention’s common stock outstanding. The reverse split will not change the number of shares of Xpention’s preferred stock authorized, which will remain at 10 million.

The Company has recently retired $100,000 of convertible debt via conversion into equity. As a result, the Company is limited in its ability to obtain the additional equity capital necessary to continue its research activities as substantially all authorized shares of common stock have been issued. The purpose of the reverse split is to decrease the number of outstanding shares, thereby permitting the Company an opportunity to raise additional capital. Initially, the reverse split would not affect any individual stockholder’s percentage ownership interest in the Company; however, if the Company is successful in raising additional equity capital the percentage ownership interest of any individual stockholder would be reduced. The purpose of the name change is to better reflect the Company’s business. The Company has received conditional commitments for additional equity capital from two existing stockholders and plans to use the funds primarily for research activities, including validation of its primary technology.

David Kittrell, President and CEO, commented, “The ability to raise additional equity capital to fund our ongoing research, including the validation of our licensed p65 technology, is critical to our ability to execute our business plan to commercialize this technology. The Board believes that it is in the best long-term interest of the Company and our stockholders to raise the additional capital necessary to continue our research activities which, if successful, would improve both the Company’s value as well as each individual stockholder’s investment despite having a reduced ownership percentage of the Company. We are encouraged that two of our existing stockholders have tentatively agreed to increase their investment into the Company to fund the research necessary for us to move forward toward the goal of producing cancer detection tests for canines and humans. Our name change will more accurately depict our mission and may broaden our stock’s appeal to a wider range of investors.”

Treatment of Stock Options, Warrants and Convertible Notes

The number of common shares into which any of Xpention’s outstanding stock options, warrants and convertible notes are convertible, as well as the relevant exercise or conversion price per share, will be proportionately adjusted to reflect the reverse split.

Fractional Shares

Xpention will not issue any fractional shares of its common stock as a result of the reverse split. Instead, the company will round up any fractional interest to the next whole number of shares. No shareholder will receive less than one share of common stock after the reverse split.

Obtaining New Stock Certificates

Xpention will adopt a new stock certificate in connection with the implementation of the reverse split.

Holladay Stock Transfer, Inc. has been retained to manage the exchange of stock certificates. Shareholders of record will receive a letter of transmittal providing instructions for the exchange of their certificates as soon as practicable following the effectiveness of the reverse split. Shareholders who hold their shares in “street name,” will be contacted by their banks or brokers with any instructions. For further information, shareholders and securities brokers should contact Holladay at 480-481-3940.

About Xpention Genetics, Inc.

Xpention Genetics, Inc. is a biotechnology company that was formed to develop both immunological and molecular tests for cancer detection in animals and humans as well as therapeutic vaccines and other treatment methods. Xpention Inc., a wholly owned subsidiary of Xpention Genetics, Inc. and The University of Texas M. D. Anderson Cancer Center signed a Patent and Technology License Agreement granting Xpention the exclusive rights to patented technology for the detection of cancer based on a tumor marker known as p65, which has been demonstrated to have elevated levels in the blood of canine and human cancer conditions.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “intends,””believes,” and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

 Contact: Trevor Justus Windfall Communications, LLC 866-590-6589  

SOURCE: Xpention Genetics, Inc.

Medistem Inc. Announces New Ticker Symbol Following Reverse Split and Name Change

Medistem Inc. (OTCBB: MEDS) today announced a change in its corporate name and trading symbol.

Effective August 11, 2008, the Company changed its name from Medistem Laboratories, Inc. to Medistem Inc. to avoid confusion with respect to its business activities. The Company also effected a 1-for-25 reverse split of its common stock and, as required under NASDAQ OMX rules, was given a new ticker symbol. The new symbol is MEDS.OB.

“We see these events as being positive and necessary steps toward pursuing short and mid-term financing objectives,” said Thomas Ichim, CEO of Medistem Inc. “Since our inception in 2005, we inherited a capital structure that had far too many shares outstanding for a Company of our size. Following this split, we have approximately 5.3 million shares outstanding which we believe is an appropriate capital structure for our organization.”

About Medistem Inc.

Medistem Inc. is a biotechnology company founded to develop and commercialize technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell derived from the menstrual blood that possesses the ability to differentiate into nine tissue types, produce large quantities of growth factors, and a large proliferative capacity. A peer reviewed publication describing this novel cell type may be found at http://www.translational-medicine.com/content/5/1/57. The company is currently focusing on use of endometrial regenerative cells for treatment of critical limb ischemia, an advanced form of peripheral artery disease that causes approximately 160,000 amputations per year.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.

Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

 For further information on Medistem Inc., please visit www.medisteminc.com or contact:  Thomas Ichim, PhD CEO 9255 Towne Center Drive Suite 450 San Diego,CA 92122 1877-ERC-STEM  

SOURCE: Medistem Inc.

Agent Orange, Prostate Cancer Linked Rockland Researcher Urges More Stringent Testing of Vietnam Veterans

By MEG HASKELL; OF THE NEWS STAFF

ROCKLAND – Military veterans exposed in Vietnam to the chemical defoliant Agent Orange have a significantly elevated risk of developing an especially aggressive form of prostate cancer, according to a new study led by a Rockland physician and researcher.

Dr. Lars Ellison, who is deployed with the U.S. Army in Iraq, said in a recent interview the research was inspired by the large number of cases of prostate cancer he and other doctors were seeing at a Department of Veterans Affairs hospital in Davis, Calif., where he practiced from 2003 to 2007.

“We noticed that a lot of veterans from Vietnam were being diagnosed with more aggressive disease,” he said. The cancers were also fast-moving, and many were not diagnosed until they already had spread to the bone or lymphatic system.

To verify and measure their observations, Ellison and professional colleagues at the University of California at Davis Medical Center used the VA’s electronic medical record system to identify about 13,000 Vietnam veterans from Northern California, half of whom had been exposed to Agent Orange during the Vietnam War and half of whom had no exposure.

Even after controlling for other risk factors – such as age, obesity, smoking, diet and medications – individuals in the group with Agent Orange exposure were twice as likely to have been diagnosed with prostate cancer, 21/2 times as likely to have an especially virulent form of the disease, and four times as likely to have metastasis at the time of diagnosis.

The implication for health care providers is clear, Ellison said. “These [veterans] are potentially harboring a much more aggressive disease than normal,” he said, and they should be managed more aggressively in response.

In addition, Ellison said, exposed veterans should make sure their doctors are aware of their high-risk status.

“They need to be very vigilant and ensure they are receiving the necessary screening tests – an annual rectal exam and a prostate- specific blood test … in order to discover any disease early.”

The study report is available online at www.ucdmc.ucdavis.edu/ cancer and will be published in the Sept. 15 issue of the journal Cancer.

Routine annual screening for prostate cancer generally begins when men are 50, and includes both a physical examination and a blood test. But certain individuals, including African-American men and men with a family history of prostate cancer, are known to be at higher risk and should start screenings at age 40 instead of 50.

Ellison’s study shows that Vietnam veterans are also high-risk, but he points out they’re already past the age where early screening can be done.

“These guys are in their 50s and 60s,” Ellison said. “They’re already too old for early screening.”

Instead, the study says health care providers should be quicker to order a prostate biopsy based on the routine blood test. The test measures a protein called prostate specific antigen, or PSA. The normal range is 0 to 4 nanograms of PSA in each milliliter of blood.

At levels higher than that, and in consideration of other risk factors, doctors often will recommend a biopsy to check for abnormal cell growth. Ellison said there is some concern the 4 ng/ml threshold is too high and should be dropped to 2.5 ng/ml for the general population.

“There is now an absolutely compelling reason to lower the acceptable threshold for the Agent Orange group,” which would encourage more men to have biopsies, Ellison said. His hope is that by treating aging Vietnam veterans as the high-risk group they are, more cases of aggressive prostate cancer will be caught before the disease has spread.

Ellison said the VA has expressed interest in his study, which was presented at a urology conference earlier this year. “Hopefully, they will try to replicate it on a larger scale,” he said.

It is estimated that the U.S. military sprayed more than 20 million gallons of Agent Orange and similar chemical defoliants in Vietnam between 1962 and 1971, according to the study. Exposure to Agent Orange since has been linked with several kinds of cancer, Type 2 diabetes and birth defects in veterans’ children.

The VA maintains a registry of veterans exposed to Agent Orange. Nationally, more than 458,700 individuals are registered, including more than 5,000 in Maine.

More information about Agent Orange is available at the VA’s Web site, www1.va.gov/Agentorange.

[email protected]

990-8291

(c) 2008 Bangor Daily News. Provided by ProQuest Information and Learning. All rights Reserved.

Rock Stars to Send DNA Into Space

Operation Immortality(TM), the project to create a digital time capsule of the human race, has joined forces with Planet Make-Over, an entertainment driven social network designed to demonstrably reverse the effects of Global Warming. This alliance aims to unite and mobilize the worldwide gaming community with Planet Make-Over’s mission by sending the digitized DNA of rock stars Eric Johnson, Patrice Pike and Planet Make-Over’s Musical Director, Stephen Bruton into space with video gaming luminary Richard Garriott as he travels to the International Space Station (ISS) on Oct. 12, 2008.

Johnson, Pike and Bruton, avid supporters of Planet Make-Over, will be adding their digitized DNA as well as their influences, instruments of choice, and examples of their work, to the “Immortality Drive,” a storage device which Garriott will store on the ISS as part of Operation Immortality. The Immortality Drive is currently in the process of being loaded with information from people all over the world at the OperationImmortality.com website.

Visitors to the website can submit their suggestions for humanity’s greatest achievements, leave their immortalized message for future generations, and may even have their DNA selected to join the rock stars on an out of this world trip to possibly become the future of mankind.

Garriott is a game developer at NCsoft and creator of the Ultima series of games and the recently released Tabula Rasa(R). The goal of Operation Immortality is to have a space-borne record of human DNA and a record of humanity’s achievements in the event a global calamity dooms the human species, like what happens in the Tabula Rasa video game.

Planet Make-Over and Operation Immortality have a shared goal of the preservation of the human species, and both believe that the power of online social networking is crucial to uniting the world towards taking action; Garriott has millions of loyal online gaming fans demonstrating the proof of this power. Garriott’s visit to space is an attractive platform for Johnson, Pike and Bruton to bring attention to Planet Make-Over’s strategy to reverse the effects of global warming through music, fun, and social networking.

“The Concept of Operation Immortality is much more than a theme to an online game. The Earth’s population needs to quickly adjust our behavior regarding global warming or else fiction quickly becomes our new reality. When we learned that Richard Garriott will be conducting environmental research while in space, the stars all aligned to support him,” said Gary Fortin, creator and executive producer of Planet Make-Over. “Planet Make-Over is about saving the planet. The message is serious but the process can, and should be fun.”

“I know first hand the power that music has to unite people, and I know that Global Warming poses a serious and pending threat to humanity,” said Eric Johnson. “The first step is to come together and collectively change our daily habits or Operation Immortality becomes way too real; this is the serious part. The fun part is involving musicians, their DNA, schematics of Fender guitars, and a record of Planet Make-Over’s strategy as part of Operation Immortality to set an historical benchmark of the moment the planet took action to reverse this threat to humanity.”

“I am very excited to have rock greats such as Johnson, Pike and Bruton bringing their message to save the Earth from environmental catastrophe,” said Garriott. “My current gaming project, Tabula Rasa, starts with the Earth being devastated by hostile aliens, however, regardless of how humanity faces its doom, Planet Make-Over and Operation Immortality are working for the same result…humanity’s survival.”

About Stephen Bruton

Stephen Bruton is the music director at Planet Make-Over and a Grammy nominated producer. Bruton is also a successful recording artist and singer/songwriter. He has also amassed a daunting resume, having served as a sideman/guitarist, songwriter, or producer for such industry notables as Bonnie Raitt, Delbert McClinton, Ray Wylie Hubbard, Hal Ketchum, Christine McVie, T-Bone Burnett, Willie Nelson, Waylon Jennings, Patty Loveless, Jimmie Dale Gilmore and Alejandro Escovedo. Bruton grew up in Ft. Worth, Texas, the son of a jazz musician and record-store owner. He got his first big break when Kris Kristofferson tapped him to fill a vacant band slot in the early ’70s. After working with an impressive array of artists for over 20 years, Bruton released his first solo album in the early ’90s. Bruton’s fourth release, “Spirit World,” a mixture of blues, country, and rock & roll, came out in early 2002, followed in 2005 by From the Five. For more information on Bruton go to: www.stephenbruton.com.

About Eric Johnson

Eric Johnson is a guitarist and recording artist from Austin, Texas. Best known for his success in the instrumental rock format, Johnson regularly incorporates jazz, fusion, new age and country and western elements into his recordings. Guitar Player magazine calls Johnson “One of the most respected guitarists on the planet.” Johnson composes and plays not just instrumental songs, but also sings and plays piano. His critically-acclaimed, platinum selling 1990 recording Ah Via Musicom produced the single “Cliffs of Dover,” for which Johnson won the 1991 Grammy Award for Best Rock Instrumental Performance. For more information about Johnson, go to: www.ericjohnson.com.

About Patrice Pike

Patrice Pike is an award-winning singer songwriter from Austin, Texas. Having been a professional musician since she was 16, she has co-created numerous records and musical groups and has performed all over the United States and Western Europe. Her most notable groups are Sister Seven and Patrice Pike and the Blackbox Rebellion. For more information on Pike, go to: www.patricepike.com.

About Operation Immortality

For information about Operation Immortality, including full terms and conditions, go to http://www.OperationImmortality.com. For information on Richard Garriott’s Tabula Rasa go to http://www.rgtr.com. Currently NCsoft is offering free trials of Tabula Rasa. The game is rated Teen by the Entertainment Software Rating Board.

About NCsoft Corporation

NCsoft North America is headquartered in Austin, Texas and is a wholly-owned subsidiary of Korea-based NCsoft Corporation. NCsoft, with its own development and publishing offices in Texas and California, also works with other NCsoft subsidiaries and third party developers throughout North America to develop and publish innovative online entertainment software products. The company has successfully launched multiple online titles in the last three years and continues to support its franchises, which include Lineage(R)/Lineage II, City of Heroes(R)/City of Villains(R), Guild Wars(R)/Guild Wars Factions(R)/Guild Wars Nightfall(R)/Guild Wars: Eye of the North(TM), Richard Garriott’s Tabula Rasa, Dungeon Runners(TM) and Exteel(TM). More information about NCsoft can be found at www.PlayNC.com.

About Planet Make Over

Planet Make-Over(R) is an interactive, entertainment driven, musician/celebrity-led, global movement to reverse the effects of global warming though social networking. The Planet Make-Over endowment for the arts is a pending 501(c)(3) non-profit organization with a mission to convert climate concerned people’s awareness into measurable action that enables the reversal of global warming through the efforts of Artists worldwide.

Planet Make-Over is designed to deliver compelling and dynamic information to millions of people via the Internet and virally spread it across social media networks through the impact of celebrity driven entertainment content beginning in January 2009.

Because Planet Make-Over relies so heavily on the artist community around the world to ignite action and increase membership, Planet Make-Over has created an endowment to assist and support artists in their efforts to contribute to the Planet Make-Over mission. These non-profit funds will be used to further their ability to reach larger audiences and continually grow the membership base of the Planet Make-Over community.

For more information go to www.planetmake-over.com.

NCsoft, the interlocking NC logo, PlayNC, Lineage, City of Heroes, City of Villains, Guild Wars, Guild Wars Factions, Guild Wars Nightfall, Guild Wars: Eye of the North, Tabula Rasa, Dungeon Runners, Exteel and all associated logos and designs are trademarks or registered trademarks of NCsoft Corporation. All other trademarks are the property of their respective owners.

Dr. Neil Kurtz Named CEO of Golden Living

Golden Living announced today that Neil Kurtz, M.D., has been named President and Chief Executive Officer of the company, effective Aug. 29. Golden Living is one of the leading providers of long-term care in the country.

Most recently, Dr. Kurtz was President and Chief Executive Officer of TorreyPines Therapeutics, Inc., a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research and development of new compounds to treat unmet clinical needs.

“I have had the good fortune to work with Dr. Kurtz over the past several months, and I can say without hesitation that he will enhance the leadership talent of our company, complement the efforts of our senior management team and bring a fresh perspective to the way we operate our business units,” said Ronald E. Silva, President and CEO of Fillmore Capital Partners and owner of Golden Living. “We are extremely fortunate to have him join our organization in this vital leadership role and set the new standard in operating quality for our industry.”

Prior to joining TorreyPines in 2002, Dr. Kurtz co-founded Worldwide Clinical Trials, a contract research organization, where he held the positions of President and Chief Executive Officer until its acquisition by United Health Group, or UHG, in September 1999. After the acquisition, Dr. Kurtz became President of Ingenix Pharmaceutical Services, a division of UHG, and also served as a member of the UHG Executive Board until joining TorreyPines.

Dr. Kurtz’s career includes senior positions with Boots Pharmaceuticals, Bayer Corporation, Bristol-Myers Squibb, and Merck. He has a deep and recognized expertise in the area of central nervous system drug discovery and development.

Dr. Kurtz currently serves on the boards of three companies: NeurogesX, a specialty pharmaceutical company; Stemedica, a company focused on stem cell research; and Medidata Solutions, a global provider of data management services. In addition, he has consulted to more than a dozen pharmaceutical companies and was a member of the faculty in the Department of Psychiatry at the University of Connecticut from 1984 to 1988 and at the University of California, Los Angeles, from July 1980 to 1981.

Dr. Kurtz holds a B.A. in psychology from New York University and an M.D. from the Medical College of Wisconsin.

“Dr. Kurtz’s career has been focused on finding new and better ways to help people through medicine. His passion for innovation and commitment to better healthcare is a perfect fit with our company’s focus on quality and service,” said Silva. “With Dr. Kurtz at the helm of Golden Living, I know that we will continue to set new standards in excellence and lead the way in long-term care.”

Dr. Kurtz will be based at Golden Living’s Fort Smith, Ark. headquarters office.

About Golden Living (www.goldenliving.com)

The Golden Living family of companies provides care and services that directly or indirectly serve the elderly and disabled, including companies that operate nursing homes and provide rehabilitation therapy, hospice care, home health services and temporary staffing services. There are 329 Golden LivingCenters (skilled nursing facilities) and 17 Golden Living Communities (assisted living facilities) in 22 states. In addition, the Golden Innovations companies are leading providers of integrated senior health care services, partnering with more than 1,000 nursing homes, hospitals and other health care organizations in 46 states. Golden Innovations companies include Aegis Therapies, AseraCare Hospice and Home Health, Aedon Staffing, Ceres Purchasing Solutions, and Vizia Health Care Design Group. Collectively, the Golden Living family of companies has nearly 40,000 employees who provide quality health care to more than 30,000 patients and residents every day.

Roskamp Institute’s Associate Clinic Director Named Chairperson of the Alzheimer’s Disease Initiative Advisory Committee

MANATEE COUNTY, Fla., Aug. 12 /PRNewswire/ — The Roskamp Institute’s Associate Clinic Director and Neuropsychologist Cheryl Luis, Ph.D., ABPP-CN was recently nominated and appointed chairperson to the Department of Elder Affairs’ (DOEA) Alzheimer’s Disease Initiative Advisory Committee (ADIAC).

“The advisory committee is very fortunate to have someone like Dr. Luis as the chairperson,” said Darrick McGhee, director of legislative affairs for the DOEA, who worked with Dr. Luis during her tenure as the chair of the ADIAC Legislative Subcommittee. “She is very passionate about Alzheimer’s disease and related disorders, and I believe she will ensure that the committee brings forth the appropriate recommendations for the patients and caregivers of our state.”

“I am honored to have been nominated and appointed as the chairperson,” said Dr. Luis, who was nominated by an ADIAC member and subsequently appointed based on majority vote. “I am excited to continue to work with the advisory committee and the Department of Elder Affairs to reduce the burden of Alzheimer’s disease to Florida residents affected by the illness.”

Dr. Luis was first appointed to the advisory committee of the Alzheimer’s Disease Initiative (ADI) within the DOEA in 2006 by former Governor Jeb Bush. The ADI was created in 1985 by Florida Legislators to meet the needs of individuals and families with Alzheimer’s disease and related disorders. The ADIAC meets quarterly and Alzheimer’s disease specialists and health care providers from around the state regularly attend and actively participate. The advisory committee represents professionals, researchers, clinicians, social and allied health workers, Alzheimer’s organizations, daycare and nursing home personal and caregivers, who are all vested in the needs of Alzheimer’s patients.

“We are proud of Cheryl and commend her on this grand accomplishment,” said Dr. Michael Mullan, director of the Roskamp Institute. “Cheryl’s hands-on experience, as a caregiver and a neuropsychologist here at the Institute, will prove to be a great asset to the committee. Her daily environment allows her to fully understand the ever-changing needs that our state’s Alzheimer’s patients and caregivers continuously face.”

Dr. Luis is currently the associate clinic director and neuropsychologist of the Roskamp Institute. Prior to the Roskamp Institute, Dr. Luis worked as a visiting and adjunct faculty member within the Department of Social and Behavior Sciences at the Farquhar Center of Nova Southeastern University, a clinical neuropsychologist of the Wien Center for Memory Disorders at Mount Sinai Medical Center & Miami Heart Institute, a post-doctoral fellow in Clinical Neuropsychology at the James A. Haley Veterans’ Hospital and a part of the Neuropsychological Assessment staff at the University of South Florida Memory Disorder Clinic.

Dr. Luis has served as the chair of the Legislative Subcommittee of the DOEA’s ADIAC and is affiliated with the Division 40 of the American Psychological Association (APA). She is the chair of Women in Neuropsychology, a national committee that serves to promote women in leadership and serves as a liaison to the APA Committee of Women in Psychology. Dr. Luis also serves as an advisory board reviewer for APA National Standards for High School Psychology Curricula.

Dr. Luis is board-certified in Neuropsychology from the American Board of Professional Psychology. She earned her doctorate, Master of Science and Bachelor of Science in Clinical Psychology from Nova Southeastern University. She has received several awards for her research in dementia, including the 2004 Dementia and Behavioral Neurology Scientific Topic Highlight Selection, 1999 Distinguished Student Achievement Award and the 1999 Student Poster Award from the National Academy of Neuropsychology. Her research has been published in numerous professional peer-reviewed scientific journals.

The Roskamp Institute is a not-for-profit research Institute located in Manatee County and Hillsborough County, Florida, that is dedicated to understanding the causes of, and finding cures for, neuropsychiatric and neurodegenerative disorders and addictions with an emphasis on Alzheimer’s disease. The Roskamp Institute’s Memory Centers also offer comprehensive cognitive and medical assessment toward differential diagnosis of Alzheimer’s disease and offers treatments and disease management options once the diagnostic evaluation is complete.

For more information regarding Dr. Luis’ appointment or the Roskamp Institute’s continued research, please contact the Roskamp Institute in Manatee County at (941) 752-2949, the Roskamp Institute Clinical Trials Division in Manatee County at (941) 752-2949, the Roskamp Institute Memory Center in Hillsborough County at (813) 979-2008, or visit us online at http://www.roskampinstitute.com/.

Roskamp Institute

CONTACT: Kristen Bridges of Roskamp Institute, +1-850-222-2140

Web site: http://www.roskampinstitute.com/